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General Introduction
      Diabetes mellitus is currently a complicated disease. There are 132 million patients with
diabetes mellitus in the world: especially in Japan, there are more than seven million diabetic
patients. This disease exhibits persistent elevations of glucose levels in serum or blood. The
elevation of glucose levels induces a bewildering list of changes in vascular or neuronal cells.
The major diabetic complications make diabetes more convoluted. There are three major diabetic
complications, i.e., diabetic retinopathy, diabetic nephropathy, and diabetic neuropathy. Although
many studies have been carried out on diabetic complications, the detailed mechanisms and
etiology underlying diabetic complications, especially diabetic neuropathies, are unclear at this
time.
      Diabetic neuropathy is the most convoluted complication. Diabetic gastropathy, ulcers,
diarrhea, and bladder dysfunction are the major peripheral neuropathies. Peripheral neuropathies
have been the primary neuroscience focus of diabetes research. In contrast to the periphery, the
brain is not usually thought to be a target of chronic diabetic complications. However, the impact
of diabetes mellitus on the central nervous system has gained attention recently (Mooradian,
1988; Ryan, 1988). Chronic diabetes mellitus afflicts the central nervous system in several ways.
Diabetes increases the risk of stroke and the extent of stroke-related damage, over-medication
with insulin or oral agents can permanently damage the brain, and diabetes may increase the
prevalence of seizure disorders. Diabetes changes brain transport, blood fiow and metabolism,
and these changes may produce a chronic encephalopathy (see McCalL 1992 for a review).
Furthermore, it is well known that diabetes or hyperglycemia influences the sensitivity of
laboratory animals to various pharmacological agents. An increased sensitivity of hyperglycemic
or diabetic animals to barbiturates (Lamson et al., 1951; Strother et al., 1971; Ackerman and
Leibman, 1975; Ackerman 1976; Strother, 1979) and a decreased sensitivity to D-amphetamine
(Fernando and Cuzon 1974; Marshall et al., 1976, 1978; Marshall, 1978a,b), p-
chloroamphetamine (MacKenzie and Trulson, 1978), and carbon tetrachloride (Hanazono et al.,
1975a, 1975b) have been demonstrated. Recently, we have reported that the pharmacological
sensitivity to ethanol in diabetic mice is less than that in non-diabetic mice (Ohsawa and Kamei,
1997). Although many investigators have shown the differential sensitivity to various centrally
acting drugs in diabetic mice, the detailed mechanisms underling this differential sensitivity to
these drugs have not been clearly defined.
      Simon and Dewey (1981) reported that mice and rats with streptozotocin-induced
-
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diabetes and spontaneously diabetic mice are significantly less sensitive than non--diabetic mice
to the antinociceptive effect of morphine. Furthermore, Kamei et al. (1992a) also demonstrated
that the antinociceptive effect of intracerebroventricularly administered morphine and [D-Ala2,
N-MePhe`, Gly-o15]enkephalin (DA]N4GO) is smaller in diabetic mice than in non-diabetic mice.
On the other hand, there were no significant differences between the antinociceptive potencies of
these pt-opioid receptor agonists between diabetic and non-diabetic mice when they were
administered intrathecally (Kamei et al., 1994a). These results indicated that the reduction in the
antinociceptive potency of p-opioid receptor agonists in diabetic mice is due to the dysfunction of
supraspinal p-opioid receptors. However, there is Iittle information availabie regarding the
mechanism responsible for these changes.
      Several studies have indicated that the binding and metabolism of neurotransmitters
within the brain, especially monoamines, are abnormal in diabetes mellitus. Lozovsky et al,
(1981) reported that the number of dopamine receptors, measured as 3H-spiperone binding, is
increased by 30-500/o in alloxan- or streptozotocin-induced diabetic rats. Kamei et al. (1994d)
indicated that the dopamine turnover ratio in the limbic forebrain is increased in diabetic mice
compared to non-diabetic mice. Thus, it has been suggested that diabetic mice have increased
limbic forebrain dopaminergic neurotransmission (Kamei et al., 1994d). Regional noradrenergic
neurotransmission is also altered in diabetes. Trulson and Himmel (1983) showed that the
forebrain noradrenaline (NA) content increases in diabetes. 3-Methoxy-4-hydroxyphenylglycol
(MHPG), a major metabolite of NA, decreases in diabetes suggesting that diabetes decreases
forebrain noradrenergic neurotransmission.
      Opioids, the prototype of which is morphine, are the most potent available analgesic
compounds. Opiates act by mimicking endogenous opioid peptides and specifically activate
membrane receptors in the nervous system. The receptors, named opioid receptors, were first
discovered in 1973 with the demonstration of stereospecific and saturable binding ofradiolabeled
opiates to brain membrane preparations (Pert and Snyder, 1973; Simon et al., 1973; Terenius,
1973). Martin and his colleagues (Gilbert and Martin, 1976; Martin et al., 1976) performed
pharmacological studies in chronic spinal dogs and found that morphine and several of its
analogs differed in their pharmacological profiles. The study ofthe pharmacological activity ofa
wide variety of alkaloid compounds and the discovery ofenkephalins (Hughes et al., 1975) led to
the classification of opioid binding sites into three classes referred to as p, 6 and K opioid
receptors (Goldstein and Naidu, 1989). Autoradiography showed a distinct distribution for each
-
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receptor class in the brain (Mansour et al., 1988) and evidence has accumulated for a differential
role ofthe three classes ofreceptors in pain modulation (Dickenson, 1991). Specific p-, 6- and K-
opioid receptor agonists have also been associated with variable acute liability and distinct mood-
altering, autonomic and neuroendocrine effects which have been shown to be mediated by each
receptor type (Millan, 1990). Recently, Evans et al. (1992) and Kieffer et al. (1992)
independently reported cloning of 6-opioid receptor from neuroblastoma x glioma NG-108-15
hybrid cells using an heterologous expression cloning strategy and ligand-binding activity to
monitor the expression of receptors. Following the identification`of the 6-opioid receptor, p-
(Chen et al., 1993) and K-opioid receptor (Yasuda et al., 1993) cDNA were also cloned.
Molecular analysis of these three opioid receptors indicated that they conform to the structural
motif of the guanine-nucleotide-binding regulatory protein (G-protein) coupled receptor
superfamily, including the conserved seven hydrophobic domains.
     Morphine, the prototypic pt-opioid receptor agonist, produces analgesia, drowsiness,
changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting,
and alternations of the endocrine and autonomic nervous systems. Morphine is used primarily for
the treatment ofpain. Some ofthe central nervous system mechanisms that reduce the perception
ofpain also produce a state ofwell being or euphoria. Morphine also is taken outside ofmedical
channels for the purpose of obtaining these effects on mood. This potential for abuse has
generated much research on separating the mechanism of analgesia from that of euphoria in the
hope of eventually developing a potent analgesic that dose not produce euphoria. Although this
research has led to advances in understanding the physiology of pain, the standard medications
for severe pain remain the derivatives of the opium poppy and synthetic drugs that activate the
same receptors. Furthermore, patients who have received opioids develop tolerance routinely, and
ifthe medication is stopped abruptly, they will show the signs ofan opioid withdrawal syndrome,
the evidence for physical dependence. Although morphine is one of the most potent analgesics,
the use of morphine and related drugs is limited clinically by these problems.
      The physiological mechanisms implicated in the development of opioid dependence and
the expression of withdrawal symptoms consist of adaptive changes that include the processes of
homologous regulation, affecting the endogenous opioid system, and heterologous regulation that
affects other neurotransmitter systems. Numerous non-opioid neurotransmitters have been
proposed to participate in this heterologous regulation. Many of the pharmacological and
biochemical studies have been focused on the central noradrenergic system, which seems to have
an important role in the expression of the somatic signs of opioid withdrawal. This involvement
-
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is supported by several lines of evidence based on the biochemical changes reported in
noradrenergic transmission during opiate dependence and withdrawal, and on the
pharmacological responses induced after opiate withdrawal by the administration of adrenergic
compounds. Much of the evidence for the noradrenergic involvement in opioid dependence has
been derived from studies of the locus coeruleus (LC). The LC is the largest cluster of
noradrenergic neurons in the brain (Dahlstrom and Fuxe, 1964; Foote et al., 1983). The firing rate
of noradrenergic neurons in the LC increases durjng naloxone-precipitated withdrawal from
morphine dependence (Aghajanian, 1978). Treatment with DSP-4, which destroys the NA-
containing neurons, prior to induction ofdependence attenuates any withdrawal signs precipitated
by systemic administration of naloxone in morphine-dependent mice (Funada et al., 1993).
Furthermore, an enhancement in the brain content of MHPG, a principal metabolite ofNA, was
found in several brain regions innervated by the LC during morphine abstinence withdrawal
behavior (Sesak et al., 1983). This increase in the levels ofthe NA metabolite was also confirmed
in the frontal cortex of mice (Funada et al., 1993). The physiological activation of LC neurons
follows a time course that closely parallels the expression of morphine abstinence withdrawal
behaviors (Rasmussen and Aghajanian, 1989). The recent development ofin vivo microdialysis
techniques in freely moving rats allows the measurement of the extracellular concentrations of
neurotransmitters in discrete areas of the central nervous system, which is a direct reflection of
the balance between synaptic release and uptakelclearance of these transmitters. Using this
technique, it has been reported that the extraneuronal NA concentration was enhanced
immediately after the expression of naloxone-precipitated morphine withdrawal symptoms,
reaching the maximal levels within 30 min after naloxone and remaining elevated for over 90
min. The symptomatology ofwithdrawal paralleled these changes in the cortical output ofNA
(Rossetti et al., 1993), which is compatible with the previous idea that some of the behavioral
signs of abstinence may be mediated by an increased activity of the noradrenergic system
(Redmond, 1987). Thus, many investigators have suggested that the central noradrenergic system
plays a significant role in morphine withdrawal.
      Another problem with the use of morphine and other opioid drugs is their potent
reinforcing propenies. Opioids and other drugs of abuse exert marked effects on mood and
motivation (Belluzzi and Stein, 1977; Stein and Belluzzi, 1978; Dum and Herz, 1987). Animals
wM readily self-administer drugs either intravenously or orally, and drugs that are self-
administered by animals correspond well with those of high abuse potential in humans. Self-
-
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administration and intracranial self--stimulation --- obviously associated with feelings ofpleasure -
-
 have been widely used to determine the motivational effects of drugs of abuse (Wise and
Bozarth, 1982; Bozarth, 1987), These operant techniques measure the primary reinforcing
processes using specific behavioral tasks such as lever-pressing. In the behavioral experiments,
place conditioning, a technique that measures the secondary reinforcing effects of drugs, assessed
the drug-induced motivational effects. In this procedure, the association that develops between
the presentation of a drug and a previously neutral stimulus (e.g., differently colored
compartments of a shuttle box) is evaluated. The results obtained with this paradigm for
rewarding drugs are largely identical to those obtained with the self-administration technique
(Spyraki, 1988; Carr et al., 1989). Besides the evaluation of rewarding propenies, the place
conditioning procedure also allows the detection of aversive (negatively reinforcing) propenies
ofdrugs, which is ofparticular importance when investigating the effects ofopioids.
      Two major dopamine systems originate in the ventral midbrain: the nigrostriatal
dopamine system and the mesolimbic dopamine system. The mesolimbic dopamine system has
been implicated in drug reinforcement. The cell bodies of this system originate in the ventral
tegmental area (VTA), originally described as the AIO group of catecholamine-containing
neurons (Dahlstrom and Fuxe, 1964), and project to the forebrain, largely the nucleus accumbens,
olfactory tubercle, frontal cortex, amygdala, and septal area (Koob, 1992). Opioids can increase
dopamine release in the nucleus accumbens as measured by in vivo microdialysis in awake,
freely moving animals (Di Chiara and Imperato, 1988). Microinjection ofopioids into the VTA, a
region containing the cell bodies oforigin ofthe mesolimbic dopamine system, lowers the reward
thresholds for brain stimulation and produces robust place preferences (Di Chiara and North,
1992). Furthermore, it has been shown that the place preferences produced by opioids appear to
have a major dopaminergic component (Spyraki et al., 1983; Shippenberg et al., 1993). Other
evidence supporting the role of dopamine in opioid reinforcement comes from lesion studies.
Dopaminergic lesions of the nucleus accumbens have been shown to antagonize morphine
(Kelsey et al., 1989) and heroin (Spyraki et al., 1983) induced place preference. Similarly,
destruction of the ascending dopaminergic pathways ipsilateral to the injection site of DAMGO
blocked DAMGO-induced place conditioning when dopamine levels were reduced by more than
900/o (Phi11ips et al., 1983). Thus, mesolimbic dopaminergic neurons may be involved in the
reinforcing effect ofopioids.
      p-, 6- And K-opioid receptors inhibit neurotransmission, and this is generally accepted as
-
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the mechanism underlying analgesia. The inhibition of neurotransmission is caused by
coordinated changes at the cellular level (Smart et al., 1994). The opioid receptors, as well as
many other hormone, lymphokine, neurotransmitter, and neuromodulator receptors, signal to
specific intracellular effectors through G-proteins (Gillman, 1987; Birnbaumer, 1990). The
family of G-protein coupled receptors share a number of structural features, including seven
conserved hydrophobic domains that form the membrane spanning regions. Through G-protein
coupling to specific second messenger systems, all three classes ofopioid receptors elicit cellular
responses such as inhibition of adenylyl cyclase, increased potassium conductance, and
inactivation of calcium channels (Simonds et al., 1985; Childers, 1991). These intracellular
changes may underlie the antinociceptive action ofopioids.
      Repeated or sustained exposure to opioids leads to a reduction in their potencies for
evoking pharmacological effects, especially those causing analgesia. This phenomenon is termed
tolerance. Chronic exposure to morphine stimulates cytosolic protein kinase C (PKC) activity in
rat brain (Narita et al., 1994a), as well as increasing membrane-bound PKC activity in rat brain
homogenates (Narita et al., 1994b) and dorsal root ganglion (DRG) neurons from laminae I and II
ofthe spinal cord (Mao et al., 1995; Mayer et al., 1995). This increase in PKC activity parallels
the development of tolerance to opioid-induced antinociception in vivo (Narita et al., 1994a,
1994b; Mao et al., 1995; Mayer et al., 1995). Furthermore, inhibition of PKC with H-7,
calphostin C or GMI ganglioside prevents the development of tolerance, while inhibition of
protein kinase A (PKA) with KT5720 dose not (Narita et al., 1994c; Narita et al., 1995; Mao et
al., 1994). Thus, chronic opioid-induced activation ofPKC may play a role in the development of
tolerance by causing coordinated changes in the cellular mechanisms that mediate
ant!noclceptlon.
      Chronic opioid exposure induced several intracellular changes. These intracellular
changes may be involved in the development and expression of opioid physical dependen'ce.
Upon chronic opioid treatment, LC neurons developed tolerance to the acute inhibitory actions of
opioids, as neuronal firing rates recovered toward pretreatment levels (Aghajanian, 1978;
Andrade et al., 1983; Christie et al., 1987). The neurons also become dependent on opioids after
chronic exposure, as indicated by the fact that abrupt cessation of opiate treatment, for example,
by administration of an opioid receptor antagonist, leads to an elevation in the firing rates in the
LC several-fold above the pretreatment level (Aghajanian, 1978; Rasmussen et al., 1990). The
rebound of adenylyl cyclase activity during withdrawal was first demonstrated by Sharma et al.
(1975), and has long been considered as a candidate for a role in generating opioid withdrawal.
-
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Type VIII adenylyl cyclase mRNA in the LC was selectively increased after ohronic morphine
treatment in the LC, and the time course ofthese changes in adenylyl cyclase mRNA was related
to the incidence ofjumping behavior during the withdrawal syndrome (Matsuoka et al., 1994).
Another argument in favor ofthe participation ofthis intracellular signal transduction pathway is
the strong attenuation in the expression of the somatic symptoms of morphine withdrawal that
results from the inhibition ofprotein kinase activities in the LC (Maldonado et al., 1995). Protein
kinases belonging to the family ofthe serinelthreonine kinases seem to be selectively implicated
since this alleviator response was induced by the local administration of the serine/threonine
kinase inhibitor H-7, but not after the microinjection of the tyrosine kinase inhibitor KB23
(Maldonado et al., 1995). The results obtained in the LC were correlated with the behavioral
manifestations of the somatic symptoms of abstinence, and suggest that many intracellular
changes throughout the brain produced by opioid withdrawal may be involved in the activation of
noradrenergic neuron in the LC,
      A role for Ca2' in the action of opioids has long been' advocated based initially on
pharmacological evidence. Previous findings may provide an explanation for some of these
effects and implicate Ca2' more definitively in the action of opioids (Hano et al., 1967). Two
acute effects of opioids commonly observed are a reduction in neurotransmitter release and
inhibition ofneuronal electrical activity. The electrophysiological evidence indicates that opioids
decrease Ca2' influx by depression of voltage-sensitive Ca2' channels (Mudge et al., 1979) and
membrane hyperpolarization of cell bodies by increased K' conductance (North and Williams,
1983). An another electrical finding that may be very important is that opioids also prolong Ca2'-
dependent after hyperpolarization. These electrical findings may be related to Ca2' disposition
and may be explained by an opioid-induced decrease in intracellular Ca2' binding. Early
pharmacological evidence pointed the way and provided strong circumstantial evidence to
implicate Ca2' in the action ofopioids. For instance, manipulating cellular calcium can alter many
ofthe observed effects ofopioids. Invariably, maneuvers that tend to elevate neuronal Ca2', either
with Ca2' itselfor with Ca2' ionophores, reduce opioid actions. On the other hand, procedures that
lower cytosolic Ca2', such as reductions in the extracellular Ca2' concentration, removal of
extracellular Ca2' with chelating agents, or blocking of Ca2' entry with La3', all enhance the
action ofopioids (Chapman and Way, 1980; Schmidt and Way, 1980).
      The increase in Ca2' accumulation requires the concomitant presence of the opioids and
this may explain the development of physical dependence. When opioids are discontinued or
-
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treatment with an antagonist removes the agonist, the high synaptosomal Ca2' content in the
absence of the agonist produces greatly increased neurotransmitter release. This neuronai
hyperexcitability then gives rise to withdrawal signs and symptoms. The abstinence syndrome
can be attenuated by reducing intracellular Ca2'. Furthermore, La3' administration reduces abrupt
or naloxone-induced withdrawal jumping in mice (Chapman and Way, 1980). The mechanisms
underlying the enhancement of intracellular calcium by chronic opioid exposure are
physiological counter-adaptation. Opioid could cause a transient displacement of Ca2' from its
intracellular binding sites to effect increased K' conductance, membrane hyperpolarization,
decreased neuronal firing, and neurotransmitter release. The Ca2' released by opioids might act to
reduce further Ca2' entry, or the Ca2' channel itselfmay be blocked by opioids, resulting in a fall
in neuronal Ca2'. However, this lowering sets in to motion other homeostatic processes within the
cell, which become increasingly manifest as opioid administration continues. In particular, the
counter-adaptive effect occurs at the intracellular binding sites. The displacement ofCa2' from its
binding sites in the presence of the opioids becomes more difficult so that a higher dose of the
opioid is required before an acute response can be elicited (tolerance). However, the counter-
adaptive effect of retained Ca2' within the cell also increases, but requires the presence of the
opioid (dependence). Removal of the opioid by discontinuing its administration or by
administering an antagonist results in a rise in intracellular Ca2', higher excitability, and
increased neurotransmitter release (abstinence syndrome; Chapman and Way, 1980).
      Excessive glucose can also be transported intracellularly, mainly by the glucose
transporter GLUT-1, and metabolized to change the redox potential, increase sorbitol production
via aldose reductase, or alter signal transduction pathways, such as the activation of
diacylglycerol (DAG) and PKC Ievels (Kaiser et al., 1993; Greene et al., 1987; Williamson et al.,
1993; King et al., 1997; De Rubertis and Craben, 1994; Sharma and Ziyadeh, 1995; Baynes,
1991). It is possible and, in fact, likely that the common pathway by which all of the intra- and
extracellular changes induced by hyperglycemia are mediating their adverse effects is the
alteration of various signal transduction pathways. Increases in total DAG content have been
demonstrated in a variety oftissues associated with diabetic vascular complications, including the
retina (Shiba et al., 1993), aorta, heart (Inoguchi et al., 1992), and renal glomeruli (Craven et al.,
1990; Ishii et al., 1996) from animal models of diabetes and patients. Furthermore, in the sciatic
nerve ofdiabetic animals, the activity ofPKC is increased. This activation ofPKC causes higher
phosphorylation ofNa'-K'-ATPase, which results in a decrease in its activity (Hermenegildo et
al., 1993). In an electrophysiological study, it has been shown that the injection ofPKC inhibitors,
-
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such as staurosporine and PKC (19-31), reduced the hyperexcitability of C-fibers in
streptozotocin-induced diabetic rats (Ahlgren and Levine, 1994). Thus, it seems likely that
several diabetic neuropathies may be caused by the activation of intracellular messengers,
especially PKC.
      Numerous investigators have indicated that chronic diabetes mellitus is associated with
pronounced changes in cellular calcium homeostasis, which in turn lead to substantial
complications in most system functions. In vascular smooth muscle cells, a definite increase of
Ca2' influx through voltage-operated sarcolemma Ca2' channels and decrease in the productivity
ofthe Ca-ATPase pump in diabetic animal lead to enhanced vascular smooth muscle contractions
(Sowers, 1990). In peripheral nerves of diabetic rats, mitochondrial and axoplasmic calcium
levels were indeed found to be increased with electron-probe X-ray microanalysis (Lowery et al.,
1990). Moreover, voltage-dependent calcium currents through L-, and N-type channels are
enhanced in DRG neurons in BBIWor rats in vivo (Hall et al., 1995). The impairment of the
activity of the Na'ICa2' exchanger (Greene et al., 1984) and Ca2'-ATPase (Janicki et al., 1994)
causes a net calcium overload. Furthermore, in sensory neurons, depolarization-induced Ca2'
transients in small DRG neurons became substantially prolonged during streptozotoein-induced
and spontaneously occurring diabetes (Kostyuk et al., 1995). The increased residual Ca2' in
synaptic terminals is very substantial for the potentiation ofsynaptic transmission (Zucker, 1989).
As altered calcium homeostasis that results in elevation of [Ca2'], may contribute to neuronal cell
injury and death (Nichotera et al., 1992), enhanced calcium levels may contribute to the
impairment ofneuronal function in diabetes mellitus.
-
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Aims and Scope
The purpose of this research is to investigate the mechanisms underlying dysfunction of the
central nervous system in diabetic mice and painful diabetic neuropathies. In my experimental
approach, behavioral and neurochemical analyses are employed.
The specific aims ofthe proposed research
In Chapter 1
      First, I shall attempt to determine the dysfunction of p-opioid receptors in diabetic mice.
The p-opioid receptor agonist inductions of several pharmacological actions, such as the Straub
tail reaction and antinociception, in diabetic mice were examined. In addition, to define the role
of the protein kinase (PK) C in the dysfunction of p-opioid receptors in diabetic mice, I have
examined the influence of central administration of PKC and PKA inhibitors on the p-opioid
receptor agonist-induced pharmacological actions in diabetic mice. Furthermore, to distinguish
between the differential modulation of p- and 6-opioid receptor agonist-induced antinociception
in diabetic mice and the changes of intracellular calcium levels, the influence of central
administration of intracellular calcium modulators on the p- and 6-opioid receptor agonist-
induced antinociception in diabetic mice were examined.
In Chapter 2
      In order to determine the effect of the dysfunction of p-opioid receptors in diabetic mice
on the expression of morphine withdrawal, I have investigated the naloxone-induced withdrawal
signs in morphine-dependent diabetic mice. Furthermore, to evaluate the role of the protein
kinase (PK) C in the changes of morphine withdrawal in diabetic mice, I have examined the
influence of central administration ofPKC and PKA inhibitors on the expression of naloxone-
induced withdrawal jumping and naloxone-induced enhancement of noradrenaline turnover in
morphine-dependent diabetic mice. Moreover, to demonstrate the role ofthe intracellular calcium
in the central dysfunction in diabetic mice, the influence of supraspinal and spinal injections of
intracellular calcium modulators on the expression of morphine withdrawal and naloxone-
induced enhancement of noradrenaline turnover in morphine-dependent diabetic mice were also
investigated.
-
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In Chapter3
      In order to evaluate the
have determined the morphine-,
diabetic mice.
rewarding effect of several addictive drugs in diabetic mice,
 methamphetamine- and cocaine-induced place preferences
I
in
-
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Chapter 1
Modification of p-opioid receptor-mediated pharmacological
action by diabetes in mice: possible involvement ofprotein
           kinase C and intracellular calcium
-
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Introduction
       It has been reported that the antinociceptive potency of morphine is decreased in
several rodent models of hyperglycemia, including a spontaneously diabetic strain mice and
streptozotocin-induced diabetes, an animal model oftype I diabetes (Simon and Dewey, 198l).
Kamei et al. (1994a) previously reported that the antinociceptive effects ofi.c.v., but not i.t.,
administration of p-opioid receptor agonists, such as morphine and [D•-Ala2, NMePhe`, Gly-
ol5]enkephalin (DAMGO), in non-diabetic mice were significantly less than those in diabetic
mice. In contrast with these p-opioid receptor agonists, Kamei et al. (1994b, 1995) recently
reported that the antinociceptive effect of i.c.v. administration of 6--opioid receptor agonists,
such as [D-Pen2, D-Pen5]enkephalin (DPDPE) and (Å})-TAN67 (Suzuki et al, 1996), in
diabetic mice were markedly greater than those in non-diabetic mice. Therefore, they
suggested that diabetic mice are selectively hypo-responsive to supraspinal p-opioid receptors
agonists and hyper-responsive to supraspinal 6-opioid receptors agonists (Kamei et al., 1994a,
1994b). However, the detailed mechanisms that are responsible for this hypo-responsiveness
to supraspinal p-receptor-mediated antinociception and hyper-responsiveness to supraspinal
6-opioid-mediated antinociception in diabetic mice are unclear.
       Various studies have demonstrated the existence oftwo pt-opioid receptor subtypes,
which have been referred to as p,-opioid and p,-opioid receptors (Heyman et al., 1988; Kamei
et al., 1993b, 1993c; Pasternak et al., 1980; Pasternak and Wood, 1986; Paul et al., 1989;
Wolozin and Pasternak, 1981). In vitro studies have indicated that naloxonazine selectively
blocks a high-affrinity morphine binding, which has been ascribed' to pti receptors (Hahn et al.,
1982). Other studies using naioxonazine have implicated pi-opioid receptors in several p-
opioid receptor-mediated actions, such as supraspinal antinociception, feeding and prolactin
release, but not in others, such as spinal antinociception, antitussive action and physical
dependence (Heyman et al., 1988; Kamei et al., l993b, 1993c; Pasternak et al., 1980;
Pasternak and Wood, 1986; Paul et al., 1989; Wolozin and Pasternak, 1981).
       Morphine contracts the sacrococcygenus muscle in mice, which results in erection of
the tail (Straub tail reaction) (Bilby et al., 1960). Previous studies have suggested that the
morphine-induced Straub tail reaction is evoked through the activation of p-opioid receptors
(Kameyama and Ukai, 1979; Narita et al., 1993). However, there is little information available
regarding the involvement of pt-opioid receptor subtypes in the morphine-induced Straub tail
reaction. Recently, Murray and Cowan (1990) suggested that 6-opioid receptors are not
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involved in the opioid agonist-induced Straub tail reaction. Thus, the morphine-induced
Straub tail reaction is usefu1 model which can serve to examine the,effect of diabetes on p-
opioid receptor functions, without the infiuence of 6-opioid receptor functions. Thus, in
Experiment 1-1, I investigated the infiuence of naloxonazine, a selective p,-opioid receptor
antagenist, on morphine-induced Straub tail reaction to determine the involvement of the pt-
opioid receptor subtypes in the morphine-induced Straub tail reaction. In addition, I
investigated the influence of diabetes on the morphine-induced Straub tail reaction to clarify
the hypothesis that diabetic mice are selectively hypo-responsive to pi-opioid receptor-
mediated pharmacological action, but not to that which is mediated by p2-opioid receptors.
       Three opioid receptors, p-, 6-, and K-opioid receptors, have recently been cloned
(Evans et al., 1992; Kieffer et al., 1992; Chen et al., 1993; Yasuda et al., 1993; Liang et al.,
1995). These three opioid receptors contain several potential phosphorylation sites in the first
and third loops and the C-terminus of intracellular domains (Miotto et al., 1995). It has been
suggested that phosphorylation of these three opioid receptors is involved in desensitization.
There is accumulating evidence that the activation of protein kinase C (PKC) regulates
several cellular functions through the phosphorylation ofproteins, including some receptors,
whose function is then down-regulated or up-regulated (Moran and Dascal, 1989). Activation
of PKC by treatment with phorbol ester potentiates the desensitization of the p-opioid
receptor•dinduced K' current (Chen and Yu, 1997). Furthermore, we recently reported that
activation of PKC by phorbol 12,13-dibutyrate leads to the desensitization of p-opioid
receptor-mediated antinociception (Narita et al., 1997). These results suggest that PKC may
be involved in the desensitization of pt-opioid receptor-mediated pharmacological action in
mice.
       Many investigators have reported that hyperglycemia or elevated glucose levels can
increase diacylglycerol (DAG) levels and activate PKC in vascular tissues, cardiac tissues, or
cultured cells (Craven and DeRubertis 1989; King et al. 1990; Tanaka et al. 1991; Inoguchi et
al. 1992). Activation of the DAG-PKC cellular signal pathway is linked to vasculature
dysfunction in diabetes (Craven and DeRubertis 1989; Wolf et al. 1990; Shiba et al. 1993).
Furthermore, Ahlgen and Levine (1994) reported that both the mechanical behavioral
hyperalgesia and C-fiber hyperexcitability in response to mechanical stimuli seen in
streptozotocin-induced diabetic rats are reduced by agents that inhibit PKC. This result
suggests that increased PKC activity might alter the excitabiiity of primary afferent
nocieeptors. It is possible that PKC may be involved in the desensitization of p-opioid
-
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receptor-mediated pharmacological actions in the mice. Thus, in Experiment 1-2, I examined
the effects ofa PKC activator and inhibitor on the i.c.v. morphine-induced Straub tai1 reaction
in diabetic and non-diabetic mice. Furthermore, in Experiment 1-3, the role of PKC in the
attenuation ofthe antinociception induced by DAMoo in diabetic mice was examined.
       There is considerable evidence ofa close relationship between opioid antinociception
and Ca2' levels within the central nervous system. Agents that increase cytosolic Ca2' in
neurons and synaptosomes block opioid antinociception when injected i.c.v. Hano et al.
(1964) reported that intracisternal administration of Ca2' antagonizes the antinociceptive
effect of morphine, a prototype p-opioid receptor agonist. The ionophores X-537A and
A23187, which facilitate Ca2' uptake by ceils, also block morphine-induced antinociception.
(Hanis et al., 1975; Vocci et al., 1980). Since ionophores act mainly by increasing
intracellular Ca2', it has been postulated that Ca2' alters intracellular events to antagonize the
antinociceptive effects of morphine (Chapman and Way, 1980). Conversely, Ca2' chelators
(i.e., ethylene glycol bis(B-aminoethyl ether)N,N'-tetraacetic acid (EGTA)) or Ca2' channel
antagonists of the verapamil, diltiazem and dihydropyridine types potentiate opioid
antinociception (Ben-Sreti et al., 1983; Hoffmeister and Tettenborn, 1986).
       Considerable evidences suggest that calcium signaling is abnormal in cardiac
myocytes (Nobe et al., 1990), vascular smooth muscle (Kamata et al., 1988) and other tissues
(Levy et al., 1994) from diabetic animals. A recent study has shown that verapamil has a
beneficial effect on the cardiac function of diabetic rats without affecting glucose metabolism
or insulin secretion (Afzal et al., 1988). It has been suggested that chronic excessive
intracellular calcium overload might induce cardiac dysfunction in chronic diabetes (Heyliger
et al., 1987; Nishio et al., 1990). Moreover, it has been suggested that the diabetic state may
change [Ca2']i in neuron and various tissues (Lowery et al., 1990; Hall et al., 1995; Kostyuk
et al., 1995). It is possible that increased cytosolic calcium may play an important role in the
modification of pa and 5-opioid receptor-mediated antinociception by diabetes. Thus, to test
this hypothesis, in Experiment 1-4, I examined the effect of intracellular calcium modulators
on the change in p- and 6-opioid receptor agonist-induced antinociception in diabetic and
non-diabetic mice.
-
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Experiment 1-1: Effects of diabetes on the morphine-induced Straub tail reaction in
                                 mice.
Materials and Methods
Animals
       Male ICR mice (Tokyo Animal Laboratories Inc., Tokyo, Japan), weighing about 20
g at the beginning ofthe experiments, were used. They had free access to food and water in an
animal room which was maintained at 22 Å} 2 OC with a 12-h light-dark cycle. Animals were
rendered diabetic by an injection of streptozotocin (200 mglkg, i.v.) prepared in O.1 N citrate
buffer at pH 4.5. Age-matched non-diabetic mice were injected with vehicle alone. The
experiments were conducted two weeks after injection of streptozotocin or vehicle. Mice with
serum glucose levels above 400 mgldl were considered diabetic.
Procedure
       The Straub tail reaction was graded using a minor modification of the numerical
scores ofKameyama et al. (1978) as follows; O = OO, O.5 = 1-300, 1 = 31-450, 1.5 = 46-600, 2.0
=
 61-900, 2.5 = more than 900. The angle was measured above the horizontal plane of the
table. Morphine was injected subcutaneously (s.c.). The Straub tail reaction was observed 20
min after s.c. administration of morphine. Motor coordination in mice was measured using
rotarod performance apparatus (3 cm in diameter, 3.25 rpm; Natsume Co., Tokyo, Japan).
Drugs
       Morphine hydrochloride was obtained from Sankyo Co. (Tokyo, Japan). 3-
Funaltrexamine and naloxonazine were synthesized by Dr. Nagase (Toray Industries, Inc.,
Kamakura, Japan). B-Funaltrexamine (20 mglkg, s,c.) and naloxonazine (35 mglkg, s.c.) were
given to mice 24 h prior to morphine treatment. The dose and schedule for B-funaltrexamine
and naloxonazine treatment in this study were determined according to previous report
(Kamei et al., 1992b, 1993a). Drugs were dissolved in O.9 O/o saline solution.
Statistical analysis
       Data are shown as the mean Å} S.E. One-way ANOVA followed by Dunnett's multiple
comparison test was used for the statistical evaluation.
-
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Results
       The pre-drug Straub tail reaction score is zero in both non-diabetic and diabetic mice.
As shown in Fig. 1-1, s.c. administration of morphine, at doses of 3 - 10 mglkg, dose-
dependently increased the Straub tail reaction score in both non-diabetic and diabetic mice.
Mice with diabetes showed significantly less sensitivity in the morphine-induced Straub tail
reaction. Indeed, there was a significant difference in the intensity of the Straub tail reaction
induced by 3, 5.6 and 10 mglkg of morphine between non-diabetic mice and diabetic mice
(Fig. 1-1). When the mice were pretreated with naloxonazine, the Straub tail reaction induced
by morphine (1O mglkg, s.c.) in both non-diabetic and diabetic mice was significantly reduced
(Table 1-1). Furthermore, the Straub tail reaction induced by morphine (10 mglkg, s.c.) was
also antagonized by pretreatment with B-funaltrexamine in both non-diabetic and diabetic
mice (Table 1-1).
       On the other hand, there was no significant difference in the duration of rotarod
performance between diabetic (114.7 Å} 25.5 s, n=6) and non-diabetic (110.0 Å} 16.4 s, n=7)
mice.
-
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Figure 1-1. Dose-response curves for the morphine-induced Straub tai1 reaction in diabetic
(open circle) and diabetic (closed circle) mice. The Straub tai1 reaction was graded using
numerical scores, and was observed 20 min after s.c. administration ofmorphine. "PÅqO.05
vs. non-diabetic mice.
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Table 1
Antagonism ofthe s.c. morphine-induced Straub tail reaction by pt-opioid receptor antagonists
in non-diabetic and diabetic mice.
Treatments Tail reaction scores
Non-diabetic mice Diabetic mice
Morphine
Morphine+B-funaltrexamine
Morphine+naloxonazine
1.90 Å} O. 18
Q90 Å} O. 16**
085 Å} O. 13**
1.30Å}O.15#
O. 75 Å} O. I5*
Q70 Å} O. 13**
The Straub tail reaction was observed 20 min after the s.c. administration of morphine (10
mgfkg). Each group consisted of 1O mice. Mice were treated with B-funaltrexamine (20 mglkg,
s.c.) or naloxonazine (35 mg/kg, s.c.) 24 h before testing.
#PÅqO.05 vs. non-diabetic mice. "PÅqO.05 and ""PÅqO.Ol vs. morphine alone.
-
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Experiment 1-2: Possible involvement of protein kinase C in the attenuation of the
morphine--induced Straub tail reaction in diabetic mice
Materials and Methods
Animals
      Male ICR mice (Tokyo Laboratory Animals Science Co., Tokyo), weighing about 20
g at the beginning of the experiments, were used. The mice were housed under the condition
as described in Chapter 1-1. Animals were rendered diabetic by an injection of streptozotocin
(200 mglkg, i.v.) prepared in O.1 N citrate buffer at pH 4.5. Age-•matched non-diabetic mice
were injected with vehicle alone. The experiments were conducted 2 weeks after injection of
streptozotocin or vehicle. Mice with serum glucose levels above 400 mgldl were considered
diabetic.
Measurement of the Straub tail reaction
      The Straub tail reaction was graded using a minor modification of the numerical
scoring system as described in Chapter 1-1. The angle was measured above the horizontal
Intracerebroventricular injection
      Intracerebroventricular (i.c.v.) administration was performed following the method
described by Haley and McCormick (1957) using a 50-pl Hamilton syringe. The injection site
was 1.5 mm from the mid line, O mm from the bregma and 3.0 mm from the surface of the
sku11. Injection volumes for i.c.v. administration were 5 pt1.
Drugs
      The drugs used were streptozotocin (Sigma Chemical Co., St. Louis, MO) and
morphine hydrochloride (Sankyo Co., Tokyo, Japan). Calphostin C and phorbol-12,13-
dibutyrate (PDBu) were purchased from Calbiochem-Novabiochem International (San Diego,
CA), and were injected lh before the i.c.v. injection of morphine. The dose and schedule for
-
20-
calphostin C and PDBu in this study were determined as described previously (Narita et al.
1997).
Data analysis
       The data are expressed as means Å} S.E. The statistical significance of differences
between groups was assessed with an analysis of variance (ANOVA) followed by the
Bonferroni test. The potency ratio for non-diabetic mice and diabetic mice was calculated
using Program 11 ofthe Pharmacological Calculation system of Tallarida and Murray (1987)
-
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Results
Effects of a protein kinase C activator, phorbol 12,13-dibutyrate (PDBu), on the
morphine--induced Straub tail reaction in diabetic and non-diabetic mice.
       As shown in Fig. 1-2A, i.c.v. administration of morphine, 15 ptg, induced a Straub
tail reaction in both diabetic and non--diabetic mice. Mice with diabetes showed significantly
less sensitivity in the i.c.v. morphine-induced Straub tail reaction. I.c.v. pretreatment with
PDBu (10 and 50 pmol) 60 min prior to an i.c.v. challenge with morphine (15 pg) attenuated
the morphine-induced Straub tail reaction in non-diabetic mice. In diabetic mice, however,
PDBu had no significant effect on the morphine (15 pg)-induced Straub tail reaction (Fig. 1-
2A). As shown in Fig. IB, i.c.v. pretreatment with calphostin C (10 pmol) 60 min prior to an
i.c.v. injection of morphine did not affect the morphine-induced Straub tail reaction in non-
diabetic mice. In diabetic mice, i.c.v. pretreatment with calphostin C, at doses of 3, and 10
pmol, progressively enhanced the morphine-induced Straub tail reaction (Fig 1-2B).
       The i.c.v.-administered morphine-induced Straub tail reaction in diabetic mice was
less than that in non-diabetic mice, as evidenced by a 2.3-fold rightward shift in the dose-
response curve (Fig. 1-3). As shown in Fig. 1-3, i.c.v. pretreatment with a protein kinase C
(PKC) activator, PDBu, at a dose of 50 pmol attenuated the i.c.v. morphine-induced Straub
tail reaction in non-diabetic mice; the dose response curve for the morphine-induced Straub
tail reaction was markedly shifted to right by 2.1-fold. The potency ratio (950/o CL) of the
morphine-induced Straub tail reaction in PDBu--treated non-diabetic mice versus that in
vehicle-treated non-diabetic mice was 2.1 (1.4 - 4.3) (Fig. 1-3). In contrast, the i.c.v.
morphine-induced Straub tail reaction in diabetic mice was not affected by i.c.v. pretreatment
with PDBu (Fig. 1-3). I.c.v. pretreatment with a PKC inhibitor, calphostin C, did not affect the
morphine-induced Straub tail reaction in non-diabetic mice (Fig. 1-3), but enhanced in
diabetic mice. The dose-response curve for the morphine-induced Straub tail reaction in latter
mice was markedly shifted to the left by 2.8--fold. The potency ratio (95 O/o CL) of the
morphine-induced Straub tail reaction in calphostin C-treated diabetic mice versus that in
-
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vehicle-treated diabetic mice was 2.8 (2.3 - 3.5) (Fig. 1-3). There was no significant
difference in the potency ofthe morphine-induced Straub tail reaction between calphostin C-
treated diabetic mice and naive non-diabetic mice. The potency ratio (95 O/o CL) of the
morphine-induced Straub tai1 reaction in calphostin C-treated diabetic mice versus that in
naive non-diabetic mice was 1.0 (O.98 - 1.07).
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Figure 1-2. Effect ofi.c.v. pretreatment with phorbol 12,13-dibutyrate (PDBu; A) and
calphostin C (B) on the i.c.v. morphine-induced Straub tai1 reaction. PDBu (1O and 50
pmol) or calphostin C (1 or 3 pmol) was injected i.c.v. 60 min before administration of
morphine (15 ml, i.c.v.). The Straub tai1 reactionwas graded using numerical scores, and
was observed 20 min after the i.c.v. administration ofmorphine. Each column represents
the mean with S.E. for 9-15 mice in each group. *PÅqO.05 vs. non-diabetic mice. #PÅqO.05
vs. respective vehicle treated group.
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Figure 1-3. Effects of i.c.v. pretreatment with phorbol 12,13-dibutyrate (diamond) and
calphostin C (triangle) on the dose-response curve for the i.c.v. morphine-induced
Straub tai1 reaction in diabetic (closed symbol) and non-diabetic mice (open symbol).
Phorbol 12,13-dibutyrate (50 pmol) or calphostin C (3 pmol) was injected i.c.v. 60 min
before the administration of morphine. The Straub tail reaction was graded using
numerical scores, and was observed 20 min after the i.c.v. administration of morphine.
Each column represents the mean with S.E. for 9-15 mice in each group. "PÅqO.05 vs.
non-diabetic mice. #PÅqO.05 vs. respective vehicle treated group.
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Experiment 1-3: Possible involvement ofprotein kinase C in the attenuation of
           DAMGO-induced antinociception in diabetic mice.
Materials and Methods
Animals
       Male ICR mice (Tokyo Laboratory Animals Science Co., Tokyo), weighing about 20
g at the beginning of the experiments, were used. The mice were housed under the condition
as described in Chapter 1-1. Animals were rendered diabetic by an injection of streptozotocin
(200 mg/kg, i.v.) prepared in O.1 N citrate buffer at pH 4.5. Age-matched non-diabetic mice
were injected with vehicle alone. The experiments were conducted 2 weeks after injection of
streptozotocin or vehicle. Mice with serum glucose levels above 400 mg/dl were considered
diabetic.
Antinociceptive assay.
       The antinociceptive response was evaluated by recording the latency in the tail-fiick
test using radiant heat as a stimulus. The intensity ofthe thermal stimulus was adjusted so that
the animal fiicked its tail in 2-4 s. A cut-off latency of30 s was used to prevent injury to the
tail. Animals which did not respond within 30 s were removed and assigned a score of 30 s.
The percent maximum possible effect (O/oMPE) was calculated for each animal as O/oMPE --
1OO x (post drug latency - pre drug latency)1(30 - pre drug latency).
Intracerebroventricular inj ection
       Intracerebroventricular (i.c.v.) administration was performed following the method
described in Chapter 1-2.
Drugs
       The following drugs were used: streptozotocin (Sigma Chemical Co., St. Louis, MO,
USA), [D-Ala2, N-MePhe`, Gly-o15] enkephalin (DAMGO; Peninsula Laboratories, Inc., San
Carlos, CA, USA), phorbol 12,13-dibutyrate (PDBu; Calbiochem-Novabiochem International,
San Diego, CA, USA) and calphostin C (Calbiochem-Novabiochem International, San Diego,
CA, USA). PDBu and calphostin C were dissolved in ethanol O.10/o in saline (O.90/o NaCl
solution). DAMGO was dissolved in saline. The doses of opioid agonist, PDBu and
-
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calphostin C in this study were determined as described previously (Narita et al. 1997).
Data ana]ysis
       The data are expressed as means Å} S.E. The statistical significance of differences
between groups was assessed with Student's t test (comparison of two groups) or an analysis
ofvariance (ANOVA) followed by the Bonferroni test (comparisons among multiple groups).
The potency ratio for non-diabetic mice and diabetic mice was calculated using Program 1 1 of
the Pharmacological Calculations system ofTallarida and Murray (1987).
-
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Results
Effect of i.c.v. pretreatment with phorbol 12,13-dibutyrate (PDBu) on the
antinociceptive effect induced by i.c.v.-administered DAMGO in diabetic and non-
diabetic mice.
       As shown in Fig. 1-4, i.c.v. administration of DAINt[GO (10 ng) produced an
average O/orvff'E of 84.2 Å} 9.3 O/o and 33.3 Å} 8.4 O/o in non-diabetic and diabetic mice,
respgctively. Diabetic mice were significantly less sensitive to i.c.v. DA]NilGO than non-
diabetic mice, as assessed by the tail-flick test. Pretreatment with PDBu (50 pmol, i.c.v.) 60
min prior to an i.c.v. challenge with DrmGO attenuated the antinociceptive effect of
DAINilGO (10 ng) in non-diabetic mice. The attenuation ofDAIV[GO-induced antinociception
in non-diabetic mice was reversed by concomitant pretreatment with calphostin C (3 pmol,
i.c.v.) In diabetic mice, however, PDBu (50 and 100 pmol) had no significant effect on the
antinociceptive effect ofDAINilGO (1O ng).
Effects of i.c.v. pretreatment with calphostin C on DAMGO-induced antinociception in
diabetic and non-diabetic mice.
       As shown in Fig. 1-5A, pretreatment with calphostin C, at a dose of 3 pmol, i.c.v.,
did not affect DA]N,fGO (10 ng, i.c.v.)-induced antinociception in non-diabetic mice.
Furthermore, calphostin C, at a dose of 3 pmol, also had no effect on the antinociception
induced by a lower dose (3 ng, i.c.v.) of DA]Nt[GO-induced antinociception. However,
pretreatment with a higher dose (10 pmol, i.c.v,) of calphostin C for 60 and 120 min
significantly increased DAMGO (3 ng, i.c.v.)-induced antinociception in non-diabetic mice
(Fig. 1--6).
       In diabetic mice, pretreatment with calphostin C (3 pmol, i.c.v.) for 60, 120 and 240
min, but not for 30 min, progressively increased DAMGO-induced antinociception. DnmGO
produced dose-dependent antinociception at 5.6-30 ng i.c.v. in diabetic mice and 3-10 ng i.c.v.
in non-diabetic mice. The antinociceptive potency ofi.c.v. Dnmoo in diabetic mice was less
than that in non-diabetic mice, as evidenced by a 2.3-fold rightward shift in the dose-response
curve for DAMoo-induced antinociception (Fig. 1-5B). Figure 1-5B shows that pretreatment
with calphoStin C (3 pmol, i.c.v.) for 60 min can prevent the rightward shift in the DAMoo
dose-response curve, which is indicative ofa decreased potency ofDAMoo in diabetic mice.
However, pretreatment with calphostin C (3 pmol) for 60 min had no effect on the dose-
-
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response curve for DAMGO-induced antinociception in non-diabetic mice.
       The effects of various doses of calphostin C on the antinociceptive effect of
DA]VIGO in both diabetic and non-diabetic mice are shown in Fig. 1-7. Pretreatment with
calphostin C for 60 min, at doses of1 to 20 pmol, did not have any effect on the
antinociception induced by DAMoo (10 ng). In diabetic mice, pretreatment with calphostin
C dose-dependently increased the antinociceptive effect ofDAMGO (1O ng).
-
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Figure 1-4. Effeot of i.c.v. pretreatment with phorbol 12,13-dibutyrate (PDBu) on
DAMGO-induced antinociception in diahetic and non-diabetic mice. PDBu (50 or 100
pmol) alone or a combination ofPDBu (50 pmol) and calphostin C (CP; 3 pmol) was
injected 60 min before the administration of DAMGO (10 ng, i.c,v.), Mice were tested
10 min after the injection ofDAMGO in the tai1-flick test. Each column represents the
mean with S.E. for 1O mice in each group. #PÅqO.05 compared with the vehicle-pretreated
group. "PÅqO.05 compared with respective non-diabetic mice.
-
30-
A Non-diabeticmice
100
N
E 50
tss"
o
Diabetic mice
30 60 120 240 30 60 120
#
240 (min)
Time
  B
100
ee
: 50
es"Åq
              o
                    3 5.6 10 30
                      DAMGO (ngtmouse, i.c.v,)
Figure 1-5. (A) effect ofcalphostin C (3 pmol, hatched column) on DAMGO-induced
antinociception after different pretreatment times in diabetic and non-diabetic mice. B)
effect ofi.c.v. pretreatment with calphostin C (3 pmol, closed symbol) and its vehicle
(open symbol) on the dose-response curves for DAMGO-induced antinociception in
diabetic (diamond) and non-diabetic (circle) mice, Calphostin C (3 pmol) was injected
i.c.v. 30, 60, 120 and 240 min (A) or 60 min (B) before the administration of DAMGO
(10 ng i.c.v.). Mice were tested 10 min after the injection ofDAMGO in the tail flick
test. Each column represents the mean with S,E. for 10 mice in each group. #PÅqO.05
compared with the vehiclepretreated group (open colunm). *PÅqO.05 compared with
respective non-diabetic mice.
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Figure 1-6. The effect of calphostin C on DAMGO-induced antinociception in non-
diabetic mice afiter difl7erent pretreatment times. Calphostin C (3 pmol, hatched column;
10 pmol, closed dotted column) was injected i.c.v. 60, 120 and 240 min before the
administration of DAMGO (5.6 ng, i.c.v,). Mice were tested 10 min after the injection
ofDAMGO in the tail-flick test. Each column represents the mean with S.E for 10 mice
in each group. "PÅqO.05 compared with the vehicle-pretreated group (open colurnn).
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Figure 1-7. Dose-response effect of i.c.v. pretreatment with calphostin C on DAMGO-
induced antinociception in diahetic and non-diabetic mice. Calphostin C and vehicle
(Vehi) were injected i.c.v. 60 min before the administration of DAMGO. Mice were
tested 10 min after the injection of DAMGO in the tai1-fiick test. Each column
represents the mean with S.E. for 10 mice in each group. #PÅqO.05 compared with the
vehicle-pretreated group. *PÅqO.05 compared with respective non-diabetic mice.
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Experiment 1-4: RoRe of intracellular calcium in modification of p- and 5-opioid
          receptor-mediated antinociception by diabetes in mice.
Materials and Methods
Animals
       Male ICR mice (Tokyo Laboratory Animals Science Co., Tokyo), weighing about 20
g at the beginning of the experiments, were used. The mice were housed under the condition
as described in Chapter 1-1. Animals were rendered diabetic by an injection of streptozotocin
(200 mglkg, i.v.) prepared in O.1 N citrate buffer at pH 4.5. Age••matched non-diabetic mice
were injected with vehicle alone. The experiments were conducted two weeks after injection
of streptozotocin or vehicle. Mice with serum glucose levels above 400 mg/dl were
considered diabetic.
Antinociceptive assay .
       The antinociceptive response was evaluated by recording the latency in the tail-fiick
test using radiant heat as a stimulus. The intensity ofthe thermal stimulus was adjusted so that
the animal flicked its tail in 2-4 s, To obtain the same magnitude of antinociceptive potency,
cut-off latencies of 10 and 30 sec were used for (-)-TAN67 and DAIVIGO, respectively.
Animals which did not respond within the cut-off time were removed and assigned a score
equivalent to the cut-offtime. The percent maximum possible effect (O/oMPE) was calculated
for each animal as O/oMPE = IQO Å~ (post-drug latency - pre-drug latency)1(cut-offtime - pre-
drug latency)
Intracerebroventricular inj ection
       Intracerebroventricular (i.c.v.) administration was performed following the method
described in Chapter 1-2.
Drugs
       The following drugs were used: streptozotocin (Sigma Chemical Co., St. Louis, Mo,
USA), [D-Ala2, N-MePhe`, Gly-olS]enkephalin (DAMoo; Peninsula Laboratories, Inc., San
Carlos, CA, USA), thapsigargin (Research Biochemical International, Natic, MA), ryanodine
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(Calbiochem-Novabiochem, San Diego, CA), EGTA (Sigma Chemical Co., St. Louis, Mo,
USA) and (-)-TAN67. (-)-TAN67 was synthesized by Dr. Nagase (Toray Laboratory,
Kamakura, Japan). Thapsigargin was dissolved in 200/o DMSO in saline (O.90/o sodium
chloride solution). DArvfGO, (-)-TAN67, EGTA, CaCl, and ryanodine were dissolved in
physiological saline. Thapsigargin was injected 1 h before the injection of agonists.
Ryanodine and CaC12 were injected 10 min before the injection of agonists. EGTA was
injected 15 min before the admjnistration of agonists. The dose and schedule for each opioid
agonist, EGTA, CaCl,, ryanodine and thapsigargin in this study were determined as described
previously (Smith and Stevens, 1995; Kamei et al., 1997)
Data analysis
       The data are expressed as means Å} S.E. The statistical significance ofdifferences
between groups was assessed with an analysis of variance (ANOVA) followed by the
Bonferroni test. The potency ratio for non-diabetic mice and diabetic mice was calculated
using Program 11 ofthe Pharmacological Calculation system ofTallarida and Murray (1987)
-
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Results
Effects of i.c.v. CaC12 and EGTA on DAMGO-induced antinociception in diabetic and
non-diabetic mice
       CaC12 injected i.c.v. (100-300 nmol) significantly and dose-dependently reduced the
antinociceptive effect ofDAMoo (10 ng, i.c.v.) in non-diabetic mice (Fig. 1-8A). As shown
in Fig. 1-8B, DAMoo given i.c.v. at doses of3-10 ng caused a dose-dependent inhibition of
the tail-flick response in non-diabetic mice. I.c.v. pretreatment with CaC12 (300 nmol)
attenuated this inhibition of the tail-flick response induced by i.c.v. DAMoo in non-diabetic
mice; the dose-response curve for DAMoo-induced antinociception was shifted to the left.
The potency ratio (950/o confidence limits (CL)) of DA]V[GO-induced antinociception in
calcium-treated non-diabetic mice versus saline-treated non-diabetic mice was 2.2 (2.0-2.5).
On the other hand, in diabetic mice, DAMoo (30 ng, i.c.v.)-induced antinociception was not
reduced by i.c.v. pretreatment with CaCl, (100-300 nmol; Fig. 1-8A). Moreover, CaCl, (300
nmol, i.c.v.) did not affect the potency ofDA]V[GO in diabetic mice. The potency ratio (950/o
CL) of antinociceptive effect of DAMoo in calcium-treated diabetic mice versus that in
saline-treated diabetic mice was 1.2 (1.0-1.3) (Fig. 1-8B). I.c.v. pretreatment with CaCl, (300
nmol) by itself had no effect on the baseline tail-flick latencies in diabetic (mean tail-flick
latencies of 2.59 Å} O.17 s, n=10 for before CaCl, treatment; 2.60 Å} O.12 s, n=10 for after
CaC12 treatment) and non-diabetic mice (mean tail-fiick latencies of 2.73 Å} O.14 s, n=10 for
before CaC12 treatment; 2.70 Å} O.15 s, n=10 for after CaCl, treatment). Furthermore, CaCl2
(100-300 nmol, i.c.v.) did not produce apparent behavioral changes, such as convulsion and
hyperlocomotion, in diabetic and non-diabetic mice.
       EGTA injected i.c.v. (1-60 nmol) significantly enhanced the antinociceptive effect of
DA]V[GO (5.6 ng, i.c.v.) in non-diabetic mice (Fig. 1-9A). Furthermore, i.c.v. pretreatment
with EGTA (30 nmol) enhanced the inhibition of the tail-flick response induced by i.c.v.
DAIV[GO in non-diabetic mice; the dose-response curve for DAIV[GO-induced antinociception
was shifted to the left. The potency ratio (950/o CL) of the DAMoo-induced antinociception
in EGTA-treated non-diabetic mice versus that in saline-treated non-diabetic mice was
2.5(1.7-3.7). Furthermore, in diabetic mice, DAMoo (10 ng, i.c.v.)-induced antinociception
was potentiated by i.c.v. pretreatment with EGTA (1-60 nmol; Fig. 1-9A). However,
significant potentiation ofDA]V{GO-induced antinociception was observed in diabetic mice at
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a higher dose of EGTA (30 and 60 nmol; Fig. 1-9A). EGTA (30 nmol, i.c.v.) increased the
potency of DAIV[GO in diabetic mice; the dose-response curve for DAIN([GO-induced
antinociception was shifted to the left. The potency ratio (950/o CL) of the antinociceptive
effect ofDAMoo in EGTA-treated diabetic mice versus that in saline-treated diabetic mice
was 2.4 (2.3-2.5) (Fig. 1-9B). Moreover, i.c.v. pretreatment with EGTA (60 nmol) by itself
had no effect on the tail-fiick latencies in diabetic (mean tail-flick latencies of 2.62 Å} O.13 s,
n= 10 for before EGTA treatment; 2.56 Å} O.14 s, n=10 for after EGTA treatment) and non-
diabetic mice (mean tail-fiick latencies of 2.59 Å} O.21 s, n=10 for before EGTA treatment;
2.64 Å} O.20 s, n==10 for after EGTA treatment). Furthermore, EGTA (1-60 nmol, i.c.v.) did not
affect general behavior in diabetic and non-diabetic mice.
Effects of i.c.v. CaCl2 and EGTA on (-)-TAN67-induced antinociception in diabetic and
non-diabetic mice
       In contrast with DA]N4GO, as shown in Fig. 1-10A, i.c.v. pretreatment with CaC12
(300 nmol) enhanced the inhibition ofthe tail-fiick response induced by i.c.v. (-)-TAN67 in
non-diabetic mice; the dose-response curve for (-)-TAN67-induced antinociception was
markedly shifted to the left. The potency ratio (950/o CL) of (-)-TAN67-induced
antinociception in calcium-treated non-diabetic mice versus saline-treated non-tdiabetic mice
was 3.6 (3.1-4.2). However, in diabetic mice, i.c.v. pretreatment with CaCl, (300 nmol) did
not affect (-)-TAN67-induced antinociception (Fig. 1-10A). The potency ratio (950/o CL) of
(-)-TAN67-induced antinociception in calcium-treated diabetic mice versus saline-treated
diabetic mice was 1.2 (O.8-1.8). As shown in Fig. 3B, i.c.v. pretreatment vvith EGTA (10
nmol) attenuated the inhibition of the tail-flick response induced by i.c.v. (-)-TAN67 in non-
diabetic mice; the dose-response curve for (-)-TAN67-induced antinociception was markedly
shifted to the right. The potency ratio (950/o CL) of (-)-TAN67-induced antinociception in
EGTA-treated non-diabetic mice versus saline-treated non-diabetic mice was 4.1 (2.3-9.1). In
diabetic mice, i.c.v. pretreatment with EGTA (10 nmoi) attenuated (-)-TAN67-induced
antinociception; the dose-response curve for (-)-TAN-67-induced antinociception was shifted
to the right (Fig. 1-10B). The potency ratio (950/o CL) of(-)-TAN67-induced antinociception
in EGTA-treated diabetic mice versus saline-treated diabetic mice was 7.7 (5.8-10.4).
-
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Effects of thapsigargin and ryanodine on DAMGO-induced antinociception in diabetic
and non-diabetic mice
       Thapsigargin injected i.c.v. (O.3-3 nmol) significantly and dose-dependently reduced
the antinociceptive effect ofDA]NilGO (10 ng, i.c.v.) in non-diabetic mice (Fig 1-11A). As
shown in Fig. 1-11B, i.c.v. pretreatment with thapsigargin (3 nmol) attenuated the inhibition
ofthe tail-flick response induced by i.c.v. DA]V[GO in non-diabetic mice; the dose-response
curve for DA]N4GO-induced antinociception was markedly shifted to the right. The potency
ratio (950/o CL) ofthe antinociceptive effect ofDrmGO in thapsigargin-treated non-diabetic
mice versus vehicle-treated non-diabetic mice was 3.0 (2.5-3.8). However, in diabetic mice,
DA}vlGO (30 ng, i.c.v.)-induced antinociception was not affected by i.c.v. pretreatment with
thapsigargin (3 nmol; Fig. 1-11A). I.c.v. pretreatment with thapsigargin did not affect the
potency of DAMoo in diabetic mice (Fig. 1-11B). The potency ratio (950/o CL) of the
antinociceptive effect ofDAIV[(iK) in thapsigargin-treated diabetic mice versus vehicle-treated
diabetic mice was 1.0 (1.0-1.1). I.c.v. pretreatment with thapsigargin (3 nmol) by itself, had
no effect on the tail-flick latencies in diabetic (tail-fiick latencies of2.72 Å} O.16 s, n==8 for
before thapsigargin treatment; 2.72 Å} O.16 s, n=8) and non-diabetic mice (mean tail-flick
latencies of2.71 Å} O.22 s, n=9 for before thapsigargin treatment; 2.83 Å} O.11 s, n==9 for after
thapsigargin treatment). Furthermore, thapsigargin (O.3-3.0 nmol, i.c.v.) did not produce any
apparent behavioral change in diabetic and non-diabetic mice, while it has been reported that
thapsigargin potently affect the intracellular calcium level (Takemura et al., 1991; Premack et
al., 1994).
       Ryanodine injected i.c.v. (O.3-3 nmol) significantly and dose-dependently enhanced
the antinociceptive effect of DAMoo (5.6 ng, i,c.v.) in non-diabetic mice (Fig. 1-12A).
Furthermore, ryanodine (3 nmol, i.c.v.) significantly enhanced the potency of DAMoo in
non-diabetic mice; the dose-response curve for DA)vfGO-induced antinociception as shifted to
the left (Fig. 1-12B). The potency ratio (95e/o CL) of DA])vrfGO-induced antinociception in
ryanodine-treated non--diabetic mice versus saline-treated non-diabetic mice was 2.2 (1.9-2.6).
In diabetic mice, DAIV[GO (10 ng, i.c.v.)-induced antinociception was also dose-dependently
enhanced by pretreatment with ryanodine (O.3-3 nmol; Fig. 1-12A). Moreover, ryanodine (3
nmol, i.c.v.) enhanced the potency ofDAMGO in diabetic mice; the dose-response curve for
DAIV[GO-induced antinociception was markedly shifted to the left (Fig. 1-12B). The potency
ratio (950/o CL) of DAMGO-induced antinociception in ryanodine-treated diabetic mice
versus saline-treated diabetic mice was 4.4 (4.0-4.8). I.c.v. pretreatment with ryanodine (3
-
38-
nmol) by itself did not affect the taii-flick latencies in diabetic (mean tai1-flick latencies of
2.78 Å} O.18 s, n--10 for before ryanodine treatment; 2.53 Å} O.12 s, n=10 for after ryanodine
treatment) and non-diabetic mice (mean tail-flick latencies of 2.36 Å} O.11 s, n=10 for before
ryanodine treatment; 2.31 Å} O.07 s, n=10 for after ryanodine treatment). Furthermore,
ryanodine (O.3-3 nmol) did not affect the general behavior in diabetic and non-diabetic mice.
Effects of thapsigargin and ryanodine on (-)-TAN67-induced antinociception in diabetic
and non-diabetic mice
       As shown in Fig. 1-13A, i.c.v. pretreatment with thapsigargin (3 nmol) potentiated
the inhibition of the tail-flick response induced by i.c.v.-administered (-)-TAN67 in non-
diabetic mice; the dose-response curve for (-)-TAN67-induced antinociception was markedly
shifted to the left. The potency ratio (950/o CL) of (-)-TAN67-induced antinociception in
thapsigargin-treated non-diabetic mice versus vehicle-treated non-diabetic mice was 3. 1 (2.5-
3.9). In diabetic mice, i.c.v pretreatment with thapsigargin (3 nmol) did not affect (-)-TAN67-
induced antinociception (Fig. 1-13A). The potency ratio (950/o CL) of (-)-TAN67•-induced
antinociception in thapsigargin-treated diabetic mice versus vehicle-treated diabetic mice was
1.4 (O.8-2.6). Ryanodine (3 nmol, i.c.v.) did not affect the potency of (-)-TAN67 in non-
diabetic mice (Fig. 1-13B). The potency ratio (950/o CL) of (-)-TAN67-induced
antinociception in ryanodine-treated non-diabetic mice versus saline-treated non-diabetic
mice was l.O (O.7-1.4). In diabetic mice, however, ryanodine (3 nmol, i.c.v.) attenuated (-)-
TAN67-induced antinociception; the dose-response curve for (-)-TAN67-induced
antinociception was markedly shifted to the right (Fig. 1-13B). The potency ratio (950/o CL) of
(-)-TAN67-induced antinociception in ryanodine-treated diabetic mice versus saline-treated
diabetic mice was 4.0 (2.7--6.2).
-
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Figure 1-7. (A) dose-response effect ofi.c.v. pretreatment with CaC12 (100 and 300 nmol,
hatched column) on DAMGO (10 or 30 nmol, i.c.v.)-induced antinociception in diabetic
and non-diabetic mice. (B) effect of i.c.v. pretreatment with CaC12 (300 nmol, closed
symbol) and its vehicle (open symbol) on the dose-response curve for DAMGO-induced
antinociception in diabetic (diamond) and non-diabetic mice (circle). Non-diabetic mice
injected with DAMGO received either saline (open circles) or CaC12 (300 nmol, closed
circles). Diabetic mice injected with DAMGO received either saline (open diamonds) or
CaC12 (300 nmol, closed diamonds). CaC12 was injected 10 min before the administration
ofDAMGO. Mice were tested 10 min after the injection ofDAMGO in the tail-fiick test.
Each column and point represents the mean with S.E. for 10-15 mice in each group.
"PÅqO.05 compared with respective non-diabetic mice. #PÅqO.05 compared with the saline
(open column)-pretreated group.
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Figure 1-8. (A) dose-response effect of i.c.v. pretreatment with EGTA (1-60 nmol,
hatched column) on DAMGO (10 or 5.6 nmol, i.c.v.)-induced antinociception in dial)etic
and non-diahetic mice. (B) effect of i.c.v. pretreatment with EGTA (30 nmol, closed
symbol) and saline (open symbol) on the dose-response curve for DAMGO-induced
antinociception in diabetic (diamond) and non-diabetic mice (circle). Non-diabetic mice
injected with DAMGO received either saline (open circles) or EGTA (30 nmol, closed
circles). Diahetic mice injected with DAMGO received either saline (open diamonds) or
EGTA (30 nmol, closed diamonds). EGTA was injected 15 min before the
administration ofDAMGO. Mice were tested 10 min after the injection ofDAMGO in
the tail-flick test. Each column and point represents the mean with S.E. for 10-15 mice
in each group. "PÅqO.05 compared with respective non-diabetic mice. #PÅqO.05 compared
with the saline (SA, open column)-pretreated group.
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Figure 1-9. (A) the effect ofi.c.v. pretreatment with CaC12 (300 nmol, closed symbol)
and saline (open circle) on the dose-response curve for (-)-TAN67-induced
antinociception in diabetic (diamond) and non-diabetic (circle) mice. Non-diabetic mice
injected with (-)-TAN67 received either saline (open circles) or CaCl2 (300 nmol, closed
circles). Diabetic mice injected with (-)-TAN67 received either saline (open diamonds)
or CaC12 (300 nmol, closed diamonds). CaC12 was injected 10 min before the
administration of (-)-TAN67, Mice were tested 30 min after the injection of (-)-TAN67
in the tail-fick test. Each point represents the mean with S.E. for 10-15 mice in each
group. (B) the effect of i.c.v. pretreatment with EGTA (10 nmol, closed symbol) and
saline (open symbol) on the dose-response curve for (-•)-TAN67 in diabetic (diamond)
and non--diahetic (circle) mice. Non-diabetic mice injected with (-)-TAN67 received
either saline (open circles) or EGTA (10 nmol, closed circles). Diabetic mice injected
with (-)-TAN67 received either saline (open diamonds) or EGTA (10 nmol, closed
diamonds). EGTA was injected 15 min before the administration of (-)-TAN67. rVlice
were tested 30 min after the injection of (-)-TAN67 in the tail-flick test. Each point
represents the mean with S.E. for 10-15 mice in each group.
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Figure 1-10. (A) dose-response effect of i.c.v. pretreatment with thapsigargin (hatched
column) on DAMGO (30 or 10 nmol, i.c.v.)-induced antinociception in diabetic and
non-diabetic mice. (B) effect of i.c.v. pretreatment with thapsigargin (3 nmol, closed
symbol) and its vehicle (open symbol) on the dose-response curve for DAMGO-
induced antinociception in diahetic (diamond) and non-diabetic mice (circle). Non-
diahetic mice injected with DAMGO received either vehicle (200/o DMSO, open circles)
or thapsigargin (3 nmol, closed circles). Diabetic mice injected with DAMGO received
either vehicle (20e/o DMSO, open diamonds) or thapsigargin (3 nmol, closed diamonds).
Thapsigargin was injected 60 mh before the administration of DAMGO. mace were
tested 10 min after the injection of DAMGO in the tail-flick test. Each column and
point represents the mean with S.E. for 10-15 mice in each group. "PÅqO.05 compared
with respective non-diabetic mice. #PÅqO.05 compared with the vehicle (open column)-
pretreated group.
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Figure 1-11. (A) dose-response effect of i.c.v. pretreatment with ryanodine (hatched
column) on DAMGO (10 or 5.6 nmol, i.c.v.)-induced antinociception in diabetic and
non-diabetic mice. (B) effect of i.c.v. pretreatment with ryanodine (3 nmol, closed
symbol) and its vehicle (open symbol) on the dose-response curve for DAMGO-induced
antinociception in diabetic (diamond) and non-diabetic (circle) mice. Non-diabetic mice
injected with DAMGO received either saline (open circles) or ryanodine (3 nmol, closed
circles). Diabetic mice injected with DAMGO received either saline (open diamonds) or
ryanodine (3 nmol, closed diamonds). Ryanodine was injected 10 min before the
administration ofDAMGO. Mice were tested 10 min after the injection ofDAMGO in
the tail-flick test Each point represents the mean with S.E. for 10-15 mice in each
group.
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Figure 1-12. (A) the effects (3 nmol, closed
circle) and its vehicle (open symbol) on the dose-response curve for (•-)•-TAN67-induced
antinociception in diahetic (diamond) and non-diabetic (circle) mice. Non-diahetic mice
injected with (-)-TAN67 received either vehicle (200/e DMSO, open circles) or
thapsigargin (3 nmol, closed circles). Diabetic mice injected with (-)-TAN67 received
eithervehicle (20e/o DMSO, open diamonds) or thapsigargin (3 nmol, closed diamonds).
Thapsigargin was injected 60 and min before the administration of (-)-TAN67. Mice
were tested 30 min after the injection of (-)-TAN67 in the tail-fiick test. Each point
represents the mean with S.E. for 10-15 mice in each group. (B) the effects of i.c.v.
pretreatment with ryanodine (closed symbol) and saline (open symbol) on the dose-
response curve for (-)-TAN67-induced antinociception in diabetic (diamond) and non-
diabetic (circle) mice. Non-diahetic mice injected with (-)-TAN67 received either saline
(open circles) or ryanodine (3 nmol, closed circles). Diabetic mice injected with (-)-
TAN67 received either saline (open diamonds) or ryanodine (3 nmol, closed diamonds).
Ryanodine was injected 10 min before the administration of (-)-TAN67, Mice were
tested 30 rnin after the injection of (-)-TAN67 in the tail-flick test. Each point
represents the mean with S.E. for 10-15 mice in each group.
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Discussion
       The results of "Experiment 1-1" clearly indicated that the Straub tail reaction
induced by s.c. administration of morphine is significantly antagonized by P-funaltrexamine,
which suggests that p-opioid receptors may play an important role in the morphine-induced
Straub tail reaction. These results are consistent with previous reports ofKameyama and Ukai
(1979) and Narita et al. (1993). In the present study, I also observed that the Straub tail
reaction induced by s.c. administration of morphine is significantly less in diabetic mice than
in non-diabetic mice. This result supports the previous suggestion that mice with diabetes are
selectively hypo-responsive to p-opioid receptor-mediated pharmacological actions (Kamei et
al., 1992a, 1992b). There was no significant difference in the pre-drug Straub tail reaction
score between diabetic and non-diabetic mice. Furthermore, motor incoordination was not
observed in diabetic mice. These results further support the conclusion that the hypo-
responsive to morphine-induced Straub tail reaction in diabetic mice may be due to the
dysfunction of p-opioid receptors, but not of motor coordination.
       It has been proposed that pi-opioid receptors, but not pt,-opioid receptors, mediate
supraspinal antinociception, since Heyman et al. (1988) and Paul et al. (i989) reported that
naloxonazine, a selective pti-opioid receptor antagonist, selectively attenuates i.c.v.
administered DAMGO-induced antinociception, but not intrathecally administered DA]Nt[GO-
induced antinociception. In this regard, Kamei et al. (1992b, 1994a) recently demonstrated
that the antinociceptive effect of i.c.v. morphine in diabetic mice was significantly less than
that in non-diabetic mice. Furthermore, the antinociceptive effect of i.c.v. morphine was
significantly reduced in both diabetic and non-diabetic mice following pretreatment with
naloxonazine (Kamei et al., 1994a). However, there were no significant differences in the
antinociceptive effects of i.t.-administered morphine in diabetic and non-diabetic mice
(Kamei et al., 1992b, 1994a). Moreover, naloxonazine had no significant effect on the
antinociceptive effect of i.t. morphine in either diabetic or non-pdiabetic mice (1994b). The
sensitivities of the antinociceptive effects of i,c.v. and i.t. morphine to naloxonazine agree
with the suggestions of other investigators (Heyman et al., 1988; Paul et al., 1989) that pti-
opioid receptors play a major role in supraspinal antinociception, while p2-opioid receptors
play a major role in spinal antinociception, Based on these results, Kamei et al. (l994a)
previously concluded that mice with diabetes are selectively hypo-responsive to pi-opioid
receptor-mediated pharmacological action, but not to that which is mediated by p2-opioid
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receptors. This hypothesis is further supported by the present results that 1) the Straub tai1
reaction induced by s.c. administration ofmorphine is significantly less in diabetic mice than
in non-diabetic mice, and 2) naloxonazine, a selective pi-opioid receptor antagonist,
significantly reduced the Straub tai1 reaction induced by s.c. administration of morphine in
both non-diabetic and diabetic mice, indicating that pi-opioid receptors play a major role in
the morphine-induced Straub tail reaction.
       Although Murray and Cowan (1990) suggested that supraspinal 6-opioid receptors
are not involved in the opioid agonist-induced Straub tail reaction, the role of spinal 6--opioid
receptors in opioid-induced Straub tai1 reaction is unclear. Narita et al, (1993) suggested that
K-opioid receptors are not involved in opioid-induced Straub tai1 reaction. Furthermore,
Kamei et al. (1992b) also suggested that there was no significant change in the function of
spinal 6-opioid receptors between diabetic and non-diabetic mice. It has been shown that the
morphine-induced Straub tail reaction is produced at the level not only ofthe supraspinal site
but a!so spinal site. In the present study, B-funaltrexamine and naloxonazine only partially
antagonized the morphine-induced Straub tail reaction in both diabetic and non-diabetic mice.
Although the detail mechanisms of this partial antagonism are unclear, it is possible that
spinal 6-opioid receptors might be involved in the morphine•-induced Straub tai1 reaction.
Further studies are needed to resolve this problem.
       There have been several suggestions regarding the possible functions of protein
kinase C (PKC), including involvement in secretion and exocytosis, modulation of ion
conductance, regulation of receptor interaction with components of the signal transduction
apparatus, smooth muscle contraction, gene expression and cell proliferation (Nishizuka,
1988). PKC regulates several cellular functions through the phosphorylation of proteins,
including some receptors. The results of "Experiment 1-2" demonstrated that the i.c.v.
morphine•-induced Straub tail-reaction in non-diabetic mice is attenuated by i.c.v. pretreatment
with PDBu (50 pmol), which stimulates PKC. Many investigators have proposed that the
phosphorylation of receptors by PKC may be a possible mechanism for the development of
desensitization (Shearman et al., 1989). Activation of PKC by phorbol ester attenuates the
opioid-induced inhibition of adenylyl cyclase activity in neuroblastoma Å~ glioma NGI08-15
hybrid cells (Louie et al., 1990). Furthermore, activation ofPKC by phorbol ester potentiates
the desensitization of pt-opioid receptor-induced K' current (Chen and Yu, 1994; Zhang et al.,
1996). We previously indicated that i.c.v. pretreatment with PDBu attenuates DAIV[GO- and
morphine-induced antinociception (Narita et al., 1997). Thus, these previous results and the
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present data suggest that the activation of PKC by phorbol ester attenuates the
pharmacological action of p-opioid receptor agonists.
       In contrast, PDBu had no significant effect on the morphine-induced Straub tai1
reaction in diabetic mice. Furthermore, i.c.v. pretreatment with calphostin C (10 pmol), which
had no significant effect on the morphine-induced Straub tai1 reaction in non-diabetic mice,
significantly and dose-dependently reversed the attenuation of the morphine-induced Straub
tail reaction in diabetic mice. Indeed, there was no significant difference in the potency ofthe
morphine-induced Straub tail reaction between calphostin C-treated diabetic mice and naive
non-diabetic mice. Calphostin C inhibits the binding of diacylglycerol to the regulatory
domain of PKC (Kobayashi et al., 1989). Thus, it is likely that the attenuation of several of
morphine's pharmacological actions, i.e. antinociception and the Straub tail reaction, in
diabetic mice may be due, in part, to the increased phosphorylation of pt-opioid receptors by
the activation ofPKC.
       The morphine-induced the Straub tail reaction involves both central and peripheral
components of the nervous system. The results from "Experiment 1-1" indicated that the
systemic morphine-induced Straub tail reaction in non-diabetic mice is greater than that in
diabetic mice. In Experiment 1-2, the i.c.v. morphine-induced Straub tail reaction in non-
diabetic mice was greater than that in diabetic mice, as with the systemic administration of
morphine. Many investigators have indicated that the central administration of morphine
induces the Straub tail reaction in mice (Narita et al., 1994; Nath et al., 1994). Diabetes
mellitus causes various complications, including dysfunction of skeletal muscles and
peripheral nerves (Pain and Garlick, 1974). It has been reported that the activation of PKC
induces the dysfunction of skeletal muscle in streptozotocin-induced diabetic mice (Nojima et
al., 1995). Thus, it is possible that the dysfunction ofperipheral neurons andlor muscle causes
the attenuation of the systemic morphine--induced Straub tail reaction in diabetic mice.
However, the i.c.v. administration of morphine induced the Straub tail reaction in both
diabetic and non-diabetic mice. Furthermore, i.c.v. pretreatment with calphostin C reverses
the attenuation of the i.c.v. morphine-induced Straub tail reaction in diabetic mice. These
results indicate that the attenuation of the morphine-induced Straub tail reaction in diabetic
mice may be due to the desensitization of supraspinal p-opioid receptors, but not the
dysfunction ofperipheral nerves and muscles, by the activation ofPKC.
       The results from "Experiment 1-3" demonstrated that i.c.v. pretreatment with PDBu
(50 pmol) attenuated the inhibition in the tail-flick test induced by i.c.v. DA]N4GO in non-
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diabetic mice. Furthermore, the attenuation of i.c.v. DArV[GO-induced antinociception by
PDBu was reversed by concomitant i.c.v. pretreatment with calphostin C, a selective PKC
inhibitor, These results are consistent with our previous observation and support the
suggestion that the attenuation by PDBu of p-opioid receptor-mediated antinociception is
specifically mediated by the activation ofPKC (Narita et al., 1997).
       In contrast, PDBu, by itself, had no significant effect on DAMGO-induced
antinociception in diabetic mice. Furthermore, pretreatment with calphostin C (3 pmol, i.c.v.),
which had no significant effect on DAMoo-induced antinociception in non-diabetic mice,
significantly and dose-dependently increased DAMGO-induced antinociception in diabetic
mice. Indeed, there was no significant difference in the potency of DAMGO-induced
antinociception between calphostin C-pretreated diabetic mice and naive non-diabetic mice.
In the present study, moreover, I found that pretreatment with a higher dose of calphostin C
(10 pmol) potentiated low-dose (3 ng, i.c.v.) Dnmoo-induced antinociception in non-
diabetic mice. As noted above, calphostin C specifically inhibits the binding ofdiacylglycerol
to the regulatory domain of PKC (Kobayashi et al., 1989), and therefore is a more selective
inhibitor than staurosporine or 1-(5-isoquinolinesulfonyl)-2-methylpiperazine hydrochloride
(Hd•7), which interact with the ATP-binding site ofPKC that shares substantial homology with
other protein kinases. The phosphorylation of receptors by PKC has been proposed to be a
possible mechanism for the development of tolerance or desensitization (Shearman et al.,
1989). According to recent cloning studies, several potential phosphorylation sites by protein
kinases are present in cloned opioid receptors, including p-opioid receptors (Miotto et al.,
1995). Previously, we reported that i.c.v. pretreatment with PDBu produced a calphostin C-
sensitive attenuation ofDAIV[GO-induced antinociception (Narita et al., 1997). These results
suggest that p-opioid receptors can be phosphorylated by the activation of PKC, and this
receptor phosphorylation by PKC leads to desensitization of p-opioid receptor-mediated
responses. Several studies have suggested that PKC systems may be up-regulated in diabetes
(Craven and DeRubertis, 1989; Wolf et al., 1990; Shiba et al., 1993). We recently reported
that at least 30 to 60 min of pretreatment is required for PDBu to desensitize p-opioid
receptor-mediated responses (Narita et al., 1997). In the present study, at least 60 min of
pretreatment was required for calphostin C to increase DAMGO-induced antinociception in
diabetic mice. Thus, it is possible that the attenuation of the antinociceptive effect of
DA]NilGO in diabetic mice may be due, in part, to the increased phosphorylation of pt-opioid
receptors by the activation ofPKC.
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       In "Experiment 1-4", i.c.v. administration of CaC12 which has been reported to
increase the intracellular concentration of calcium, attenuated the antinociceptive effect of
DAMGO, an p-opioid receptor agonist in non-diabetic mice. Moreover, i.c.v. administration
of EGTA, which has been reported to reduce the intracellular concentration of calcium,
enhanced the antinociceptive effect of DA}vlGO in non-diabetic mice. This observation is
consistent with a previous report that calcium antagonized morphine-induced antinociception
while EGTA potentiated morphine-induced antinociception (Harris et al, 1975). Thus, these
results and present results indicate that pt-opioid receptor agonist-induced antinociception is
reduced by an increase in intracellular Ca2' levels. In the present study, I observed that
pretreatment with thapsigargin reduced DAMoo-induced antinociception in non-diabetic
mice. This result is consistent with a previous finding that i.c.v. pretreatment with
thapsigargin reduced the antinociceptive effect of morphine (Smith and Stevens, 1995). It has
been reported that thapsigargin selectively inhibits Ca2' uptake into the inositol 1,4,5-
uisphosphate (P3)-sensitive microsomal Ca2' pool by inhibiting ATP/Mg2'-dependent A[rPase
(Bian et al., 1991). The subsequent depletion ofthis pool activates a low-conductance, Ca2'-
selective, non-voltage activated membrane current (Takemura et al., 1991; Premack et al.,
1994). Thus, the increase in cytosolic Ca2' caused by thapsigargin blocks the antinociceptive
effect of DAMoo. Furthermore, pretreatment with ryanodine potentiates the antinociceptive
effect ofDAMGO. It has been reported that ryanodine blocks Ca2' release from Ca2'lcaffeine-
sensitive microsomal pools, which is involved in the phenomenon of Ca2'-induced Ca2'
release (McPherson et al., 1991). It has been reported that ryanodine blocks Ca2' release and
accumulation by either preventing the opening of ryanodine channels or stabilizing an open
subconductance state (McPherson et al., 1991). Furthermore, it has been reported that
ryanodine reduces the rate at which [Ca2']i increases with Ca2' entry (Friel and Tsien, 1992).
Thus, it is possible that the potentiation of DAIV[GO-induced antinociception caused by
ryanodine may be due to a decrease in [Ca2']i. Therefore, the present results suggest that an
increase in cytosolic Ca2' levels antagonize pt-opioid receptor agonist-induced
antmoclceptlon.
       In contrast to DA]N4GO, I observed that calcium injected i.c.v. enhanced the
antinociceptive effect of (-)-TAN67, a selective 6,-opioid receptor agonist (Kamei et al.,
1997), in non-diabetic mice. Moreover, i.c.v. EGTA blocked (-)-TAN67-induced
antinociception in non-diabetic mice. Bhargava and Zhao (1996) reported that competitive
and noncompetitive antagonists ofthe N-methyl-D-aspartate (NMDA) receptor antagonize the
-
50-
analgesic action of6i-opioid receptor agonists. Furthermore, recent studies have reported that
calcium channel blockers attenuate the antinociception induced by 6 and K but not p-opioid
receptor agonists (Spampinato et al., 1994). These results and those of the present study
suggest that 6-opioid receptor agonist-induced antinociception is potentiated by an increase in
intracellular Ca2' levels. Thus, the present results suggest that cytosolic calcium differentially
modulates the p- and 6-opioid receptor-induced antinociception. Furthermore, in the present
study, I observed that (-)-TAN67-induced antinociception in non-diabetic mice is potentiated
by i.c.v. pretreatment with thapsigargin. As mentioned above, thapsigargin causes the increase
in cytosolic calcium levels. Therefore, it is possible that 6-opioid receptor agonist-mediated
antinociception is potentiated by the increase in cytosolic calcium levels. Thus, the present
results suggest that cytosolic calcium differentially modulates the p- and 6-opioid receptor
agonist-induced antinociception. On the other hand, (-)-TAN67-induced antinociception in
non-diabetic mice was not affected by pretreatment with ryanodine, which decreased
cytosolic calcium levels. It is not clear why ryanodine does not affect (-)-TAN67-induced
antinociception in non-diabetic. It has not been shown that the p and 6 opioid receptors
regulating antinociception are always expressed on the same neuron, or even in the same
pain-regulating neural pathway. Thus, it is possible that p-opioid receptor expressing neurons
show the expected changes in calcium levels in response to ryanodine, while neurons
expressing 6-opioid receptor are not directly affected by ryanodine. However, Miyamae et al.
(1993) reported that a cloned 6-opioid receptor expressed in Xenopus oocytes can mediate
agonist activation of phospholipase C. It has recently been reported that 6-opioid receptor-
mediated increases in intracellular [Ca2']i result from IP3-induced Ca2' release from
intracellular stores (Smart and Lambert, 1996a). It is suggested that the activation of6-opioid
receptor enhances [Ca2']i presumably via a phospholipase C mechanism (Connor et al., 1994).
Thus, it is possible that the lack of an effect by ryanodine on (-)-TAN67-induced
antinociception may be due to the differences between ryanodine receptor- and IP3 receptor-
mediated intracellular calcium release.
       The detailed mechanisms which underlie this differential modulation ofthe pt- and 6-
opioid receptor agonist-induced antinociception by intracellular calcium are unclear. Welch
and Daie Dunlow (1993) reported that the antinociception produced by intrathecal injection of
morphine was panially blocked by glyburide, an A[I'P-gated potassium channel blocker, but
not apamin, a calcium-gated potassium channel blocker, whereas that produced by DPDPE
was completely reduced by apamin. These results suggest that the antinociception induced by
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p-opioid receptor agonists is mediated by the activation of A[I'P-gated potassium channels,
whereas that induced by 5-opioid receptor agonists is mediated by the activation of calcium-
gated potassium channels. Therefore, it is possible that 6-opioid receptor-mediated
antinociception may be mediated through the enhancement of intracellular calcium levels. It
is likely that the differential modulation of pt- and 6-opioid receptor agonist-induced
antinociception by intracellular calcium may be due to the different mechanisms of pt- and 6-
opioid receptor-mediated signal transduction. On the other hand, recent study has
demonstrated a differential distribution of pt and 6 receptors in the rat brain. The u opioid
receptors were detected in some conical and thalamic nuclei, including the pretectal region,
which involved in the central pain-inhibiting system, and 6 opioid receptors in cortex and
limbic structures (Goodman et al, 1980). Thus, it is possible that there are several supraspinal
sites at which the p- and 6- opioid receptor agonists can induce antinociception. Furthermore,
it has been reported that antinociception is produced by microinjection of morphine, a p-
opioid receptor agonist, into a variety ofbrain sites including the periaqueductal gray (PAG),
locus coeruleus, mesencephalic reticular formation and structures within the rostral
ventromedial medulla (Jensen and Yaksh, 1986). In contrast to pt-opioid receptor agonists, the
brain sites which mediate the antinociception induced by 6-opioid receptor agonists have yet
to be identified. Microinjection of DPDPE into either the PAG or the locus coeruleus did not
produce antinociception (Bodnar et al., 1988). Thus, it is possible that DAMoo and
(-)TAN67 dose not act on the same brain region to produce antinociception. Therefore, it
seems likely that differential modulation of p- and 6-opioid receptor agonist-induced
antinociception by intracellular calcium may reflect the differences in the primary sites of
action of p- and 6-opioid receptor agonists.
       The antinociceptive effect of DAMGO in diabetic mice is less than that in non-
diabetic mice. I observed that agents which increase intracellular calcium, i.e. Ca2' and
thapsigargin, did not affect DAMoo-induced antinociception in diabetic mice. Moreover,
agents which reduce intracellular calcium levels, i.e. EGTA and ryanodine, significantly
potentiated the antinociceptive effect of DAMGO in diabetic mice. However, the effective
dose of EGTA for the potentiation of DrmGO-induced antinociception in diabetic mice is
greater than that in non-diabetic mice. Thus, it is likely that the attenuation of DAMGO-
induced antinociception in diabetic mice may be due to enhanced intracellular calcium levels.
The antinociceptive effTect of (-)-TAN67 in diabetic mice is greater than that in non-diabetic
mice. Moreover, EGTA blocks the antinociceptive effect of (-)-TAN67 in diabetic mice. On
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the other hand, calcium does not affect (-)-TAN67•-induced antinociception in diabetic mice.
These results suggest that the enhancement of (-)-TAIN67-induced antinociception in diabetic
mice may be due in part to the enhancement of the Ca2' level. It has been reported that
chronic excessive intracellular calcium overload might induce cardiac dysfunction in chronic
diabetes (Heyliger et al., 1987; Nishio et al., 1990). In peripheral nerves of diabetic rats,
mitochondrial and axoplasmic calcium levels were found to be increased by electron-probe X-
ray microanalysis (Lowery et al., 1990). Moreover, voltage-dependent calcium currents
through L- and N-channels are enhanced in dorsal root ganglion neurons ofBBIWor rats and
diabetic mice in vivo (Hall et al., 1995; Kostyuk et al., 1995). These results suggest that the
diabetic state may affect [Ca2']i in neurons and various tissues. Thus, these results and the
present data strongly suggest that the enhancement of 6-opioid receptor agonist-induced
antinociception in diabetic mice may be due to increased [Ca2']i. Furthermore, it has been
suggested that the ability of caffeine, a ryanodine receptor agonist, to mobilize Ca2' from
intracellular stores is impaired in the diabetic aorta, since caffeine-induced contraction is
significantly reduced in diabetic aorta compared with that in control aorta. Moreover, it has
been reported that the activity of Ca2'-ATPase is impaired in the diabetic rat (Janicki et al,
1994). In the present study, I observed that the antinociception induced by (-)-TAN67 in
diabetic mice, but not in non-diabetic mice, was reduced by pretreatment with ryanodine.
Furthermore, i.c.v. pretreatment with thapsigargin, which inhibits Ca2'-ATPase, affected both
DAMoo- and (-)-TAN67-induced antinociception in non-diabetic mice, but not in diabetic
mice. Therefore, these results strongly suggest that diabetic state may alter intracellular
calcium store function. It is possible that the modification of DA]V[GO- and (-)-TAN67-
induced antinociception by diabetes may be due to excessive intracellular calcium overload
following changes in calcium store function. In conclusion, the antinociceptive effects of p-
and 6-opioid receptor agonists are modulated differently by intracellular calcium. Furthermore,
changes in of p- and 6-opioid receptor agonist-induced antinociception in diabetic mice may
be due to excessive intracellular calcium overload caused by the dysfunction ofcalcium store
function.
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Chapter 2
Modification ofnaloxone-precipitated withdrawal syndrome
by diabetes in mice: possible involvement ofprotein kinase C
              and intracellular calcium
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Introduction
       Chronic administration of morphine produces physical dependence, which is
exhibited by various specific and vegetative signs after withdrawal of morphine or
administration of an opioid antagonist (Blasic et al., 1973; Wei et al., 1973). The degree of
physical dependence on morphine may be assessed by the intensity ofthe withdrawal signs,
or by the amount ofnaloxone required to precipitate an effect ofa given intensity (Way et al.,
1968). Morphine withdrawal signs are characterized by the expression ofjumping, ptosis,
"wet dog" shakes and diarrhea (Way et al., 1968; Way et al., 1969).
       Suzuki et al. (1992) previously suggested that pt-opioid receptor subtypes may be
differentially modulate some naloxone-precipitated withdrawal signs in morphine-dependent
mice, since morphine-dependent CXBK mice, which are known to be selectively deficient in
pi-opioid receptors, possess a differential sensitivity to naloxone challenge with regard to
body weight loss, diarrhea and ptosis and jumping and body shakes (Suzuki et al., 1992a).
Furthermore, Kamei et al. (1994a) proposed that mice with diabetes are selectively
hyporesponsive to activation of p,-opioid receptors, but are normally responsive to activation
of pt2-opioid receptors. Thus, it is possible that p,-opioid receptor-mediated naloxone-
precipitated withdrawal signs may be selectively reduced in morphine-dependent diabetic
mice, as in CXBK mice.
       Thus, in Experiment 2-1, I compared the development of morphine dependence in
diabetic and non-diabetic mice to clarify our hypothesis that diabetic mice are selectively
hyporesponsive to pti-opioid receptor-mediated pharmacological action, but not to that
mediated by pt,-opioid receptors.
       The effects of opioids on gastrointestinal motor function have been attributed both to
action within the central nervous system and to direct action on peripheral receptors within
the enteric nervous system (Heyman et al., 1988; Porreca and Burks, 1983; Porreca et ai,
1984; Tavani et al, 1980). Pick et al (1991) and Heyman et al (1988) suggested that the
antitransit propenies of p-opioid receptor agonists, such as morphine and [D-Ala2, N-methyl-
Phe`, Gly5-ol]enkephalin (DAN[GO), are mediated mainly by naloxonazine-insensitive (p2)
opioid receptors, since the gastrointestinal antitransit effect of p-opioid receptor agonists is
antagonized by pretreatment with B-funaltrexamine, but not with naloxonazine. On the other
hand, naloxonazine antagonizes ltopioid receptor-mediated supraspinal antinociception,
implying that pti-opioid receptors mediate supraspinal antinociception (Heyman et al, 1988;
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Paul et al., 1989). We previously reported that the antinociceptive effects ofi.c.v., but not i.t.,
administration of pt-opioid receptor agonists in non-diabetic mice were markedly greater than
those in diabetic mice (Kamei et al, 1992a, 1992b, 1994a). Furthermore, in Chapter 1, I
indicated that the morphine-induced Straub tail reaction, which is mediated mainly by pi-
opioid receptors, was greater in non-diabetic mice than in diabetic miee. Therefore, Kamei et
al. (1994a) suggested that diabetic mice are selectively hyporesponsive to pi-opioid receptor-
mediated pharmacological action, but not to that which is mediated by p2-opioid receptors. In
Experiment 2-2, to examine the hypothesis, I investigated the influence of diabetes on the
inhibition ofgastrointestinal transit by the s.c. administration of morphine in mice.
       The central noradrenergic system has been hypothesized to play an important role in
the development of physical dependence on p-opioid agonists and in the expression of their
withdrawal signs (Redmond and Krysatal, 1984). It has been reported that the firing rate of
noradrenergic neurons in locus ceruleus (LC), which is a cluster of noradrenaline (NA)-
containing cell bodies in the brain, increases during naloxone-precipitated withdrawal from
morphine dependence (Aghajanian, 1978). Furthermore, in a biochemical study, the level of
3-methoxy-4-hydroxyphenylethyleneglycol (MHPG), the major metabolite of NA, in the
cerebral cortex which projects from the LC, increased following naloxone injection in
morphine-dependent rats (Crawley et al., 1979), These biochemical changes and various
withdrawal signs were blocked by clonidine, an ct,-agonist (Crawley et al., 1979; Tseng et al.,
1975; Laverty and Roth, 1980). Thus, these reports suggest that the central noradrenergic
system may play a significant role in morphine withdrawal.
       The aim of Experiment 2-3 was to investigate the role of noradrenergic systems in
the modulation of naloxone-precipitated morphine withdrawal by diabetes. The effects of
diabetes on naloxone-precipitated jumping and naloxone-induced changes in NA turnover
were evaluated in morphine-dependent mice.
       The cellular and molecular bases of opiate addiction remain largely unknown (Cox,
1990; Nestler, 1992). The sensitization ofthe adenylate cyclasel cyclic AMPI cyclic me-
dependent protein kinase (PKA) transduction system has been demonstrated to be robust and
to show a consistent compensatory response to the sustained inhibition of opioid receptors. It
has been reported that the acute administration of opiate receptor agonists induces the
inhibition of adenylate cyclase through guanine nucleotide-binding Gilo proteins and
decreases the basal production of cyclic AMP (Nestler et al., 1989). In contrast, chronic
treatment with these drugs results in upny-regulation of this transduction system. Indeed, it has
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been reported that chronic treatment with morphine increases both basal and stimulated
production of cyclic AMP (Sharma et al., 1975, Garcia-Sevilla et al., 1987) and specific G
protein and their messenger (m)RNAs (Nestler et al., 1993; Escriba et al., 1994; Parolaro et al.,
1993). Moreover, chronic treatment with morphine also enhances the activity ofPKA (Nestler
et al., 1988, Terwilliger et al., 1991) and increases the abundance of adenylate cyclase mRNA
(Matsuoka et al., 1994). Therefore, up-regulation of the adenylate cyclasel cyclic AMP
transduction system is currently the best-characterized potential mechanism for opiate
tolerance and dependence (Nestler, 1992; Nestler et al., 1989; Collier and Roy, 1974; Collier,
1980).
       Several recent studies have indicated that protein kinase C (PKC) is involved in
opiate tolerance and dependence (Mayer et al., 1995; Narita et al., 1994; Smart et al., 1996b).
Pretreatment with an inhibitor of serinelthreonine kinase (H7) inhibited the development of
tolerance to supraspinal antinociception induced by opiates in rats (Narita et al., 1994).
Recently, Maldonado et al., (1995) reported that the behavioral expression of naloxone-
precipitated withdrawal syndromes was strongly attenuated by the administration of H7 into
the locus coeruleus or into the periaqueductal gray matter. It has also been reported that i.c.v.
pretreatment with H7 reduced naloxone-precipitated jumping in acutely morphine-dependent
mice (Bilsky et al., 1996). Furthermore, a marked decrease (50 O/o) in the immunoreactivity of
PKC-ct and P isoforms (cytosolic and membrane-bound isoenzymes) has recently been found
in postmortem brains of heroin addicts and'in brains of morphine-dependent rats (Busques et
al., 1995). Moreover, it has been reported that both PKA and PKC were markedly activated in
chronically morphine-treated rats paakimura et al., 1997). These findings suggest that the
PKC system may also play a major role in opiate addiction.
       Many investigators have reported that hyperglycemia or elevated glucose levels can
increase diacylglycerol (DAG) levels and activate PKC in vascular tissue, cardiac tissues or
cultured cells (Craven and De Rubenis, 1989; King et al., 1990; Inoguchi et al., 1992; Tanaka
et al., 1991). Activation of the DAG-PKC cellular signal pathway is linked to vasculature
dysfunction in diabetes (Craven and De Rubertis, 1989; Wolf et al., 1990; Shiba et al., 1993).
Furthermore, in Chapter 1, I indicated that calphostin C, a protein kinase C inhibitor, reverses
the attenuation of DA]V[GO-induced antinociception in diabetic mice to the level in non-
diabetic mice. In contrast to PKC, it has been reported that the hepatic PKA activity measured
both in the absence and presence of cyclic AMP is decreased in streptozotocin-induced
diabetic animals (Khandelwal et al., 1977; Davies et al., 1995). Decreased PKA activity is
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caused by decreased phosphorylation ofthe cyclic AMP response element binding protein in
the diabetic rat (Davies et al., 1995). The induction ofphysical dependence on morphine was
significantly decreased in genetically diabetic mice (Shook et al., 1986). Although the
mechanisms of this modulation of the naloxone-precipitated jumping in the morphine-
dependent mice by diabetes are not yet clear, it is possible that functional changes in protein
kinase activity may be involved.
       Therefore, the primary aim of Experiment 2-4 was to investigate the involvement of
PKC and PKA in the modulation of naloxone-precipitated morphine withdrawal in mice.
Furthermore, I examined the involvement of PKC and PKA on the naloxoned-induced
enhancement ofNA turnover in the frontal cortex of morphine-dependent mice. Moreover, to
evaluate the modification of naloxone-precipitated jumping in morphine-dependent mice by
diabetes, the effect of protein kinase inhibitors on the expression of naloxone-precipitated
morphine withdrawal and naloxone-induced enhancement of NA turnover in the frontal
cortex were evaluated in morphine-dependent diabetic and non-diabetic mice.
       Many acute opiate effects can be partially explained by the inhibition of Ca2' ion fiux
in neuronal cells (Guerrero-Mufioz et al., 1979) and by a reduction in synaptosomal Ca2'
content (Ross et al., 1977). It has been reported that intracisternal administration of Ca2" and
Ca2' ionophores antagonizes the antinociceptive effect of morphine, a prototype pt-opioid
receptor agonist (Chapman et al., 1980; Hano et al., 1964). Conversely, Ca2' chelators (i.e.,
ethylene glycol bis(P-aminoethyl ether)N,N'-tetraacetic acid (EGTA)) or Ca2' channel
antagonists of the verapamil, diltiazem and dihydropyridine types potentiate opioid
antinociception (Ben-Sreti et al., 1983; Hoffmeister and Tettenborn, 1986). Ca2' seems to play
a basic role not only in the acute effects of opiates but also in the development of tolerance
and physical dependence. Chronic morphine administration has been shown to produce, as a
contra-adaptive reaction, an increase in Ca2' uptake in various brain preparations, resulting in
an increase ofvesicular Ca2' content (Yamamoto et al., 1978). Furthermore, it is reported that
N- and L-type Ca2' channel blockers prevent naloxone-precipitated withdrawal syndromes in
morphine-dependent mice and rats (Barrios and Baeyens, 1991; Basilico et al., 1992;
Bourreau et al., 1996). In contrast to Ca2" channel blockers, L-type Ca2" channel stimulators
increased naloxone-precipitated withdrawal signs in acute morphine-dependent mice (Barrios
and Baeyens, 1991). Thus, it is possible that influx of calcium through the L- and N-type Ca2'
channels plays an important role in the expression of naloxone-precipitated withdrawal signs
in morphine-dependent animals.
-
58-
       Previously, it has been reported that metabolic glutamate receptor antagonist
attenuates naloxone-precipitated withdrawal signs in rats given chronic subcutaneous
morphine (Fundytus and Coderre, 1994). Activation of metabolic glutamate receptors
stimulates phospholipase C which hydrolyzes phosphatidyl inostol to produce diacylglycerol
and inositol-1,4,5-trisphosphate (IP,) (Schoepp and Conn, 1993). IP, promotes the release of
Ca2' from internal stores on the endoplasmic reticulum. Furthermore, it has been reported that
during morphine withdrawal, phosphatidyl inosjtol turnover has been found be greatly
enhanced (Pellegrini-Giampietro et al., 1988). Thus, these reports suggest that enhancement
ofthe release of Ca2' from internal stores may be involved in the expression of naloxone-
precipitated withdrawal signs in morphine-dependent animals.
       It has been reported that veratrine, which contains a Na' channel activator,
veratridine, could release NA from brain synaptosomes even in a Ca2' free medium, possibly
as a result of mobilization of intracellular stores (Schoepp and Conn, 1993). Furthermore,
ryanodine induced a modest decrease in NA overflow, whereas cyclopiazonic acid, an
inhibitor of sacroplasmic reticulum Ca2'-ATPase, slightly increased NA overflow in rat vas
deferens (Bourreau, 1996). These results suggest that internal Ca2" stores could participate in
the process ofNA release. Thus, it is possible that the naloxone-induced enhancement ofNA
turnover in the frontal cortex modulated by enhancement ofintracellular [Ca2']i followed by
the release ofCa2' from intracellular Ca2' stores.
       Considerable evidenc,es suggest that calcium signaling is abnormal in cardiac
myocytes (Nobe et al., 1990), vascular smooth muscle (Kamata et al., 1988) and other tissues
(Levy et al., 1994) from diabetic animals. A recent study has shown that verapamil has a
beneficial effect on the cardiac function ofdiabetic rats without affecting glucose metabolism
or insulin secretion (Afzal et al., 1988). It has been suggested that chronic excessive
intracellular calcium overload might induce cardiac dysfunction in chronic diabetes (Heyliger
et al., 1987; Nishio et al., 1990). Moreover, it has been suggested that the diabetic state may
change [Ca2']i in neuron and various tissues (Hall et al., 1995; Kostyuk et al., 1995; Lowery et
al., 1990). Furthermore, in Chapter 1-4, changes in p- and 6-opioid receptor agonist-induced
antinociception in diabetic mice may be due to excessive intracellular calcium overload
caused by the dysfunction of calcium store function. Therefore, it is possible that the
dysfunction of calcium store function in diabetic mice may affect the naloxone-precipitated
withdrawal jumping in morphine-dependent diabetic mice. Thus, the primary aim of
Experiment 2-5 was to investigate the involvement ofintracellular caicium in the modulation
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of naloxone-precipitated morphine withdrawal in mice. Furthermore, I examined the role of
intracellular calcium on the naloxone-induced enhancement of NA turnover in the frontal
cortex of morphine-dependent mice. Moreover, to evaluate the modification of naloxone-
precipitated jumping in morphine-dependent mice by diabetes, the effects of intracellular
calcium modulators on the expression of naloxone-precipitated morphine withdrawal and
naloxone-induced enhancement of NA turnover in the frontal cortex were evaluated in
morphine-dependent diabetic and non-diabetic mice.
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Experiment 2-1: Modification of development of morphine dependence by diabetes
Materials and Methods
Animals
       Male ICR mice (Tokyo Laboratory Animals Science Co., Tokyo), weighing about 20
g at the beginning of the experiments, were used. The mice were housed under the condition
as described in Chapter 1-1. Animals were rendered diabetic by an injection of streptozotocin
(200 mglkg, i.v.) prepared in O.1 N citrate buffer at pH 4.5. Age-matched non-diabetic mice
were injected with vehicle alone. The experiments were conducted two weeks after injection
of streptozotocin or vehicle. Mice with serum glucose levels above 400 mgldl were
considered diabetic.
Chronic administration of morphine
       Morphine was injected s.c. daily at 9 a.m. and 7 p.m. According to the schedule
described by Maldonado et al. (1989), the morphine dose was increased progressively from 8
to 45 mglkg over a period of 5 days. The doses ofmorphine (mglkg) injected at 9 a.m. and 7
p.m. were: lst day (8, 15), 2nd day (20, 25), 3rd day (30, 35), 4th day (40, 45) and 5th day (45
at 9 a.m. only), respectively.
Morphine withdrawal
       Withdrawal signs were precipitated by injecting naloxone (O.3, 1, 3 and 10 mglkg, s.c.
in a volume of 10 mllkg) 2 h after the final morphine administration. After the naloxone
challenge, mice were immediately placed on a circular platform (30 cm diameter x 70 cm
height). Naloxone-precipitated withdrawal signs were recorded for 60 min according to our
previous papers (Suzuki et al., 1984, 1992a, 1992b). The number of mice which expressed
withdrawal jumping was counted for 15 min after the naloxone injection. The numbers of
mice which expressed other withdrawal signs, such as ptosis, diarrhea, and body shakes,
within 60 min after naloxone injection were also recorded. Body weight was measured before
and 15, 30, 45 and 60 min after naloxone injection.
Drugs
The drugs used in the present study were streptozotocin (Sigma Chemical Co., St.
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Louis, MO, USA), morphine hydrochloride (Sankyo Co., Tokyo Japan) and naloxone
hydrochloride (Research Biochemicals Inc., Wayland, MA, USA). All drugs were dissolved
in saline solution.
Statistical analysis
       Differences in weight loss were analyzed using one-way analysis of variance
followed by Dunnett's multiple comparison test. The ED50 values, the ED50 ratio and their
95 O/o confTidence intervals for naloxone-precipitated withdrawal signs were computed
according to Litchfield and Wilcoxon (1949) using Program 47 of the Pharmacological
Calculations system of Tallarida and Murray (1987).
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Results
Naloxone-precipitated withdrawal signs in morphine dependent diabetic mice.
      Naloxone-precipitated jumping tended to increase in a dose-related manner in
morphine-dependent non-diabetic and diabetic mice (Fig. 2-l). However, diabetes reduced the
number ofanimals respond to naloxone-precipitated jumping to half.
      Naloxene-precipitated body shakes also tended to increase in a dose-related manner
in morphine-dependent non-diabetic and diabetic mice (Fig. 2-2). Diabetes produced a
rightward shift of the dose response curve of the naloxone-precipitated body shakes in
morphine-dependent mice. Thus, diabetes reduced the number of animals respond to
naloxone-precipitated body shakes to about halÅí
      There was no significant difference in the incidence of naloxone-induced diarrhea
between morphine-dependent diabetic mice and morphine-dependent non-diabetic mice (Fig.
2-3A). The loss ofbody weight induced by naloxone increased in a dose-related manner in
morphine-dependent non-diabetic and diabetic mice. However, the naloxone-induced body
weight loss in diabetic mice was significantly greater than that in non-diabetic mice 60 min
after administration of naloxone (Fig. 2-4). Furthermore, the loss ofbody weight 60 min after
administration of naloxone (3 mglkg, s.c.) in chronically saline-treated (morphine-non-
dependent) diabetic mice (7.9 Å} 1.1 O/o, n=1O) was also significantly (PÅqO.Ol) greater than that
in chronically saline-treated (morphine-non-dependent) non-diabetic mice (2.4 Å} O.2 O/o,
n=10).
      The incidence of ptosis induced by naloxbne in morphine-dependent diabetic mice
was similar to that in morphine-dependent non-diabetic mice (Fig. 2-5B).
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Figure 2-1. Naloxone-precipitated jumping in morphine-dependent diabetic and non-
diabetic mice. Diabetic and non-diabetic mice were treated with morphine (8 - 45 mg/kg,
s.c.) twice a day for 5 days. Withdrawal jumping was observed for 15 min after
administration of naloxone (s.c.). Each point represents the number of animals
responding within 10 animals.
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Figure 2-2. Naloxone-precipitated body shakes in morphine-dependent diabetic and
non-diabetic mice. Diabetic and non-diabetic mice were treated with morphine (8 - 45
mg/kg, s.c.) twice a day for 5 days. Withdrawal body shakes was observed for 60 min
after administration of naloxone (s.c.). Each point represents the number of animals
responding within 10 animals.
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Figure 2-3. Naloxone-precipitated diarrhea (A) and ptosis (B) in morphine-dependent
diabetic and non-diabetic mice. Diabetic and non-diabetic mice were treated with
morphine (8 - 45 mg/kg, s.c.) twice a day for 5 days. Withdrawal signs were observed
for 60 min after administration of naloxone (s.c.). Each point represents the number of
animals responding within 10 animals.
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Figure 2-4. Body weight loss 60 min after naloxone challenge in morphine-dependent
diabetic and non-diabetic mice. Diabetic and non-diabetic mice were treated with
morphine (8 - 45 mg/kg, s.c.) twice a day for 5 days. Withdrawal was precipitated by
naloxone (s.c.). Each point represents the number of animals responding within 10
animals.
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Experiment 2-2: Effect of diabetes on the morphine-induced inhibition of
                     gastrointestinal transit.
Materials and Methods
Animals
       Male ICR mice (Tokyo Laboratory Animals Science Co., Tokyo), weighing about 20
g at the beginning of the experiments, were used. The mice were housed under the condition
as described in Chapter 1-1. Animals were rendered diabetic by an injection of streptozotocin
(200 mglkg, i.v.) prepared in O.1 N citrate buffer at pH 4.5. Age-matched non-diabetic mice
were injected with the vehicle alone. The experiments were conducted 2 weeks after injection
of streptozotocin or vehicle. Mice with serum glucose levels above 400 mgldl were
considered diabetic.
Gastrointestinal transit
       Mice were fasted for 12 h before the experiments. Thirty min after s.c. administration
of morphine, or saline, a 50/o aqueous suspension of charcoal in 100/o gum arabic solution was
administered p.o. at a volume of O.1 mllmouse. Thirty minutes after charcoal administration,
the animal was killed by cervical dislocation and its small intestine was removed. The small
intestine was placed on a ruled template and both the length from the pylorus to the cecum
and the distance traveled by the charcoal were measured. The O/e transit was calculated as: 100
x (length from the pylorus to the cecum - distance traveled by the charcoal)11ength from the
pylorus to the cecum. To calculate the antitransit effect of morphine, O/o transit for each animal
was compared with the mean O/o transit in the saline-treated group according to the formula:
percent inhibition = 100 x (mean O/o transit of saline-treated mice - O/o transit of morphine-
treated mouse)lmean O/o transit ofsaline-treated control mice.
Data analysis
       Data are expressed as the mean Å} S.E. Statistical significance of differences was
assessed with a one-way analysis ofvariance (ANOVA) with repeated measures followed by a
Dunnett's test. A level of probability of O.05 or less was accepted as significant. The ED50
values and their 950/o confidence intervals (950/o CI) for the antitransit effect of morphine were
computed according to Litchfield and Wilcoxon (1949) using Program 47 of the
-
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Pharmacological Calculations system of Tallarida and Murray (1987).
Drugs
       Streptozotocin was purchased from Sigma Chemical Co., St. Louis, MO, USA
Morphine hydrochloride was purchased from Sankyo, Co., Tokyo, Japan. P-Funaltrexamine
and naloxonazine were synthesized by Dr. Nagase (Toray Industries, Kamakura, Japan). All
drugs were dissolved in O.90/o saline solution. B-Funaltrexamine (40 mg!kg) and naloxonazine
(35 mglkg) were injected s.c. 24 hr before testing.
-
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Results
       Subcutaneous injection of morphine (1-10 mglkg) dose-dependently inhibited
gastrointestinal transit in both non-diabetic and diabetic mice (Fig 2-6). The ED50 values
(950/o CI) for the antitransit effect of morphine were 1.3 (1.0 - 1.8) mg/kg in non-diabetic mice
and 2.4 (O.9 - 6.0) mglkg in diabetic mice. There was no significant difference in the
antitransit properties ofmorphine between non-diabetic and diabetic mice.
       When the mice were pretreated with B-funaltrexamine (40 mglkg, s.c.), the antitransit
effects of morphine (10 mglkg, s.c.) were significantly reduced in both non-diabetic (Fig. 2-
7A) and diabetic (Fig. 2-7B) mice. In contrast, pretreatment with the selective pi-opioid
receptor antagonist naloxonazine (35 mg/kg, s.c.) 24 hr before testing failed to antagonize the
morphine (10 mglkg, s.c.)-induced inhibition of gastrointestinal transit in both non-diabetic
and diabetic mice.
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Figure 2-5. Dose-response curves for the antigastrointestinal transit effect of morphine
in non-diabetic (open circles) and diabetic (closed circles) mice. Each point represents
the mean with S.E. from 8 animals.
-
71-
1OO
- 50
' 6
=
es
ts
" lil
.g
6
g
--
ua
es 1OO
Åé
g
E
.D-
=llg so
b"
CONTROLNXZ FNA
o
Morphine 10 mg/kg, s.c.
CONTROLNXZ FNA
Morphine 10 mglkg, s.c.
Figure 2-6. Effects of P-funaltrexamine (FNA) and naloxonazine (NXZ) on the
antitransit effeets of morphine (10 mgllcg, s.c.) in both non-diabetic (A) and diabetic (B)
mice. Mice were treated with FNA (40 mglkg, s.c.) or NXZ (35 mg/kg, s.c.) 24 h before
testing. Each column represents the mean with S.E. from 8 animals. *PÅqO.Ol vs.
morphine alone.
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Experiment 2-3: Role of noradrenergic functions in the modification of naloxone-
   precipitated withdrawal jumping in morphine-dependent mice by diabetes
Materials and Methods
Animals
       Male ICR mice (Tokyo Laboratory Animals Science Co., Tokyo), weighing about 20
g at the beginning of the experiments, were used. The mice were housed under the condition
as described in Chapter 1-1. Animals were rendered diabetic by an injection of streptozotocin
(200 mglkg, i.v.) prepared in O.1 N citrate buffer at pH 4.5. Age-matched non-diabetic mice
were injected with vehicle alone. The experiments were conducted 2 weeks after injection of
streptozotocin or vehicle. Mice with serum glucose levels above 400 mg!dl were considered
diabetic.
Chronic administration of morphine
      Morphine was injected s.c. daily at 9 A.M. and 7 P.M. According to the schedule
described in Chapter 2-1, the morphine dose was increased progressively from 8 to 45 mglkg
over a period of 5 days.
Morphine withdrawal
      Withdrawal signs were precipitated by injecting naloxone (O.3 mglkg, s.c. in a
volume of 10 mllkg) 2 hr after the final morphine administration. After the naloxone
challenge, mice were immediately placed in an acrylic cylinder (30 cm high, 20 cm in
diameter). The number ofjumps during each 5-min period was counted for 15 min after
naloxone injection.
Neurochemical analysis
       The concentrations of noradrenaline (NA) and 3-methoxy-4-hydroxyphenyleneglycol
(MHPG) were estimated using high-performance liquid chromatography (HPLC) with
electrochemical detection (ECD), as previously described (12). Non-dependent (chronically
saline-treated) mice (diabetic and non-diabetic) and morphine-dependent mice (diabetic and
non-diabetic) were sacrificed 5, 10 and 15 min after naloxone (O.3 mglkg, s.c.) or saline (10
mllkg, s.c.) injection, and then immersed in a dry ice-ethanol solution. The brain was quickly
-
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removed and the cerebral cortex was dissected on an ice-cold glass plate. The HPLC system
consisted ofa delivery pump (EP-300, Eicom Co., Japan), an analytical column (EICOMPAC,
MA-50DS, Eicom Co., Japan) and a guard column (Eicom, Japan). The electrochemical
detector (EC-1OO, Eicom, Japan) included a graphite electrode (WE-3G, Eicom, Japan).
Drugs
       The drugs used were streptozotocin (Sigma Chemical Co., St. Louis, MO), morphine
hydrochloride (Sankyo Co., Tokyo, Japan) and naloxone hydrochloride (Sigma Chemical Co.,
St. Louis, MO). All drugs were dissolved in O.90/o saline solution.
Statistical analysis
       Differences in the number ofjumps and NA turnover were analyzed using a one-way
analysis of variance followed by Dunnett's multiple comparison test. NA turnover was
determined as the NA ratio: NA ratio = MHPG (nglg ofwet tissue)fNA (nglg ofwet tissue).
-
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Resuks
Naloxone-precipitated withdrawal jumping in morphine-dependent diabetic mice
       The time-course of naloxone-precipitated jumping in morphine-dependent diabetic
and non-diabetic mice is shown in Figure 2-8. Subcutaneous injection of naloxone (O.3
mglkg) invariably provoked withdrawal jumping within 2 to 15 min in morphine-dependent
non-diabetic mice and reached its maximum within 5 min after naloxone injection. In
morphine-dependent diabetic mice, s.c. injection of naloxone (O.3 mglkg) also provoked
withdrawal jumping within 15 min. However, the number of naloxone-precipitated
withdrawal jumps within 5 min after naloxone challenge was significantly less in morphine-
dependent diabetic mice than in morphine-dependent non-diabetic mice (Fig. 2-8).
Effects of diabetes on naloxone-induced changes in the Ievel of NA turnover in the
       The level of NA turnover in the frontal cortex was significantly lower in diabetic
mice than in non-diabetic mice (Fig. 2-9A, B, C). Chronic treatmerrt with morphine did not
significantly modify the level of NA turnover in either non-diabetic or diabetic mice.
Furthermore, the level ofNA turnover did not significantly change after saline challenge in
either morphine-dependent non-diabetic or morphine-dependent diabetic mice. As shown in
Figure 2-9A and B, the level ofNA turnover in frontal cortex in morphine-dependent non-
diabetic mice was significantly increased 5 and 10 min after naloxone (O,3 mgfkg, s.c.)
injection, compared with that in the saline-challenged morphine-dependent group. Although
the level of NA turnover in frontal cortex in morphine-dependent diabetic mice was
significantly increased 10 min after naloxone challenge, a naloxone-induced increased in the
NA tumover was not observed 5 min after naloxone challenge (Fig. 2-9 A, B).
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Figure 2-8. Time course of naloxone precipitpted jumping in morphine-dependent
diabetic (closed circle) and non-diabetic (open circle) mice. Withdrawal was
precipitated by naloxone (O.3 mglkg, s.c,), and the number ofjumps during each 5-min
period was counted for 15 min after naloxone injection. Each point represents the mean
with S.E. of 10 mice. 'PÅqO.05 vs. non-diabetic mice
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Figure 2-9. Naloxone-precipitated changes in the rate of noradrenaline turnover (NA ratio) in
the cortex ofdiabetic and non-diabetic mice after chronic morphine (MOR) treatment. Mice
were sacrificed 5 (A), 10 (B) and 15 (C) min after s.c. injection of naloxone (NLX) or saline
(SAL). Each group consisted 6 mice. NA turnover was determined as the NA ratio. NA ratio
== MHPGfNA. $ PÅqO.05 vs. respective non-diabetic mice. * PÅqO.05 vs. respective saline
(SAL)--challenged chronic saline (SAL)-treated group. # PÅqO.05 vs. respective saline (SAL)-
challenged chronic morphine-treated group.
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Experiment 2-4: Modification of the expression of naloxone-precipitated
      withdrawal signs in morphine-dependent mice by diabetes:
             possible involvement of protein kinase C.
Materials and Methods
Animals
       Male ICR mice (Tokyo Laboratory Animals Science Co., Tokyo), weighing about 20
g at the beginning ofthe experiments, were used. The mice were housed under the condition
as described in Chapter 1-1. Animals were rendered diabetic by an injection of streptozotocin
(200 mglkg, i.v.) prepared in O.1 N citrate buffer at pH 4.5. Age-matched non-diabetic mice
were injected with vehicle alone. The experiments were conducted 2 weeks after the injection
of streptozotocin or vehicle. Mice with serum glucose levels above 400 mgldl were
considered diabetic.
Chronic administration of morphine
      Morphine was injected s.c. daily at 9 AM. and 7 P.M. According to the schedule
described in Experiment 2-1, the morphine dose was increased progressively from 8 to 45
mg/kg over a period of5 days.
Morphine withdrawal
       Withdrawal signs were precipitated by injecting naloxone (O.3 mglkg, s.c. in a
volume of 10 mllkg) 2 h after the final morphine administration. After the naloxone challenge,
mice were immediately placed in acrylic cylinder (30 cm high, 12 cm in diameter). The
number ofjumps during a 5-min period was counted for 30 min after naloxone injection.
Neurochemical analysis
       The concentrations ofnoradrenaline (NA) and 3-methoxy-4-hydroxyphenyleneglycol
(MHPG) were estimated using high-performance liquid chromatography (HPLC) with
electrochemical detection (ECD), as previously described (34). Morphine-dependent diabetic
and nond-diabetic mice were sacrificed 5 min after naloxone (O.3 mglkg, s.c.) or saline (10
mllkg, s.c,) injection, then immersed in a dry ice-cold solution. The brain was quickly
removed and the cerebral cortex was dissected on an iced-cold glass plate, The HPLC system
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consisted ofa delivery pump (EP-300, Eicom Co., Japan), an analytical column (EICOMPAC
MA-50DS, Eicom Co., Japan) and a guard column (Eicom, Co., Japan). The electrochemical
detector (EC-100, Eicom Co., Japan) included a graphite electrode (WE-•3G, Eicom Co.,
Japan).
Intracerebroventricular injection
       Intracerebroventricular (i.c.v.) administration was performed following the method
described in Chapter 1-2.
Drugs
       The drugs used were streptozotocin (Sigma Chemical Co., St. Louis, MO), morphine
hydrochloride (Sankyo Co., Tokyo, Japan), and naloxone hydrochloride (Sigma Chemical Co.,
St. Louis, MO). Calphostin C, phorbol-12,13-dibutyrate (PDBu) and (8R,9S,11S)-(-)-9-
hydroxy-9-n-hexyloxy-carbonyl-8-methyl-2,3,9,20-tetrahydro-8-,11-epoxy-IH,8H,11H-
2,7b,11a-triazadibenzo[a,g]cycloocta[cde]-trinden-1-one (KT5720) were purchased from
Calbiochem-Novabiochem International (San Diego, CA). Calphostin C and KT-5720 were
injected 1hr before the injection ofnaloxone. PDBu was injected lhr before the last injection
of morphine. The dose and schedule for calphostin C, PDBu and KT-5720 in this study were
determined as described previously (Narita et al., 1997),
Data analysis
       The data are expressed as means Å} S.E. The statistical significance of differences
between groups was assessed with Student's t-test (comparison of two groups) or an analysis
of variance (ANOVA) followed by Dunnet's test (comparison among multiple groups). NA
turnover was determined as the NA ratio: NA ratio=MHPG (ng/g ofwet tissue) / NA (ng/g of
wet tissue).
-
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Results
Influence of a protein kinase C (PKC) inhibitor, calphostin C, on naloxone-precipitated
withdrawal jumping
       The effect of calphostin C, a PKC inhibitor, on the number of naloxone-precipitated
withdrawal jumps in morphine--dependent diabetic and non-diabetic mice is shown in fig. 2-
10. Naloxone-precipitated withdrawal jumps were markedly attenuated by the i.c.v.
administration ofcalphostin C (20 pmol) in morphine-dependent non-diabetic mice. However,
naloxone-precipitated withdrawal jumping in morphine-dependent diabetic mice was
increased by i.c.v. pretreatment with calphostin C (20 pmol). As shown in fig. 2-11, the
number of naloxone-precipitated withdrawal jumps within 5 min after naloxone challenge
was dose-dependently attenuated by i.c.v. pretreatment with calphostin C (3-20 pmol) in
morphine-dependent non-diabetic mice. However, the number of naloxone-precipitated
withdrawal jumps in morphine-dependent diabetic mice was dose-dependently enhanced by
i.c.v. pretreatment with calphostin C (10 and 20 pmol).
Influence of a cyclic AMP-dependent protein kinase (PKA) inhibitor, KT-5720 on
naloxone-precipitated withdrawal jumping
       The effect of KT-5720, a PKA inhibitor, on the number of naloxone-precipitated
withdrawal jumps in morphine-dependent diabetic and rion-diabetic mice is shown in fig. 2-
12. In morphine-dependent non-diabetic mice, naloxone-precipitated withdrawal jumping
within 5 and 10 min after naloxone challenge was attenuated by i.c.v. pretreatment with KT-
5720. However, i.c.v. pretreatment with KT-5720 did not affect naloxone-precipitated
withdrawal jumping in morphine-dependent diabetic mice. As shown in fig. 2-13, the number
of naloxone-precipitated withdrawal jumps within 5 min after naloxone challenge in
morphine-dependent non-diabetic mice, but not in morphine-dependent diabetic mice, was
dose-dependently attenuated by i.c.v. pretreatment with KT5720 (1O and 20 pmol).
Influence of a PKC activator, phorbol-12,13-dibutyrate (PDBu), on
naloxone-precipitated withdrawal jumping in morphine-dependent
diabetic mice
the expression of
diabetic and non-
The effect of phorbol-12,13-dibutyrate (PDBu), a PKC activator, on the number of
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naloxone-precipitated withdrawal jumps in morphine-dependent diabetic and non-diabetic
mice is shown in fig. 2-14. In morphine-dependent non-diabetic mice, but not in morphine-
dependent diabetic mice, naloxone-precipitated withdrawal jumping within 5 min after
naloxone challenge was attenuated by i.c.v. pretreatment with PDBu (10 pmol). As shown in
fig. 2-15, i.c.v. pretreatment with PDBu (3 and 10 pmol) 3 h before naloxone injection dose-
dependently attenuated naloxone-precipitated withdrawal jumping within 5 min after
naloxone injection. However, i.c.v. pretreatment with PDBu (3 and 10 pmol) had no
significant effect on naloxone-precipitated withdrawal jumping within 5 min after naloxone
injection in morphine-dependent diabetic mice.
Influences of protein kinase C and A modulator on
llevel of NA turnover in the frontal cortex
naloxone-induced changes in the
       The level ofNA turnover in the frontal cortex was significantly lower in morphine-
dependent diabetic mice than in morphine-dependent non-diabetic mice (Fig. 2-16A and B).
The level of NA turnover in frontal cortex in morphine-dependent non-diabetic mice was
significantly increased 5 min after naloxone challenge, compared with that in the saline-
challenged morphine-dependent non-diabetic mice (Fig 2-16A and B). However, a naloxone-
induced increase in the NA turnover was not observed 5 min after naloxone challenge in
morphine-dependent diabetic mice (Fig. 2-16A and B). As shown in fig. 2-16A, a naloxone-
induced increased in the NA turnover was attenuated by pretreatment with calphostin C (20
pmol, i.c.v.) and KT5720 (20 pmol, i.c.v.) in morphine-dependent non-diabetic mice (Fig. 2-
16A). In morphine-dependent diabetic mice, i.c.v. pretreatment with neither calphostin C nor
KT5720 affected the NA turnover in naloxone-challenged morphine-dependent diabetic mice
(Fig. 2-16A). I.c.v. pretreatment with PDBu (10 pmol) 1 h before last injection of morphine
attenuated a naloxone-induced increase in NA turnover in the frontal cortex in morphine-
dependent non-•diabetic mice (Fig. 2-16B). However, i.c.v. pretreatment with PDBu (10 pmol)
had no significant effect on the level of NA turnover in the frontal cortex in naloxone-
challenged morphine-dependent diabetic mice (Fig 2-16B).
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Figure 2-9. The effect of a protein kinase C inhibitor, calphostin C, on the time course
of the number of naloxone-precipitated withdrawal jumps in morphine-dependent
diabetic and non-diabetic mice. Calphostin C (20 pmol) and vehicle were injected i.c.v.
Ih before the administration of naloxone (O.3 mglkg, s.c.). Each point represents the
mean Å} S.E. of 9•-10 mice. *PÅqO.05 versus non-diabetic mice. #PÅqO.05 versus the
respective vehicle-treated groups.
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Figure 2-10. The dose-related effect ofa protein kinase C inhibitor, calphostin C, on the
number of naloxone-precipitated withdrawal jumps within 5 min after naloxone
challenge in morphine-dependent diabetic and non-diabetic mice. Calphostin C (3 pmol,
10 pmol and 20 pmol) and vehicle were injected i.c.v. Ih before the administration of
naloxone (O.3 mglkg, s.c.). Each point represents the mean Å} S.E. of 9-10 mice. "PÅqO.05
versus non-diabetic mice. #PÅqO.05 versus the respective vehicle-treated groups.
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Figure 2-11. The effect of a protein kinase A inhibitor, KT-5720, on the time course of
the number of naloxone-precipitated withdrawal jumps in morphine-dependent diabetic
and non-diabetic mice. KT-5720 (20 pmol) and vehicle were injected i.c.v. Ih before the
administration of naloxone (O.3 mglkg, s.c.). Each point represents the mean Å} S.E. of
10-12 mice. "PÅqO.05 versus non-diabetic mice. #PÅqO.05 versus the respective vehicle-
treated groups.
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Figure 2-12. The effect of a protein kinase A inhibitor, KT-5720, on the number of
naloxone-precipitated withdrawal jumps in morphine-dependent diabetic and non-
diabetic mice. KT-5720 (10 and 20 pmol) and vehicle were injected i.c.v. Ih before the
administration of naloxone (O.3 mglkg, s.c.). Each point represents the mean Å} S.E. of
10-12 mice. "PÅqO.05 versus non-diabetic mice. #PÅqO.05 versus the respective vehicle-
treated groups.
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Figure 2-13. The effect of a protein kinase C activator, phorbol-12,13-dibutyrate
(PDBu), on the time course of the number of naloxone-precipitated withdrawal jumps in
morphine-dependent diabetic and non-diabetic mice. PDBu (10 pmol) and vehicle were
injected i.c.v. 1 h before the last injection of morphine (45 mg/kg, s.c.). Each point
represents the mean Å} S.E. of 10 mice. 'PÅqO.05 versus non-diabetic mice. #PÅqO.05
versus the respective vehicle-treated groups.
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Figure 2-14. The dose-related effect of a protein kinase C activator, phorbol-12,13-
dibutyrate (PDBu), on the number of naloxone-precipitated withdrawal jumps within 5
min after naloxone challenge in morphine-dependent diabetic and non-diabetic mice.
PDBu (3 pmol and 10 pmol) and vehicle were injected i.c.v. 1 h before the last injection
of morphine (45 mglkg, s.c.). Each point represents the mean Å} S.E. of 10 mice.
"PÅqO.05 versus non-diabetic mice. #PÅqO.05 versus the respective vehicle-treated
groups.
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Figure 2-15. The effects of protein kinase C and A inhibitor (A) and protein kinase C
activator (B) on a naloxone-induced increase of NA turnover in frontal cortex in
morphine-dependent diabetic and non-diabetic mice. Calphostin C (CP; 20 pmol, ic.v.)
and KT5720 (KT; 20 pmol, i.c.v.) and vehicle were injected 1 h before the last injection
of naloxone (O.3 mglkg, s.c.) (A). PDBu (10 pmol) and vehicle were injected i.c.v. 1 h
before the last injection of morphine (45 mglkg, s.c.). Each column represents the mean
with S.E. of 5-•10 mice. 'PÅqO.05 versus saline-challenged morphine-dependent non-
diabetic mice. #PÅqO.05 versus naloxone challenged chronic morphine-treated group.
$PÅqO.05 versus respective non-diabetic mice.
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  Experiment 2-5: Role of intracellular calcium on the modulation of
naloxon"precipitated withdrawal jumping in morphine-dependent mice
                          by diabetes.
Materials and Methods
Animals
       Male ICR mice (Tokyo Laboratory Animals Science Co., Tokyo), weighing about 20
g at the beginning ofthe experiments, were used. The mice were housed under the condition
as described in Chapter 1-1. Animals were rendered diabetic by an injection of streptozotocin
(200 mglkg, i.v.) prepared in O.1 N citrate buffer at pH 4.5. Age-matched non-diabetic mice
were injected with vehicle alone. The experiments were conducted 2 weeks after the injection
of streptozotocin or vehicle. Mice with serum glucose levels above 400 mgldl were
considered diabetic.
Chronic administration of morphine
       Morphine was injected s.c. daily at
described in Experiment 2-1, the morphine
mglkg over a period of5 days.
9 A.M
dose was
and 7 PM.
 increased
According to the
progressively from
schedule
 8 to 45
Morphine withdrawal
       Withdrawal signs were precipitated by injecting naloxone (O.3 mglkg, s.c. in a
volume of 1O mllkg) 2 h after the final morphine administration. After the naloxone challenge,
mice were immediately placed in acrylic cylinder (30 cm high, 12 cm in diameter). The
number ofjumps during a 5-min period was counted for 30 min after naloxone injection.
Neurochemical analysis
       The concentrations of noradrenaline (NA) and 3-methoxy-4-hydroxyphenyleneglycol
(MHPG) were estimated using high-performance liquid chromatography (HPLC) with
electrochemical detection (ECD), as previously described (34). Morphine-dependent diabetic
and non-diabetic mice were sacrificed 5 min after naloxone (O.3 mglkg, s.c.) or saline (10
mllkg, s.c.) injection, then immersed in a dry ice-cold solution. The brain was quickly
removed and the cerebral cortex was dissected on an ice-cold glass plate. The HPLC system
-
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consisted ofa delivery pump (EP-300, Eicom Co., Japan), an analytical column (EICOMPAC
MA-50DS, Eicom Co., Japan) and a guard column (Eicom, Co., Japan). The electrochemical
detector (EC-100, Eicom Co., Japan) included a graphite electrode (WE-3G, Eicom Co.,
Japan).
Intracerebroventricular inj ection
       Intracerebroventricular (i.d.v.)
described in Experiment 1-2.
administration was performed following the method
Drugs
       The drugs used were streptozotocin (Sigma Chemical Co., St. Louis, MO), morphine
hydrochloride (Sankyo Co., Tokyo, Japan), and naloxone hydrochloride (Sigma Chemical Co.,
St. Louis, MO). Ryanodine was purchased from Calbiochem-Novabiochem International (San
Diego, CA). Thapsigargin was purchased from Research Biochemical International (Natic,
MA). Ryanodine was injected 15 min before the injection of naloxone. Thapsigargin was
injected lh before the injection of naloxone. The dose and schedule for ryanodine and
thapsigargin in this study were determined as described previously (Smith and Stevens, 1995).
Data analysis
       The data are expressed as means Å} S.E. The statistical significance of differences
between groups was assessed with Student's t-test (comparison of two groups) or an analysis
ofvariance (ANOVA) followed by Dunnet's test (comparison among multiple groups). NA
turnover was determined as the NA ratio: NA ratio == MHPG (nglg ofwet tissue) 1 NA (nglg
ofwet tissue).
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Results
Influence ofa ryanodine on naloxone-precipitated withdrawal jumping
       Subcutaneous injection of naloxone (O.3 mg/kg) invariably provoked withdrawal
jumping within 2 to 15 min in morphine-dependent non-diabetic mice and reached its
maximum within 5 min after naloxone injection (Fig. 2-17A, 2-18A). In morphine-dependent
diabetic mice, s.c. injeetion of naloxone (O.3 mglkg) also provoked withdrawal jumping
within 15 min. However, the number ofnaloxone-precipitated withdrawal jumps within 5 min
after naloxone challenge was significantly less in morphine-dependent diabetic mice than in
morphine-dependent non-diabetic mice (Fig. 2-18A, 1-18B). The effects of ryanodine on the
number of naloxone-precipitated withdrawal jumps in morphine-dependent diabetic and non-
diabetic mice are shown in fig. 2-17. Naloxone-precipitated withdrawal jumping was
markedly attenuated by the i.c.v. administration of ryanodine (1.0 nmol) in morphine-
dependent non-diabetic mice. However, naloxone-precipitated withdrawal jumping in
morphine--dependent diabetic.mice was not affected by i.c.v. pretreatment with ryanodine (1.0
nmol). As shown in fig. 2-17B, the number ofnaloxone-precipitated withdrawal jumps within
5 min after naloxone challenge was dose-dependently attenuated by i.c.v. pretreatment with
ryanodine (O.3 and 1.0 nmol) in morphine-dependent non-diabetic mice. However, the
number ofnaloxone-precipitated withdrawal jumps in morphine-dependent diabetic mice was
not affected by i.c.v. pretreatment with ryanodine (O.3 and 1.0 nmol).
Infiuence ofthapsigargin on naloxone-precipitated withdrawal jumping
       The effect of thapsigargin on the number of naloxone-precipitated withdrawal jumps
in morphine-dependent diabetic and non-diabetic mice is shown in fig. 2-18. In morphine-
dependent non-diabetic mice, but not in morphine-dependent diabetic mice, naloxone-
precipitated withdrawal jumping within 5 min after naloxone challenge was attenuated by
i.c.v. pretreatment with thapsigargin (1.0 nmol). As shown in fig. 2-18B, i.c.v. pretreatment
with thapsigargin (O.3 and 1.0 nmol) 1 h before naloxone injection dose-dependently
increased naloxone-precipitated withdrawal jumps within 5 min after naloxone injection.
However, i.c.v. pretreatment with thapsigargin (O.3 and 1.0 nmol) had no significant effect on
the number of naloxone-precipitated withdrawal jumping within 5 min after naloxone
-
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injection in morphine-dependent diabetic mice.
Influences of ryanodine and thapsigargin on naEoxone-induced changes
NA turnover in the frontal cortex
in the level of
       The level ofNA turnover in the frontal cortex was significantly lower in morphine-
dependent diabetic mice than in morphine-dependent non-diabetic mice (Fig. 2-19A and B).
The level ofNA turnover in the frontal cortex in morphine-dependent non-diabetic mice was
significantly increased 5 min after naloxone challenge, compared with that in the saline-
challenged morphine-dependent non-diabetic mice (Fig 2-19A and B). However, a naloxone-
induced increase in the NA turnover was not observed 5 min after naloxone challenge in
morphine-dependent diabetic mice (Fig. 2-19A and B). As shown in fig. 2-19A, a naloxone-
induced increase in the NA turnover was attenuated by pretreatment with ryanodine (1.0 nmol,
i.c.v.) in morphine-dependent non-diabetic mice (Fig. 2-19A). I.c.v. pretreatment with
ryanodine did not affect the NA turnover in naloxone-challenged morphine-dependent
diabetic mice (Fig. 2-19A). I.c.v. pretreatment with thapsigargin (1.0 nmol) 1 h before the
injection of naloxone increased a naloxone-induced increase in NA turnover in the frontal
cortex in morphine-dependent non-diabetic mice (Fig. 2-19B). However, this enhancement of
the naloxone-induced increase in NA turnover was not statistically significant.
-
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Figure 2-16. (A) The effect of ryanodine on the time course of the number of naloxone-
precipitated withdrawal jumps in morphine-dependent diabetic and non-diabetic mice.
(B) The dose-related effect of ryanodine (O.3 and 1.0 nmol) on the number of naloxone-
precipitated withdrawal jumps within 5 min after naloxone challenge in morphine-
dependent diabetic and non-diabetic mice. Ryanodine (O.3 or 1.0 nmol) and saline were
injected 15 min before the administration of naloxone (O.3 mglkg, s.c.). Each point or
column represents the mean Å} S.E. of 9-10 mice. *PÅqO.05 versus non-diabetic mice.
#PÅqO.05 versus the respective saline-treated groups.
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Figure 2-17. (A) The effect of thapsigargin on the time course of the number of
naloxone-precipitated withdrawal jumps in morphine-dependent diabetic and non-
diabetic mice. (B) The dose-related effect of thapsigargin on the number of naloxone-
precipitated withdrawal jumps within 5 min after naloxone challenge in morphine-
dependent diabetic and non-diabetic mice. Thapsigargin (O.3 and 1.0 nmol) and vehicle
were injected i.c.v. Ih before the administration of naloxone (O.3 mglkg, s.c.). Each
point or column represents the mean Å} S.E. of 9-10 mice. *PÅqO.05 versus non-diabetic
mice. #PÅqO.05 versus the respective vehicle-treated groups.
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Figure 2-18. The effects of ryanodine (A) and thapsigargin (B) on naloxone-induced
increase of NA turnover in the frontal cortex in morphine-dependent diabetic and non-
diabetic mice. Ryanodine (Ryn; 1.0 nmol) and saline were injected 15 min before the
administration of naloxone (O.3 mg/kg, s.c.) (A). Thapsigargin (1.0 nmol) and vehicle
were injected i.c.v. 1 h before the administration of naloxone (O.3 mglkg, s.c.). Each
column represents the mean with S.E. of 4-5 mice. *PÅqO.05 versus saline-challenged
morphine-dependent non-diabetic mice. #PÅqO.05 versus naloxone challenged chronic
morphine-treated group. $PÅqO.05 versus respective non-bdiabetic rnice.
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Discussion
       The results of"Experiment 2-1" show that morphine-dependent diabetic mice exhibit
a differential sensitivity to naloxone challenge with regard to body weight loss, and jumping
and body shakes. Indeed, the naloxone-induced loss of body weight is much greater in
diabetic mice than in non-diabetic mice, whereas naloxone-induced jumping and body shakes
are relatively less in diabetic mice. Suzuki et al. (1992a) previously demonstrated that
naloxone-precipitated jumping and body shakes are much less in CXBK mice than in
C57BL16 mice. However, they found no significant difference in naloxone-precipitated
diarrhea, body weight loss and ptosis between CXBK and C57BL16 mice (Suzuki et al.,
1992a). Moskowitz and Goodman (1985) found that the CXBK mouse is deficient in p-opioid
receptors, whereas the 6-opioid receptor population is less consistently altered. Furthermore,
they demonstrated that the CXBK mouse was particularly deficient in pi-opioid receptor
binding (Moskowitz and Goodman, 1985). Based on these results, Suzuki et al. (1992a)
previously suggested that naloxone-precipitated jumping and body shakes in morphine-
dependent mice may be mediated by pt,-opioid receptors, but that diarrhea, body weight loss
and ptosis appeared to be mediated by p,- andlor 6-opioid receptors. Furthermore, Kamei et al.
(1994a) proposed that the diabetic mouse is selectively deficient in pi-opioid receptors, but
not in Ii2-opioid receptors. Thus, the present and previous findings support the hypothesis that
naloxone-precipitated jumping and body shakes in morphine-dependent mice may be
mediated by p,-opioid receptors.
       Cowan et al. (1988) reported that rats treated with p- but not 6-opioid agonists
showed ptosis after naloxone injection. Moreover, Suzuki et al. (1992a) reported that there
was no difference in the incidence of naloxone-precipitated ptosis between morphine-
dependent CXBK and C57BL/6 mice. Thus, they have concluded that naloxone-precipitated
ptosis may be mediated by p2-, but not pi- or 6-opioid receptors. In the present study,
naloxone-precipitated ptosis in diabetic mice was not different from that in non-diabetic mice,
suggesting that p2-opioid receptor--mediated function in the development of physical
dependence on morphine is not altered in diabetic mice, as compared to that in non-diabetic
mice.
       In the present study, although the incidence of naloxone-precipitated diarrhea in
morphine-dependent diabetic mice was similar to that in morphine-dependent non-diabetic
mice, the amount of naloxone-precipitated body weight loss in morphine-dependent diabetic
-
96-
mice was significantly greater than that in morphine-dependent non-diabetic mice. This result
is not consistent with previous result using CXBK mice (Suzuki et al., 1992a). The amount of
naloxone-precipitated body weight loss in morphine-dependent CXBK mice was similar to
that in morphine-dependent C57BL16 mice, as was the incidence of naloxone-precipitated
diarrhea (Suzuki et al., 1992a). Heyman et al. (1988) reported that morphine and DA]NilGO
mediated their antitransit effects at a naloxonazine-insensitive site, referred to as p2-opioid
receptor. Based on these results, we suggested that naloxone-precipitated diarrhea and body
weight loss appeared to be mediated by p,- andfor 6-opioid receptors (Suzuki et al., 1992a).
As mentioned above, it is suggested that pt,-opioid receptor--mediated function in the
development ofphysical dependence on morphine is not altered in diabetic mice, as compared
to that in non-diabetic mice. Furthermore, Kamei et al. (1992a, 1994b) previously suggested
that supraspinal 6-opioid receptors are up-regulated in diabetic mice, since the antinociceptive
effect of i.c.v. [D-Pen2'5]enkephalin (DPDPE), a selective 6-opioid receptor agonist, in
diabetic mice was significantly greater than that in non-diabetic mice. Moreover, Miyamoto et
al. (1993a, 1993b) recently suggested that 6-opioid receptors were involved in the
development of morphine dependence. Thus, naloxone-precipitated body weight loss may be
mediated by 6-opioid receptors. However, it is well-known that naloxone-precipitated body
weight loss in morphine-dependent animals may be primarily due to naloxone-precipitated
diarrhea (Goode, 1971). It has been assumed that the diarrhea which results from morphine
withdrawal is caused by an increase in gastrointestinal motility (Kaymakcalan and Temelli,
1964; Collier et al., 1972; Brown et al., 1988). In this regard, accumulating evidence suggests
that autonomic neuropathy is a common complication in diabetic patients. In fact, it has been
reported that diarrhea is common in patients with diabetes mellitus, suggesting that diabetes is
associated with dysfunction ofthe autonomic nervous system ofthe gut (Hosking et al., 1978).
In the present study, furthermore, I observed that the amount of naloxone-precipitated body
weight loss in chronically saline-treated (non-dependent) diabetic mice was also significantly
greater than that in chronically saline-treated (non-dependent) non-diabetic mice. Furthermore,
in Chapter 2-2, I demonstrated that there was no significant difference between the ED50
values of the naloxonazine-insensitive antitransit effect of morphine in non-diabetic and
diabetic mice. Namely, diabetes failed to alter the p,-opioid receptor-mediated antitransit
effect ofmorphine. Thus, it is also possible that the potent naloxone-precipitated body weight
loss in morphine-dependent diabetic mice, as compared to that in morphine-dependent non-
diabetic mice, may be due to the intensity ofthe increase in gastrointestinal motility caused by
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dysfunction ofthe autonomic nervous system ofthe gut.
       In conclusion, the present results suggest that pti-opioid receptor•-mediated function
in the development ofphysical dependence on morphine in diabetic mice is significantly less
than that in non-diabetic mice, and support our hypothesis that mice with diabetes are
selectively hypo-responsive to pi-opioid receptor-mediated pharmacological action, but not to
that which is mediated by p,-opioid receptors.
       In Experiment 2-2, I indicated that the antitransit effect of s.c. morphine is
significantly antagonized by pretreatment with B-funaltrexamine, but not by pretreatment with
naloxonazine. These results are consistent with the findings ofHeyman et al. (1988) and Pick
et al. (1991), and suggest that pt2-opioid receptors may play an important role in the antitransit
effect of morphine.
       The results of Experiment 2-2 also demonstrated that the dose-dependent antitransit
effect of morphine can be observed not only in non-diabetic, but also in diabetic mice.
Furthermore, there was no significant difference between the ED50 values of the antitransit
effect of morphine in non-diabetic and diabetic mice. The antitransit effect of s.c. morphine in
diabetic mice is also significantly antagonized by pretreatment with P-funaltrexamine, but not
by pretreatment with naloxonazine. Moreover, there is no significant difference in the effect
ofB-funaltrexamine on morphine-induced antitransit effect between diabetic and non-diabetic
mice. Kamei et al. (1992 eq b, 1994a) previously reported that diabetic mice are selectively
hypotesponsive to pti-opioid receptor-mediated pharmacological actions, i.e. supraspinal
antinociception, but not to those mediated by p,-opioid receptors, i.e. spinal antinociception
(Kamei et al, 1994a) and the antitussive effect (Kamei et al, 1994c). This hypothesis is further
supported by the present results.
       In the present study, the antitransit effect of morphine was not completely
antagonized by pretreatment with B-funaltrexamine. In this regard, Porreca and Burks (1983)
suggested that 6-opioid receptors may mediate the antigastrointestinal transit effects of
opioids at the spinal cord level, since i.t. administration of6-opioid receptor agonists such as
D-Ala2-D-Leu5-enkephalin, D-See-Leu-enkephalin-(Thr6) and D-Pen2-L-Cys5-enkephalin,
consistently inhibited gastrointestinal transit. These results suggest that the antitransit effects
of opioids are mediated by both pt- and 6••opioid receptors. Kamei et al. (1992b) previously
reported that there was no significant difference in the supraspinal and spinal 6-opioid
receptor-mediated antinociceptive effects between non-diabetic and diabetic mice. Thus, it
seems likely that spinal 6-opioid receptors may have an important role in the antitransit effect
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of morphine in both non-diabetic and diabetic mice. This possibility appears to provide a
plausible explanation for the partial antagonism of P-funaltrexamine on the antitransit effect
ofmorphine.
       In conclusion, the results from Experiment 2-2 demonstrated that diabetes failed to
alter the l.i?-opioid receptor-mediated antitransit effect of morphine. This conclusion supports
the hypothesis that diabetic mice are selectively hyporesponsive to pi-opioid receptor-
mediated pharmacological action, but not to that which is mediated by p2-opioid receptors.
       In Experiment 2-3, I indicated that morphine-dependent diabetic mice jump less
within 5 min after naloxone challenge than morphine-dependent non-diabetic mice. This
result supports the previous suggestion that morphine-dependent diabetic mice exhibit a less
sensitivity to naloxone challenge with regard to withdrawal jumping.
       In the present study, I observed a significant increase in NA turnover in the frontal
cortex in morphine-dependent non-diabetic mice 5 min after naloxone challenge, when the
incidence ofwithdrawal jumping was at its peak. The central noradrenergic system has been
hypothesized to be involved in morphine dependence and withdrawal (Redmond and Krysatal,
1984). In a microinjection study using naltrexone, it was shown that the LC region is the most
sensitive site for the expression ofmorphine withdrawal signs (Maldonado et al., 1992). It has
been reported that the firing rate of noradrenergic neurons in the LC, which is a cluster of
NA-containing cell bodies in the brain, increases during naloxone-precipitated withdrawal
from morphine (Aghajanian, 1978). Furthermore, it has been reported that treatment with
DSP-4, a noradrenergic neurotoxin that selectively damages the NA-containing nerve endings
that project from the LC, before the naloxone challenge suppresses the expression of
morphine withdrawal signs, including jumping and "wet dog" shakes (Funada et al., 1994).
Moreover, in a biochemical study, the level of 3-methoxy-4-hydroxyphenylethyleneglycol
(MHPG), the major metabolite of NA, in the cerebral cortex which projects from LC,
increased following naloxone challenge in morphine-dependent rats and mice (Crawley et al.,
1979; Funada et al., 1994). These reports and the present study strongly suggest that LC
noradrenergic neurons are involved in morphine dependence andlor withdrawal.
       In the present study, I found that NA turnover in the frontal cortex was significantly
lower in chronically saline-treated (non-dependent) diabetic mice than in chronically salineny-
treated (non-dependent) non-diabetic mice. Thus, it is likely that noradrenergic
neurotransmission in the frontal cortex, especially in the LC, may be reduced in diabetic mice,
compared with that in non-diabetic mice. Furthermore, the results of our experiment suggest
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an association between noradrenergic neurotransmission in the frontal cortex and the
incidence of naloxone-precipitated withdrawal jumping. Indeed, NA turnover in the frontal
cortex had not changed at 5 min after naloxone challenge in morphine-dependent diabetic
mice, although the incidence of naloxone-induced jumping was significantly lower in
morphine-dependent mice than in morphine-dependent non-diabetic mice at this point. In
contrast, the NA turnover in frontal cortex was significantly increased at 10 min after
naloxone challenge in morphine-dependent mice, when the incidence of naloxone-induced
jumping was increased to the levels that were observed in morphine-dependent non-diabetic
mice.
       In conclusion, the findings of Experiment 2-3 raise possibility that the reduction in
noradrenergic neurotransmission in the LC noradrenergic system may be associated with the
reduction in the incidence of naloxone-precipitated withdrawal jumping at 5 min after
naloxone challenge in morphine-•dependent diabetic mice, as compared with that in non-
diabetic mice.
       In Experiment 2-4, I found that the i.c.v. administration of a PKC inhibitor,
calphostin C, attenuated the expression of naloxone-precipitated withdrawal jumping in
morphine-dependent non-diabetic mice. Moreover, the expression of naloxone-precipitated
withdrawal jumping was also attenuated by i.c.v. pretreatment with the PKA inhibitor KT-
5720 in morphine-dependent non-diabetic mice. Furthermore, naloxone-induced increase in
NA turnover in the frontal cortex in morphine-dependent non-diabetic mice is attenuated by
i.c.v. pretreatment with either calphostin C and KT5720 1 hr before naloxone challenge. Many
investigators indicated that chronic morphine administration increases levels of adenylyl
cyclase and PKA in the LC (Nestler et al., 1992; Duman e al., 1988). These adaptations have
been shown to increase the electrical excitability of LC neurons (Alreja and Aghajanian,
1991; Kogan et al., 1992; Shiekhattar and Aston-Jonse, 1993) and appear to contribute to
activation ofthe LC seen on precipitation ofwithdrawal (Kogan et al., 1992; Rasmmussen et
               -dal., 1990). Thus, it is also possible that the attenuation of naloxone-induced increase in the
level of NA turnover in the frontal cortex in morphine-dependent non-diabetic mice is
produced by the inhibition of PKA by KT5720 in LC. Furthermore, several recent studies
have indicated that PKC activity is involved in opiate tolerance and dependence (Collier.
1980; Mayer et al., 1995). It was reported that chronic treatment with morphine induced a
modest, naloxone-sensitive, increase in cytosolic, but not membrane, PKC activity in rat brain
(ponslmedulla but not cortex and midbrain regions)(Narita et al., 1994). Furthermore, H-7
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have been inhibited the withdrawal signs and the increase in glutamate levels, which induce
NA release in the frontal cortex, in the LC of opioid-dependent animal (Tokuyama et al.,
1997). Thus, it is possible that the activation of PKC, as well as PKA, in the LC may be
modulate naloxone-induced increase of NA turnover in the frontal cortex and the naloxone-
precipitated withdrawal jumping in morphine-dependent rodents.
       In the present study, i.c.v. pretreatment with PDBu 1 hr before the last injection of
morphine attenuated increase in NA turnover in the frontal cortex and the naloxone-
precipitated withdrawal jumping in morphined-dependent non-diabetic mice. The mechanisms
which underlie the attenuation of naloxone-induced increase in NA turnover in the frontal
cortex and the expression of naloxone-precipitated withdrawal jumping in morphine-
dependent non-diabetic mice by PKC activator are unclear. It was reported that the abundance
of p-opioid receptors was not significantly altered in morphine-dependent human and rats
(Garcia-Sevilla et al., 1997). The phosphorylation ofreceptdrs by PKC has been proposed to
be a possible mechanism for the development of desensitization (Shearman et al., 1989). It is
reported that activation of PKC by phorbol ester potentiates the desensitization of p-opioid
receptor induced K' current (Chen and Yu, 1994). We recently reported that the activation of
PKC by PDBu leads to the desensitization of p-opioid receptor-mediated antinociception
(Narita et al., 1997). In view of these results, present data suggests that attenuation of
naloxone-induced increase in NA turnover in the frontal cortex and the expression of
naloxone-precipitated withdrawal jumping by the activation of PKC may be due to the
desensitization of pt-opioid receptor. However, it was reported that long term treatment with
phorbol ester has desensitized or downregulated PKC in mouse neuroblastoma NIE-15 cells,
when the cells were treated with 100 nM PDBu for 24 hr (Lai and El-Fakahany, 1988). In the
present study, the effect of PDBu on naloxone-precipitated withdrawal jumping in morphine
dependent non-diabetic mice exerts the same effect as the PKC inhibitor. Therefore, it is also
possible that the effect of PDBu on naloxone-induced increase in NA turnover in the frontal
cortex and naloxone-precipitated withdrawal jumping in morphine-dependent non-diabetic
mice may be due to the desensitization or down-regulation of PKC. Because desensitization
ofPKC by phorbol ester requires a long-term treatment, it is unlikely that the desensitization
of PKC by phorbol ester produce the attenuation of naloxone-induced increase in NA
turnover in the frontal cortex and naloxone-precipitated withdrawal jumping in morphine-
dependent non-diabetic mice. Therefore, it is most likely that the attenuation of naloxone-
induced increase in NA turnover in the frontal cortex and naloxone-precipitated withdrawal
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jumping in morphine-dependent non-diabetic mice may be due to the desensitization of p-
opioid receptors induced by activation ofPKC.
       In Experiment 2-4, I observed that morphine-dependent diabetic mice jump less
within 5 min after naloxone challenge than morphine-dependent non-diabetic mice.
Furthermore, NA turnover in the frontal cortex was not affected by naloxone challenge.
Moreover, the expression of naloxone-precipitated withdrawal jumping in morphine-
dependent diabetic mice was not attenuated by i.c.v. pretreatment with the protein kinase A
inhibitor KT-5720. There was a significant increase in the number of naloxone-precipitated
withdrawal jumps within 5 min after naloxone challenge in morphine-dependent diabetic
mice by i.c.v. pretreatment with calphostin C. Furthermore, I observed that pretreatment with
a PKC activator, phorbol-12,13--dibutyrate (PDBu), 1 h before morphine injection attenuated
the naloxone-precipitated withdrawal jumping in morphine-dependent non-diabetic mice, but
not in morphine-dependent diabetic mice. This result suggests that the activation of PKC by
PDBu before morphine injection inhibits the expression of naloxone-precipitated withdrawal
jumping in morphine--dependent non-diabetic mice. Thus, it is likely that the attenuation of
naloxone-precipitated withdrawal jumping in morphine-dependent diabetic mice may be due
to the increased activity ofPKC, since i.c.v. pretreatment with calphostin C increased, while
i.c.v. pretreatment with PDBu did not affect, the number of naloxone-precipitated withdrawal
jumps in morphine-dependent diabetic mice. In the present study, pretreatment with KT5720
did not affect the NA turnover in naloxone-challenged morphine-dependent diabetic mice.
This result is consisted with behavioral data. Although pretreatment with calphostin C
increased the naloxone-precipitated withdrawal jumping in morphine-dependent diabetic mice,
pretreatment with calphostin C did not affect the NA turnover in naloxone-challenged
morphine-dependent diabetic mice. This result contravenes the hypothesis that naloxone-
precipitated withdrawal jumping is produced by the increase of NA turnover in the frontal
cortex. There is accumulating evidence that the activation ofPKC regulates several cellular
functions through the phosphorylation ofproteins, including some receptors, whose function
is then down-regulated (Moran and Dascal, 1989). It has been reported that the activation of
PKC by phorbol esters induces to decrease the affinity andlor responsiveness of ct- and P-
adrenergic receptors (Corvera and Garcia-Sainz, 1984; Sibley et al., 1984). Many
investigators have reported that hyperglycemia or elevated glucose levels can increase
diacylglycerol (DAG) levels and activate PKC in vascular tissue, cardiac tissues or cultured
cells (Craven and De Rubenis, 1989; King et al., 1990; Inoguchi et al,, 1992; Tanaka et al.,
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l991). Furthermore, in Chapter 1, I indicated that calphostin C, a protein kinase C inhibitor,
reverses the attenuation ofDAMoo-induced antinociception in diabetic mice to the level in
non-diabetie mice. Thus, it is expected that activation ofPKC in diabetic mice may induce the
phosphorylation ofseveral proteins, including some receptors, in the brain. In view ofthese
data and present data, it is possible that the enhancement of naloxone-precipitated withdrawal
jumping in calphostin C-treated morphine-dependent diabetic mice may be result from the
inhibition of phosphorylation of several receptors and proteins, including oc- and B-adrenergic
receptors, but not from the enhancement of NA release, induced by PKC. However, further
detail studies are necessary before this possibility can be established with greater certainty.
       In conclusion, the results of Experiment 2-t4 indicate that both the brain PKC and
PKA systems may play a major role in morphine dependence. Elucidating the possible in vivo
cross-communication between these regulatory enzymes may be important for a better
understanding of the cellular and molecular bases of morphine addiction. Moreover, the
functional up-regulation in intracellular PKC systems may be partly associated with the
reduction in the incidence ofnaloxone-precipitated withdrawal jumping 5 min after naloxone
challenge in morphine-dependent diabetic mice.
       In Experiment 2-5, pretreatment with ryanodine attenuated naloxone-precipitated
withdrawal jumping in morphine-dependent non-diabetic mice, Furthermore, naloxone-
induced enhancement of noradrenaline (NA) turnover in morphine-dependent non-diabetic
 mice was also attenuated by pretreatment with ryanodine. It has been reported that ryanodine
 blocks the Ca2'/caffeine sensitive microsomal pools, which are involved in the phenomenon
 ofCa2'-induced Ca2' release (McPherson et al., 1991). Furthermore, it has been reported that
 ryanodine reduces the rate at which [Ca2'], increases with Ca2' entry (Friel and Tsien, 1992).
 Furthermore, it is reported that ryanodine reduces the NA overflow (Bourreau, 1996). Thus, it
 is likely that the attenuation of naloxone-precipitated withdrawal jumping and NA turnover in
 morphine-dependent non-diabetic mice caused by ryanodine may be due to a decrease in
 [Ca2'],. In contrast to ryanodine, thapsigargin enhanced the naloxone-precipitated withdrawal
 jumping in morphine-dependent non-diabetic mice. Moreover, thapsigargin also increased
 naloxone-induced enhancement of NA turnover in morphine-dependent non-diabetic mice.
 Thapsigargin selectively inhibits Ca2' uptake into the IP3-sensitive microsomal Ca2' pool by
 inhibiting ATPIMg-dependent ATPase (Bian et al., 1991). The subsequent depletion of this
 pool activates a low-conductance, Ca2'-sensitive, non-voltage activated membrane current
 (Premack et al., 1994; Takemura et al., 1991). Thus, it is possible that thapsigargin increases
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[Ca2']i. It has been reported that cyclopiazonic acid, an inhibitor of endoplasmic reticulum
Ca2'-ATPase inhibitor, enhances the NA overflow in rat vas defences (Bourreau, 1996). Thus,
it is possible that NA release in neurons may modulate the intracellular [Ca2"]i. Therefore,
thapsigargin-induced enhancement of naloxone-precipitated withdrawal jumping and
naloxone-induced increase in NA turnover in morphine-dependent non-diabetic mice may be
due to the increase in [Ca2']i.
       Many investigators have indicated that the blockade of L- and N-type calcium
channels inhibits the expression of naloxone-precipitated withdrawal signs in morphine-
dependent mice and rats (Basilico et al., 1992; Bongianni et al., 1986; Tokuyama et al., 1995).
In contrast to calcium channel blocker, L-type calcium channel opener, Bay K 8644, increases
the severity of naloxone-precipitated withdrawal in acute morphine-dependent rats (Banios
and Baeyens, 1991). Furthermore, it has been reported that naloxone-induced enhancement of
NA metabolism is blocked by L-type calcium channel blockers, nimodipin and verapamil
(Bongianni et al., 1986). Hence, infiux of Ca2' into the cytoplasm through the calcium
channels may be involved in the expression of naloxone-precipitated withdrawal signs and
naloxone-induced activation of NA neurons in morphine-dependent animals. Intracellular
calcium modulators used in this study have the same propenies as calcium channel blocker or
activator, since ryanodine suppresses and thapsigargin increases the naloxone-induced
withdrawal jumping in morphine-dependent non-diabetic mice. However, Fundytus and
Coderre (1994) reported that a single injection of thapsigargin prior to the precipitation of
withdrawal failed to increase the severity of abstinence symptoms in morphine-dependent rats.
This result contradicted our present data. In the study of Fundtus and Coderre (1994),
thapsigargin was injected 10 min prior to naloxone injection, whereas in the present study,
thapsigargin was injected 60 min before injection ofnaloxone. Furthermore, the estimation of
naloxone-precipitated withdrawal in the present study also differed from Fundytus and
Coderre (1994). Thus, differences in the results between our data and the results ofFundytus
and Coderre (1994) may be due to different experimental conditions.
       In Experiment 2-5, I observed that morphine-dependent diabetic mice jump less
within 5 min after naloxone challenge than morphine-dependent non-diabetic mice.
Furthermore, NA turnover in the frontal cortex was not affected by naloxone challenge.
Moreover, the expression of naloxone-precipitated withdrawal jumping in morphine-
dependent diabetic mice was not affected by pretreatment with either thapsigargin or
ryanodine. It has been reported that chronic excessive intracellular calcium overload might
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induce cardiac dysfunction in chronic diabetes (Heyliger et al., '1987; Nishio et al., 1990). In
peripheral nerves of diabetic rats, mitochondrial and axoplasmic calcium levels were found to
be increased by electron-probe X-ray microanalysis (Lowery et al., 1990). Moreover, voltage-
dependent calcium currents through L- and N-channels are enhanced in dorsal root ganglion
neurons ofBBfWor rats and diabetic mice in vivo (Hall et al., 1995; Kostyuk et al., 1995).
These results suggest that the diabetic state may affect calcium homeostasis in neurons and
various tissues. Furthermore, it has been suggested that the ability of caffeine, a ryanodine
receptor agonist, to mobilize Ca2' from intracellular stores is impaired in the diabetic aorta,
since caffeine-induced contraction is significantly reduced in the diabetic aorta compared with
that in the control aorta. Moreover, it has been reported that the activity of Ca2'-ATPase is
impaired in the diabetic rat (Janicki et al., 1994). Therefore, it is possible that diabetes is an
anomalous intracellular calcium homeostasis. In the present study, i.c.v. pretreatment with
thapsigargin and ryanodine did not affect the naloxone-precipitated withdrawal jumping in
morphine-dependent diabetic mice. Thus, it is possible that the attenuation of naloxone-
precipitated withdrawal jumping in morphine-dependent diabetic mice may be due to
anomalous intracellular calcium homeostasis followed by changes in calcium store function.
       In conclusion, the results of Chapter 2 suggested that the attenuation of naloxone-
precipitated withdrawal jumping in morphine-dependent diabetic mice may be due to the
dysfunction ofcentral noradrenergic systems, followed by the activation ofPKC and increase
in [Ca2']i.
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Chapter 3
Modification ofreinforcing effect of several addictive drugs
                by diabetes in mice
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Introduction
       The conditioned place preference paradigm is reliable technique for measuring the
reinforcing propenies ofdrugs, and is particularly usefu1 for evaluating the reinforcing effects
of addictive drugs, such as morphine, methamphetamine and cocaine. The conditioned place
preference paradigm was recently used to demonstrate that morphine has a strong
conditioning effect in mice as well as rats (Suzuki et al., 1993). Moreover, an additional
important feature of the conditioned place preference paradigm is that both agonist and
antagonists can be evaluated without any complicating behavioral motor effects (Hoffman,
1989).
       The reinforcing effects of opioids, such as morphine and heroin, have been
demonstrated using self-administration and conditioned place preference procedure in rodents
and other mammalians. The place conditioning study in rats and mice provided evidence that
motivational effects of pt- and 6-opioid agonists result from the activation of pt- and 6-opioid
receptors in the central neuron systems, respectively (Shippenberg et al., 1987; Suzuki et al.,
1991, 1993, 1994). Such findings suggest that the activation of supraspinal pt- and/or 6-opioid
receptors is required for the expression of the reinforcing effect of opioids. Suzuki et al.
(1993) previously demonstrated that systemic administered morphine produced a place
preference in pi-opioid receptor-deficient CXBK mice. Furthermore, the morphine-induced
place preference in mice was not blocked by pretreatment naloxonazine, a selective pi-opioid
receptor antagonist. Based on these results, Suzuki et al. (1993) suggested that morphine
produces its motivational effects via naloxonazine-•insensitive pt-opioid receptors; namely p2-
opioid receptors. Furthermore, they suggested that 6i- and 6,-opioid receptors may be
involved in the modulation of the reinforcing effect of morphine, since the morphine-induced
place preference is blocked by pretreated with naltrindole, a selective 6-opioid receptor
antagonist, 7-benzylidenenaltrexone, a selective 6i-opioid receptor antagonist, and naltriben, a
selective 6,-opioid receptor antagonist (Suzuki et al., 1994).
       It has been reported that the antinociceptive potency, but not maximal effect, of
morphine was decreased in several rodent models of hyperglycemia, including a
spontaneously diabetic strain mice, streptozotocin-induced diabetes, a model animal oftype I
diabetes (Simon and Dewey, 1981). In Chapter 2, I indicated that the induction of physical
dependence on morphine was also significantly decreased in streptozotocin-induced diabetic
mice. In a clinical study, Morley et al. (1984) showed a significant decreased pain tolerance in
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diabetic patients and in normal fasted subjects and suggested that the painfu1 neuropathy
experienced by some diabetic patients might involve an interaction ofglucose with the action
of endogenous opioid peptides.
       Recently, Kamei et al. (l994a) demonstrated that the potency of naloxonazine-
sensitive pharmacological actions of pt-opioid receptor agonists, i.e. supraspinal
antinociception, Straub tail reaction and locomotor-enhancing effect, in diabetic mice were
markedly reduced as compared with in non-diabetic mice. Furthermore, in Chapter 2, I
indicated that pi-opioid receptor-mediated naloxone-precipitated signs of withdrawal from
physical dependence on morphine in diabetic mice are significantly less than those in non-
diabetic mice. In contrast, there was no significant difference in naloxonazine-insensitive
pharmacological actions of p-opioid receptor agonist, i.e. spinal antinociception and
antitussive effect, between diabetic mice and non-diabetic mice (Kamei et al., 1993a, b,
1994a). Therefore, we proposed that mice with diabetes are selectivelY hyporesponsive to
activation of pi-opioid receptors, but are normally responsive to p,--opioid receptors. On the
other hand, Kamei et al. (1994b) previously reported that the 7-benzylidenenaltrexone-
sensitive antinociceptive effect of [D-Pen2'5]enkephalin (DPDPE) was significantly greater in
diabetic mice than in non-diabetic mice, whereas there was no significant difference in the
naltriben-sensitive antinociceptive effect of [D-Ala2]deltorphinell between diabetic and non-
diabetic mice. These findings suggested that mice with diabetes are selectively
hyperresponsive to activation of6i-opioid receptors, but are normally responsive to 62-opioid
receptors. Therefore, functional abnormalities in pt- and 6-opioid receptor functions of
diabetic animals may alter the reinforcing effect of morphine.
       Thus, in Experiment 3-1, I compared the morphine-induced place preference in
diabetic and non-diabetic mice to clarify the hypothesis that functional abnormalities in p-
and 6-opioid receptor functions of diabetic animals may alter the reinforcing effect of
morphine.
       It has been reported that the psychostimulant-induced place preference is abolished
by pretreatment with dopamine receptor antagonists. Indeed, amphetamine-induced place
preference was antagonized by pretreatment with haloperidol, a dopamine receptor antagonist
(Spyraki et al., 1982), or 7-chloro-8-hydroxy-3-methyl-1--phenyl-2,3,4,5--tetrahydro-IH-3-
benzazepine (SCH23390), a selective dopamine D, receptor antagonist (Leone and Di Chiara,
1987). Furthermore, microinjection of (+)-amphetamine into the nucleus accumbens resulted
in a place preference (Carr and White, 1986). Moreover, amphetamine increases extracellular
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dopamine in various terminal dopamine areas, as estimated by brain microdialysis studies in
free-moving rats (Di Chiara and Imperato, 1988). Based on these results, Di Chiara (1995)
proposed that enhanced dopamine release from the nucleus accumbens may play a critical
role in the acquisition and expression ofpsychic dependence on drugs of abuse.
       Dopamine D3 receptors are part of the dopamine D2-like receptor family (Sokoloff et
al. 1990; Seeman and Van Tol 1994). Dopamine D, receptors are found mainly in limbic
regions ofthe brain, and are involved in cognition, emotion and endocrine functions (Leveque
et al., 1992). The dopamine receptor agonist 7-hydroxy-N,N-di-n-propyl-2-aminotetralin (7-
OH-DPAT) reportedly has a 50- to 100-hold higher affinity for dopamine D3 receptors than
dopamine D, receptors in genetically transfected cells (Levesque et al. 1992). Thus, 7-OH-
DPAT has been used to investigate possible dopamine D, receptor-mediated functions. Recent
evidence has suggested that dopamine D3 receptors may modulate the reinforcing effects of
cocaine and morphine. Since the self-administration of cocaine in rats was decreased by co-
administration of 7-OH-DPA r, Caine and Koob (1993) suggested that preferential stimulation
of dopamine D3 receptors by a low dose of 7-OH-DPAT may modulate the reinforcing
propenies of cocaine. Furthermore, Suzuki et al. (1995) reported that morphine-induced
hyperlocomotion was attenuated by pretreatment with 7-OH-DPA[r. They also indicated that
the morphine-induced increase in the dopamine metabolites 3,4-dihydroxyphenylacetic acid
(DOPAC) and homovanillic acid (HVA) in the limbic forebrain (nucleus accumbens and
olfactory tubercle) was attenuated by 7-OH-DPAT. These results suggest that the activation of
the presynaptic dopamine D, receptors in the mesolimbic dopamine system may attenuate the
expression of morphine-induced hyperlocomotion. Moreover, it has been reported that the
acquisition and' expression of the morphine-induced place preference are antagonized by
pretreatment with 7-OH-DPAT (Fonseca et al., 1995). These results suggest that the activation
ofdopamine D3 receptors attenuates the rewarding properties ofopioids.
       It is reported that spontaneous locomotor activity in diabetic mice was significantly
greater than that in non-diabetic mice (Kamei et al. 1994d). Furthermo.re, haloperidol and
SCH23390, a selective dopamine Di receptor antagonist, significantly reduced spontaneous
locomotor aetivity in diabetic mice, but not in non-diabetic mice (Kamei et al. 1994d).
Moreover, dopamine turnover (DOPAC+HVAIdopamine) in the limbic forebrain in diabetic
mice was significantly higher than that in non-diabetic mice (Kamei et al. 1994d). These
results led to propose the possibility that neurotransmission in mesolimbic dopamine systems
may be enhanced, rather than reduced, in diabetic mice relative to that in non-diabetic mice
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(Kamei et al., 1994d). Thus, it is possible that methamphetamine-induced place preference
may be greater in diabetic mice than in non-diabetic mice.
       Thus, in Experiment 3-2, I compared methamphetamine-induced place preference in
diabetic and non-diabetic mice to clarify the hypothesis that functional abnormalities in
mesolimbic dopamine systems, especially dopamine D3 receptor function, in diabetic mice
may alter the reinforcing effect ofmethamphetamine.
       Although the reinforcing and stimulant properties of cocaine and related drugs have
been shown to correlate with their binding propenies at the dopamine transporter (Bergman et
al., 1989; Rjtz et al., 1987), it is possible that the cocaine-induced place preference may be
changed in diabetic mice. The aim of Experiment 3-3 was to compared the cocaine-induced
place preference in diabetic and non-diabetic to clarify the hypothesis that functional
abnormalities in mesolimbic dopamine systems in diabetio mice may alter the reinforcing
effect ofcocaine.
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Experiment 3-1: Modification of morphine-induced place preference by diabetes
Materials and Methods
Animals
      Male ICR mice (Tokyo Laboratory Animals Science Co., Tokyo), weighing about 20
g at the beginning of the experiments, were used. The mice were housed under the condition
as described in Chapter 1-1. Animals were rendered diabetic by an injection of streptozotocin
(200 mglkg, i.v.) prepared in O.1 N citrate buffer at pH 4.5. Age-matched non-diabetic mice
were injected with vehicle alone. The experiments were conducted 2 weeks after injection of
streptozotocin or vehicle. Mice serum glucose levels above 400 mg!dl were considered
diabetic.
Place conditioning
      Place conditioning was conducted as previously described using a minor
modification ofbiased procedure (Suzuki et al., 1991) according to the method ofBardo et al.
(1984). The apparatus used was a shuttle box (15 x 30 x 15 cm) which was divided into two
compartments of equal size. One compartment was white with a textured floor and the other
was black with a smooth floor. For conditioning, mice were immediately confined to the
white compartment after drug injections and to the black compartment after saline injections.
Saline conditioning was conducted before confinement to both compartment. In addition,
some group of mice was immediately confined to the black compartment after morphine
injection and to the white compartment after saline injections. Conditioning sessions (3 for
drug: 3 for vehicle) were conducted for a 60-min period once a day. The order of the 6
conditioning sessions was conducted alternating. On day 7, tests of conditioning were
performed as follows: the partition separating the two compartments was raised 7 cm above
the fioor, and a neutral platform was inserted along the seam separating the compartments.
Mice were not given any injections before test session. The time spent in each compartment
during a 900-s session was then measured by a infrared beam sensor (KN-80, Natume, Tokyo,
Japan) in a blinded fashion. The position ofthe rnouse was defined by the position of its body.
All sessions were conducted under conditions ofdim illumination (40 lux) and white masking
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noise. Mice exhibited no preference for either ofthe place states under these conditions.
Drugs
Streptozotocin was purchased from Sigma Chemical Co., St. Louis, MO, USA. Morphine
hydrochloride was purchased from Sankyo, Co., Tokyo, Japan. B-Funaltrexamine,
naloxonazine, 7-benzylidenenaltrexone, naltriben and 2-methyl-4aa-(3-hydroxyphenyl)-
1,2,3,4,4a,5,12,12aa-octahydroquinolino[2,3,3-g]isoquinoline (TAN-67) were synthesized by
Dr. Nagase (Toray Industries, Kamakura, Japan). All drugs were dissolved in O.90/o saline
solution. B-Funaltrexamine (10 and 20 mg/kg, s.c.) and naloxonazine (35 mglkg, s.c.) were
injected 24h before injection of morphine. 7-Benzylidenenaltrexone (O.3 and O.7 mglkg, s.c.)
was injected 30 min before injection of morphine. Naltriben (O.1 and O.5 mglkg, s.c.) was
injected 30 min before injection of morphine. The dose and schedule for each opioid receptor
antagonist in this study were determined as described previously (Suzuki'et al., 1993, 1994).
Each antagonist was injected before each morphine injection. Glucose was injected 30 min
before inj ection of morphine.
Data analysis
       Conditioning scores represent the time spent in the drug-paired place minus the time
spent in the vehicle-paired place and are expressed as mean Å} S.E.. Statistical analysis of
difference between groups was assessed with Wilcoxon rank-sum test (comparison of two
groups) or one-way analysis of variance (ANOVA) followed by Kruskal-Wallis test
(comparison between multiple groups). The potency ratio of the morphine-induced place
preference between non-diabetic mice and diabetic mice was calculated using Prograrn 11 of
the Pharmacological Calculations systems of Tallarida and Murray (1987).
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Results
Effects ofdiabetes on morphine-induced place preference
       As shown in Fig. 3-1, none of the mice receiving saline in conditioning sessions
exhibited a significant preference for either compartment of the test box. Testing of
experimentally saline-treated mice on the test session revealed that neither non-diabetic nor
diabetic mice showed a significant preference for one side of the test box over the other. The
place conditioning produced by morphine is shown in Fig. 3-1. In non-diabetic mice,
morphine, at dose ranges from 3 to 30 mglkg, s.c., caused a dose-related preference for the
drug-associated place, and significant conditioning was observed at doses of 5, 10 and 30
mglkg. In diabetic mice, morphine (1 mglkg) induced a slight place preference, although this
effect was not statistically significant. Significant conditioning was observed at doses of3, 5
and 10 mg/kg in diabetic mice. At these doses, all diabetic mice exhibited preference for the
drug-associated place. On the other hand, when morphine (5 mg/kg, s.c.) was paired with
black compartment, morphine also caused a significant place preference in both diabetic
(mean conditioning score of 178.9 Å} 67.9 s, n==7) and non-diabetic mice (mean conditioning
score of 117.2 Å} 34.6 s, n=8). Pretreatment with glucose (30 mmoVkg, i.p.) increased the
serum glucose levels ofnon-diabetic mice (432.3 Å} 11.3 mgldl, n= 8) to the level ofdiabetic
mice. However, morphine-induced place preference in non-diabetic mice was not affected by
pretreatment with glucose. There was no significant difference. in the morphine-induced place
preference between glucose-treated non-diabetic (139.6 Å} 38.1 s, n==8) and glucose-
untreated non-diabetic mice (i12.9 Å} 36.4 s, n=10).
Influence of p-opioid receptor antagonists pretreatment upon the morphine-induced
place preference
       P-Funaltrexamine (10 and 20 mg!kg, s.c.), a selective p-opioid receptor antagonist,
caused aversion for the drug-associated place, and significant conditioning aversion was
observed at dose of20 mgfkg in non-diabetic mice (Fig. 3-2). However, B-funaltrexamine did
not cause neither a place aversion nor place preference in diabetic mice. Moreover,
naloxonazine (35 mg/kg, s.c.), a selective p,-opioid receptor antagonist, caused a significant
place aversion in non-diabetic mice, but not in diabetic mice.
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       The effects of pretreatment with P-funaltrexamine on the place preference produced
by morphine in both diabetic and non-diabetic mice are shown in Fig. 3-3. After pretreatment
with saline, morphine (5 mglkg) produced a significant preference for drug-paired place in
both non-diabetic mice and diabetic mice. Thus, pretreatment with saline did not alter this
effect of morphine. However, the morphine-induced place preference was significantly
antagonized by pretreatment with B-funaltrexamine in both non-diabetic and diabetic mice.
The mean conditioning score of morphine (5 mg!kg) in both non-diabetic and diabetic mice
pretreated with B-funaltrexamine at doses of 1O mg/kg and 20 mg/kg were significantly lower
than those in saline-pretreated non-diabetic and diabetic mice, respectively. Furthermore,
morphine (3 mg/kg)-induced place preference in diabetic mice was also antagonized by
pretreatment with P-funaltrexamine. On the other hand, as shown in Fig. 3-4, pretreatment
with naloxonazine did not modify the morphine (5 mglkg)-induced place preference in non-
diabetic mice. The mean conditioning score did not significantly differ from that in mice that
had been pretreated with saline. Furthermore, naloxonazine also had no effect on morphine-
induced place preference in diabetic mice. Indeed, there was no significant difference in the
mean conditioning score of morphine (3 and 5 mglkg) between saline-pretreated diabetic mice
and naloxonazine-treated diabetic mice. Thus, pretreatment with naloxonazine did not modify
the appetitive effect of morphine in either diabetic or non-diabetic mice.
Influence of 6i- and 6,-opioid receptor antagonists pretreatment upon morphine-induced
place preference
       7-Benzylidenenaltrexone (O.3 and O.7 mg/kg, s.c.), a selective 6i-opioid receptor
antagonist, alone caused neither place preference nor place aversion in both non-diabetic and
diabetic mice. Furthermore, naltriben (O.1 and O.5 mglkg, s.c.), a selective 6,-opioid receptor
antagonist, alone also did not cause either a place preference or a place preference. The effects
of 7-benzylidenenaltrexone and naltriben on the morphine-induced place preference are
shown in Fig. 3-5 and 3-6. Morphine-induced place preference was antagonized by
pretreatment with naltriben in a dose-related manner in both diabetic and non-diabetic mice.
Indeed, naltriben, at a dose of O.5 mglkg, significantly abolished the morphine (5 mglkg)-
induced place preference. In diabetic mice, naltriben, at a dose of O.5 mglkg significantly
antagonized the morphine (3 mglkg)-induced place preference. Moreover, naltriben, at a dose
of O.5 mglkg, significantly suppressed the morphine (5 mglkg)-induced place preference in
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diabetic mice. On the other hand, 7-benzylidenenaltrexone, at a dose of O.7 mg/kg,
significantly abolished the morphine (5 mglkg)-induced place preference in non-diabetic mice.
Moreover, 7-benzylidenenaltrexone, at a dose of O.7 mglkg, also abolished the morphine (10
mglkg)-induced .place preference in non-diabetic mice. In diabetic mice, although the lower
dose (3 mgfkg) of morphine-induced place preference was significantly suppressed by
pretreatment with 7-benzylidenenaltrexone, at a dose of O.7 mglkg, the higher dose of
morphine (5 mglkg)-induced place preference was not antagonized by pretreatment with 7-
benzylidenenaltrexone.
       As shown in Fig. 3-3 and 3-6, the morphine (5 mgfkg)-induced place preference in
diabetic mice was significantly but not completely suppressed by pretreatment with P-
funaltrexamine, and was not affected by 7-benzylidenenaltrexone. However, when B-
funaltrexamine (10 mglkg) and 7-benzylidenenaltrexone (O.7 mglkg) was co-pretreated with
morphine, the morphine (5 mglkg)-induced place preference in diabetic mice was completely
abolished (morphine alone, 199.4 Å} 42.0 s, n=8; morphine with B-funaltrexamine, 71.2 Å} 44.9
s, n=8; morphine with B-funaltrexamine and 7-benzylidenenaltrexone, 19.1 Å} 52.1 s, n=8).
TAN-67-induced place preference in diabetic mice
       The place conditioning produced by TAN-67, a non-peptidic selective 6-opioid
receptor agonist, is shown in Fig. 3-7. In non-diabetic mice, TAN-67, at doses of 10, 30 and
56 mg/kg, s.c., cause neither a place preference nor a place aversion for the drug-associated
place. However, in diabetic mice, TAN-67 caused a dose-dependent place preference. TAN-67,
at a dose of 10 mglkg, induced a slight place preference, although this effect was not
statistically significant. Significant conditioning was observed at a dose of30 mg/kg.
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Figure 3-1. Place conditioning produced by morphine (circle) in non-diabetic (open
symbol) and diabetic (closed symbol) mice. Ordinate: mean difference (s) between
times spent on drug- and saline-paired sides of test box. Each point represents the mean
Å} S.E. of 10-16 mice. The asterisk denotes significant preference conditioning
(Wilcoxon test: 'PÅqO.05, "'PÅqO.Ol vs. respective saline alone (triangle)).
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Figure 3-2. Place conditioning produced by 6-funaltrexamine (FNA, 10 and 20 mglkg,
s.c.) and naloxonazine (NXZ, 3S mg/kg, s.c.) in non-diabetic and diabetic mice. Each
column represents the mean Å} S.E. of 7-12 mice. The asterisk denotes significant place
aversion conditioning (Wilcoxon test: 'PÅqO.05 vs. saline (SAL) alone).
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Figure 3-3. Effect of 6-funaltrexamine (FNA, 10 and 20 mg/kg, s.c.) on morphine (3 or
5 mglkg, s.c.)-induced conditioned place preference in non-diabetic and diabetic mice.
Each column represents the mean Å} S.E. of 7-13 mice. The asterisk denotes significant
preference conditioning (Wilcoxon test: 'PÅqO.05, ""PÅqO.Ol vs. saline (SAL) alone).
The sharp denotes significant difference from morphine alone (Wilcoxon test: #PÅqO.05).
Significant difference from respective morphine (5 mglkg) alone (Kruskal-Wallis test
followed by Wilcoxon test: $PÅqO.05).
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Figure 3-4. Effect of naloxonazine (NXZ, 35 mglkg, s.c.) on morphine (3 or 5 mglkg,
s.c.)-induced conditioned place preference in non-diabetic and diabetic mice. Each
column represents the mean Å} S.E. of 7-12 mice. The asterisk denotes significant
preference conditioning (Wilcoxon test: 'PÅqO.05, "PÅqO.Ol vs. saline (SAL) alone).
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Figure 3-5. Effects of naltriben (NTB, O.1 and O.5 mglkg, s.c.) on morphine (3 or 5
mgtkg, s.c.)-jnduced conditioned place preference jn non-diabetjc and djabetic mice.
Each column represents the mean Å} S.E. of 7-14 mice. The asterisk denotes significant
preference conditioning (Wilcoxon test: 'PÅqO.05, "*PÅqO.Ol vs. saline (SAL) alone).
The sharp denotes significant difference from morphine alone (Wilcoxon test: #PÅqO.05).
Significant difference from respective morphine (5 mglkg) alone (Kruskal-Wallis test
followed by VVilcoxon test: $PÅqO.05).
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Figure 3-6. Effect of 7-benzylidenenaltrexone (BNTX, O.3 and O.7 mglkg, s.c.) on
morphine (3 or 5 mglkg, s.c.)-induced conditioned place preference in non-diabetic and
diabetic mice. Each column represents the mean Å} S.E. of 7-13 mice. The asterisk
denotes significant preference conditioning (Wilcoxon test: 'PÅqO.05, "PÅqO.Ol vs.
saline (SAL) alone). The sharp denotes significant difference from morphine alone
(Wilcoxon test: #PÅqO.05). Significant difference from respective morphine (5 mglkg)
alone (Kruskal-Wallis test followed by Wilcoxon test: $PÅqO.05).
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Figure 3-7. Place conditioning produced by TAN-67 (10 and 30 mglkg, s.c.) in non-
diabetic and diabetic mice. Ordinate: mean difference (s) between times spent on drug-
and saline- paired sides of the test box. Each column represents the mean Å} SE of 7-16
mice. The asterisk denotes significant preference conditioning (Wilcoxon test: *PÅqO.05
vs. saline alone).
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Experiment 3-2: Effects of diabetes on methamphetamine-induced place preference
                               in mice.
Materials and Methods
Animals
      Male ICR mice (Tokyo Laboratory Animals Science Co., Tokyo), weighing about 20
g at the beginning ofthe experiments, were used. The mice were housed under the condition
as described in Chapter 1-1. Animals were rendered diabetic by an injection of streptozotocin
(200 mglkg, i.v.) prepared in O.1 N citrate buffer at pH 4.5. Age-matched non-diabetic mice
were injected with vehicle alone. The experiments were conducted 2 weeks after injection of
streptozotocin or vehicle. Mice with serum glucose levels above 400 mgtdl were considered
diabetic.
Place conditioning
      Place conditioning was conducted as previously described using a minor
modification of an unbiased procedure (Suzuki et al., 1990). The apparatus used was a shuttle
box (15 x 30 x 15 cm: w x 1 x h) which was divided into two compartments of equal size. One
compartment was white with a textured floor and the other was black with a smooth floor. For
conditioning, mice were confined to one compartment after drug injections and to the other
compartment after saline injections. Conditioning session consisted of 6 alternate day
injections of drug or vehicle (saline). Immediately following drug injection, mice were
confined to one compartment. Following vehicle injections they were confined to the other
compartment. Treatment compartment and the presentation order of drug and vehicle were
counterbalanced for each drug dose. Conditioning sessions were 60 min in duration. On day 7,
tests of conditioning were performed as follows: the partition separating the two
compartments was raised to 7 cm above the floor, and a neutral platform was inserted along
the seam separating the compartments. The time spent in each compartment during a 900-sec
session was then measured in a blinded fashion by an infrared beam sensor (KN-80, Natume,
Tokyo, Japan). The position ofthe mouse was defined by the position ofits body. All sessions
were conducted under conditions ofdim illumination and masking white noise.
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Drugs
       Streptozotocin was purchased from Sigma Chemical Co., St. Louis, MO, USA.
Methamphetamine hydrochloride was purchased from Dainippon Seiyaku, Co., Tokyo, Japan.
7-OH-DPAT {(Å})-7-hydroxy-N,N-di-n-propyl-2-aminotetralin} and quinpirole (trans-(-)-4aR-
4a,5,6,7,8,8q9-octahydro-5-propyl-IH-pyrazolo[3,4-g]quinoline) were purchased from
Research Biochemicals, Inc., Natick, MA, USA). Streptozotocin was dissolved in O.1 N
citrate buffer. Other drugs were dissolved in sterile O.9 O/o NaCl solution. 7-OH-DPA[[' was
injected s.c. at 10 min before methamphetamine injection. Quinpirole was injected i.c.v. 10
min before methamphetamine administration. Intracerebroventricular (i.c.v.) administration (5
pVmouse) was performed according to the method described in Experiment 1-2 using a 50 pl
Hamilton syringe. Each antagonist was injected before each conditioning session for
methamphetamine. The dose, route and schedule for quinpirole and 7-OH-DPAT in this study
were determined as described previously (Kamei et al. 1996a; Funada et al, 1995).
Data analysis
       Conditioning scores represent the time spent in the drug-paired place minus the time
spent in the vehicle-paired place and are expressed as mean Å} S.E. Dose-response curves were
analyzed using a one-way random factorial analysis ofvariance and linear regression analysis.
The Wilcoxon test was used to determine whether individual doses produced a significant
conditioning (*PÅqO.05).
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Results
Effects of diabetes on methamphetamine-induced place preference
       As shown in Fig. 3-8, none ofthe mice that received saline in conditioning sessions
exhibited a significant preference for either compartment of the test box. The mean
conditioning scores were -2.0 Å} 33.8 s (n=8) for non-diabetic mice and -1.3 Å} 47.5 s (n=8) for
diabetic mice. The place conditioning produced by methamphetamine is also shown in Fig. 3-
8. In non-diabetic mice, methamphetamine, at dose ranges from O.3 to 3 mglkg, s.c., caused a
dose-related preference for the drug-associated place, and significant conditioning was
observed at doses of 1 and 3 mglkg. In diabetic mice, methamphetamine (O.1 mglkg)
produced a slight place preference, but this effect was not statistically significant. Significant
conditioning was observed at doses ofO.3 mglkg and 1 mglkg in diabetic mice. At these doses,
all ofthe diabetic mice exhibited preference for the drug-associated place.
Effect of quinpirole on methamphetamine-induced place preference
       The effect ofpretreatment with quinpirole, a dopamine D2D3 receptor agonist, on the
place preference produced by methamphetamine is shown in Fig. 3-9. Methamphetamine (3
mglkg for non-diabetic mice and O.3 mglkg for diabetic mice) following i.c.v. pretreatment
with saline produced a significant preference for the drug-paired place in both non-diabetic
mice (163.6 Å} 51.6 s, n=8) and diabetic mice (166.1 Å} 53.5 s, n==8). However,
methamphetamine-induced place preference was significantly antagonized by i.c.v.
pretreatment with quinpirole (5 nmol) in both non-diabetic and diabetic mice. The mean
conditioning score for methamphetamine following pretreatment with quinpirole in non-
diabetic and diabetic mice was -12.9 Å} 31.6 s (n=8) and l7.8 Å} 48.0 s (n=12), respectively.
Effect of 7-OH-DPAT on methamphetamine-induced place preference
       The effect of 7-OH-DPAT, a selective dopamine D, receptor agonist, on
methamphetamine-induced place preference is shown in Fig. 3-10. Methamphetamine (3
mglkg for non-diabetic mice and O.3 mglkg for diabetic mice) following s.c. pretreatment
with saline produced a significant preference for the drug-paired place in both non-diabetic
mice (176.5 Å} 45.0 s, n=8) and diabetic mice (163.6 Å} 37.5 s, n=8). This methamphetamine-
induced place preference was significantly antagonized by pretreatment with 7-OH-DPAT
(O.1 mgfkg) in non-diabetic mice. The mean conditioning score for methamphetamine
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following pretreatment with 7-OH-DPA[r (-31.1 Å} 40.0 s, n=8) was significantly (PÅqO.05)
lower than that in saline-pretreated non-diabetic mice. On the other hand, a significant
methamphetamine-induced place preference was not observed in 7-OH-DPA[r (O.1 mglkg)-
pretreated diabetic mice. However, a statistically significant difference in methamphetamine-
induced place preference was not observed between saline-pretreated diabetic mice and 7-
OH-DPA[T-pretreated diabetic mice.
7-OH-DPAT-induced place conditioning in diabetic mice
       The place conditioning produced by 7-OH-DPAT, a dopamine D3 receptor agonist, is
shown in Fig. 3-11. In non-diabetic mice, 7-OH-DPAT produced a significant aversion for the
drug-associated place. 7-OH-DPAr, at doses of I and 3 mglkg, induced a significant place
aversion (mean conditioning scores of-101.4 Å} 58.9 s, n=8 for 1.0 mglkg, s.c. and -188.3 Å}
64.7 s, n=8 for 3.0 mglkg, s.c.). However, in diabetic mice, 7-OH-DPAT produced neither a
preference nor aversion for the drug-associated place (mean conditioning scores of-5.0 Å} 58.2
s, n=8 for 1.0 mglkg, s.c. and -59.8Å}33.0 s, n=8 for3.0 mg/kg, s.c.).
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Figure 3-8. Place conditioning produced by methamphetamine in diabetic (closed
symbol) and non-diabetic (open symbol) mice. Each point represents the mean
conditioning score Å} S.E. of 8-12 mice. The asterisks denote significant preference
conditioning (Wilcoxon test: 'PÅqO.05 vs. respective saline alone (triangle)).
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Figure 3-9. Effect of quinpirole (Quinp; 5 nmol, i.c.v.) on methamphetamine (MAP)-
induced place preference in diabetic and non-diabetic mice. Each column represents the
mean conditioning score Å} S.E. of 8-12 mice. The asterisks denote significant
preference conditioning (Wilcoxon test: "PÅqO.05 vs. saline (SAL) alone). The sharp
denotes a significant difference from methamphetamine alone (Wilcoxon test: #PÅqO.05).
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Figure 3-10. Effect of 7-OH-DPAT (DPAT; O.1 mglkg, s.c.) on methamphetamine
(MAP)-induced place preference in diabetic and non-diabetic mice. Each column
represents the mean conditioning score Å} S.E. of 8-12 mice. The asterisks denote
significant preference conditioning (Wilcoxon test: "PÅqO.05 vs. saline (SAL) alone).
The sharp denotes a significant difference from methamphetamine alone (Wilcoxon test:
#PÅqO.05).
-
 129 -
c.
8
,.ESI
.g
g
eS`])
E
VHÅí
8
g
a.
8•
1oo
o
-
1oo
-
2oo
-
3oo Non-diabetic mice Diabetic mice
Figure 3-11. Place conditioning produced by 7-OH-DPAT (1 mglkg, s.c., hatched
column; 3 mglkg, s.c., dotted column) in diabetic and non-diabetic mice. Each column
represents the mean conditioning score Å} S.E. of 8-12 mice. The asterisks denote
significant aversion conditioning (Wilcoxon test: "PÅqO.05 vs. saline alone (open
column).
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Experiment 3-3: Effects of streptozotocin-induced diabetes on
place conditioning action of cocaine in mice
Materials and Methods
Animals
       Male ICR mice (Tokyo Laboratory Animals Science Co., Tokyo), weighing about 20
g at the beginning ofthe experiments, were used. The mice were housed under the condition
as described in Chapter 1-1. Animals were rendered diabetic by an injection of streptozotocin
(200 mg/kg, i.v.) prepared in O.1 N citrate buffer at pH 4.5. Age-matched non-diabetic mice
vvere injected with vehicle alone. The experiments were conducted 2 weeks after injection of
streptozotocin or vehicle, Mice with serum glucose levels above 400 mgldl were considered
diabetic.
Place conditioning
      Place conditioning was conducted as previously described using a minor
modification of an unbiased procedure as described in Experiment 3-2. The apparatus used
was a shuttle box (15 x 30 x 15 cm: w x 1 x h) which was divided into two compartments of
equal size. One compartment was white with a textured floor and the other was black with a
smooth floor. For conditioning, mice were confined to one compartment after drug injections
and to the other compartment afier saline injections. Conditioning session consisted of 6
alternate day injection of drug or vehicle (saline). Immediately, following drug injection, mice
were confined to one compartment. Following vehicle injection they were confined to the
other compartment. Treatment compartment and the presentation order ofdrugs vehicle were
counterbalanced for each drug dose. Conditioning sessions were 60 min in duration. On day 7,
tests of conditioning were performed as follows: the partition separating the two
compartments was raised to 7 cm above the floor, and a neutral platform was inserted along
the seam separating the compartments. The time spent in each compartment during a 900-s
session was then measured in a blinded fashion by an infrared beam sensor (KN-80, Natume,
Tokyo, Japan). The position of the mouse was defined by the position of its body. All sessions
were conducted under conditions oflim illumination and masking white noise.
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Drugs
       Streptozotocin was pufchased from Sigma (St. Louis, MO, USA.). Cocaine
hydrochloride was purchased from Takeda Pharmaceutical Industries, Inc. (Ohsaka, Japan).
Streptozotocin was dissolved in O.1 N citrate buffer Cocaine hydrochloride was dissolved in
sterile O.9 O/o NaCl solution.
Data analysis
       Conditioning scores represent the time spent in the drug-paired place minus the time
spent in the saline-paired place and are expressed as mean Å} S.E. Dose-response curve was
analyzed using a one-way random factorial analysis ofvariance and liner regression analysis.
The Wilcoxon test was used to determine whether individual doses produced a significant
conditioning (*ÅqO.05).
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Results
       As shown in Fig. 3-12, none of the mice receiving that received saline in
conditioning sessions exhibited a significant preference for either compartment ofthe test box.
The mean conditioning scores were -2.0 Å} 33.8 s (n=8) for non-diabetic mice and -1,3 Å} 47.5
s (n=8) for diabetic mice. The place conditioning produced by cocaine is shown in Fig. 3-12.
In non-diabetic mice, cocaine, at dose ranges from 1 to 30 mglkg, s.c., caused a dose-related
preference for the drug-associated place, and significant conditioning was observed at doses
of 10 and 30 mglkg. In diabetic mice, cocaine (10 mg/kg) caused a slight place preference,
but this effect was not statistically significant. Significant conditioning was observed at doses
of30 mglkg in diabetic mice. At this dose, all diabetic mice exhibited preference for the drug-
associated place. However, there was no significant difference in the cocaine-induced place
preference between diabetic and non-diabetic mice.
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Figure 3-12. Place conditioning produced by cocaine in diabetic (closed circle) and non-
diabetic (open circle) mice. Each point represents the mean conditioning score Å} S.E. of
8-12 mice. The asterisks denote significant preference conditioning (Wilcoxon test:
*PÅqO.05 vs. respective saline alone (triangle)).
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Discussion
       The results of Experiment 3-1 demonstrated that morphine produced dose-related
conditioned place preference in both diabetic and non-diabetic mice. Furthermore, the
morphine-induced place preference was significantly antagonized by pretreatment with the B-
funaltrexamine, a selective p-opioid receptor antagonist, but not naloxonazine, a selective pti-
opioid receptor antagonist in both diabetic and non-diabetic mice. Similarly, Suzuki et al.
(1993) demonstrated that the morphine-induced place preference was not suppressed by
pretreatment with naloxonazine, whereas B-funaltrexamine completely suppressed morphine-
induced place preference. Furthermore, they reported that morphine produced a B-
funaltrexamine-sensitive place preference in p,-opioid receptor deficient CXBK mice.
Therefore, the present results along with the findings of Suzuki et al. (1993) strongly support
the hypothesis that the morphine-induced place preference may be mediated by naloxonazine-
insensitive p-opioid receptors (namely, pt2-opioid receptors).
       In the present study, place aversion was observed following s.c. administration of
naloxonazine and B-funaltrexamine in non-diabetic mice, but not in diabetic mice. It has been
shown that opioid receptor antagonists, such as naloxone and naltrexone, produce a
conditioned place aversion in rats (Bechara and van der Kooy, 1985; Mucha and Herz, 1984)
and mice (Mucha and Walker, 1987). Recent evidence suggests that the aversive properties of
naloxone primarily refiect an antagonism of the activity of central P-endorphin-containing
neurons in mediobasal arcute hypothalamus (Mucha et al., 1984). In receptor binding studies,
it has been reported that naloxonazine inhibits [3H]B-endorphin binding, suggesting that
[3H]P-endorphin might label p, sites (Houghten et al., 1984). Furthermore, it should be noted
that a reasonable naloxonazine dose to obtain a p, selectivity in mice would be 35 mglkg, s.c.
(Ling et al., 1986). In the present study, naloxonazine (35 mglkg, s.c.) produced a conditioned
place aversion, suggesting that selective blockade of p,-opioid receptors results in aversive
motivational states. Possibly, P-endorphinergic pathway would be involved in the aversive
properties of naloxonazine. Nevertheless, the morphine-induced place preference was not
blocked by pretreatment with naloxonazine in both non-diabetic and diabetic mice. These
findings also strongly support the possibility that the motivational effect of morphine may be
mediated by p2-opioid receptors. Recently, Kamei et al. (1994a) proposed that mice with
diabetes are selectively hyporesponsive to activation ofp,-opioid receptors, but are normally
responsive to p2-opioid receptors, since naloxonazine-sensitive, but not naloxonazine-
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insensitive pharmacological actions of p-opioid receptor agonists in diabetic mice were
markedly reduced as compared with in non-diabetic mice. This possibility might be supported
by the present findings that naloxonazine and P-funaltrexamine did not produce place
aversion in diabetic mice.
       The morphine (5 mglkg)-induced place preference in non-diabetic mice was
antagonized by pretreatment with either 7-benzylidenenaltrexone, a selective 6i-opioid
receptor or naltriben, a selective 62-opioid receptor antagonist. These results are also
consistent with previous findings that 6i- and 62-opioid receptors may be involved in the
modulation ofthe reinforcing effect of morphine (Suzuki et al., 1994). The morphine-induced
place preference in diabetic mice was suppressed by pretreatment with naltriben. Furthermore,
the lower dose (3 mglkg) of morphine-induced place preference in diabetic mice was
significantly antagonized by pretreatment with 7-benzylidenenaltrexone. These results
indicate that the motivational effect ofmorphine in diabetic mice is also niodulated by the 6i•-
and 62-opioid receptor. In the present study, the morphine (5 mg/kg)-induced place preference
in diabetic mice was significantly but not completely antagonized by pretreatment with B-
funaltrexamine and was not affected by 7-benzylidenenaltrexone. However, when mice were
pretreated with both P-funaltrexamine and 7-benzylidenenaltrexone, the morphine (5 mglkg)-
induced place preference in diabetic mice was completely abolished. It is not clear whether
the lack of the effect of 7-benzylidenenaltrexone on morphine-induced place preference in
diabetic mice may be caused by the increasing the dose of morphine overcoming the 7-
benzylidenenaltrexone antagonism or the up-regulation of 6i-opioid receptor-mediated
functions. In this regard, Kamei et al. (1994b) previously demonstrated that the
antinociceptive effect of DPDPE was significantly greater in diabetic mice than in non-
diabetic mice, whereas there was no significant difference in the antinociceptive effect of [D-
Ala2]deltorphin II between diabetic and non-diabetic mice. Furthermore, pretreatment with 7-
benzylidenenaltrexone, but not naltriben, significantly antagonized the antinociceptive effect
ofDPDPE. In contrast, the antinociceptive effect of [D-Aja2]deltorphin II was antagonized by
naltriben, but not by 7-benzylidenenaltrexone (Kamei et al., 1994b).
       Recently, Kamei et al. (1995) demonstrated TAN-67, a novel non-peptidic 6-opioid
receptor agonist, produced a marked and dose-dependent 7-benzylidenenaltrexone--sensitive,
but not naltriben-sensitive, antinociceptive effect in both non-diabetic and diabetic mice.
Furthermore, the antinociceptive effect of TAN-67 is significantly greater in diabetic mice
than that in non-diabetic mice (Kamei et al., 1995a). Based on these results, it is suggested
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that mice with diabetes are selectively hyperresponsive to 6,-opioid receptor-mediated
antinociception, but are normally responsive to activation of 6,-opioid receptors. In the
present study, I demonstrated that TAN-67 produced significant place preference in diabetic
mice, but not in non-diabetic mice. This result suggests that the motivational effect mediated
by 6,-opioid receptors, which is silent in non-diabetic mice, fu1fi11 its function in diabetic mice.
On the other hand, higher dose of morphine (10 mg/kg)-induced place preference in non-
diabetic mice was significantly antagonized by 7-benzylidenenaltrexone. Thus, it seems likely
that the lack of the effect of 7-benzylidenenaltrexone on high dose of morphine (5 mglkg)-
induced place preference in diabetic mice might be due to the up-regulation of 6-opioid
receptor-mediated functions.
       In the present study, I also demonstrated that the maximal conditioning of morphine
in diabetic mice was relatively higher than that in non-diabetic mice. Furthermore, the mean
conditioning score of morphine, at a dose of 3 mglkg, was significantly greater in diabetic
mice than that in non-diabetic mice. However, when glucose was administered to non-diabetic
mice to raise their serum glucose levels, morphine-induced place preference in non-diabetic
mice was not changed. This result suggests that the enhancement of morphined•induced place
preference in diabetic mice was not due to their higher serum glucose levels. In this regard, a
conditioned reinforcing effect of morphine has been observed following its injection into
nucleus accumbens (Koob and Goeders, 1989; Olds, 1982). Furthermore, it is reported that
morphine binds with relatively high affmity to 6-opioid receptors (Magnan et al., 1982), and
6- rather than pt-opioid receptors are predominate in this region (Mansour et al., 1988).
Therefore, the reinforcing effects of intra-nucleus accumbens morphine may reflect an
interaction with 6- rather than p-opioid receptors. Thus, it is possible that the enhancement of
morphine-induced place preference in diabetic mice as compared to non-diabetic mjce may be
due to the up-regulation of6i••opioid receptor-mediated.
       Many studies have indicated that morphine increases the activity of mesolimbic and
nigrostriatal dopamine-containing neurons (Gysling et al., 1983; Matthews et al., 1984).
Furthermore, it has been reported that acute morphine treatment increases dopamine release
and metabolism in the caudate putamen and the nucleus accumbens (Di Chiara and Imperato,
1988; Wood et al., 1982). There is evidence that the motivational effect of morphine is
mediated by dopamine neurons in these regions (Botarth and Wise, 1981; Phillips and
LePiane, 1980; Spyraki et al., 1983; Van der Kooy et al., 1982). Locomotor activity in the
experimental animals has been shown to be closely related to the activity ofthe mesolimbic
-
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dopaminergic system. Kamei et al. (1995b) recently demonstrated that spontaneous locomotor
activity in diabetic mice was significantly greater than that in non-diabetic mice. This
enhanced spontaneous locomotor activity in diabetic mice was reduced by pretreatment with
either SCH23390, a selective dopamine Dl receptor antagonist, 7-benzylidenenaltrexone or
naltrindole (Kamei et al., 1994d). Furthermore, Kamei et al. (1994d) also demonstrated that
the dopamine turnover in limbic forebrain (including nucleus accumbens and olfactory
tubercle) is increased in diabetic mice as compared to non-diabetic mice. On the other hand,
morphine-induced increase in dopamine turnover in the mouse limbic forebrain was
significantly suppressed by naltrindole (Naritra et al., 1993). Based on these results, Kamei et
al. (1994d) previously suggested that the enhanced spontaneous locomotor activity in diabetic
mice may be result from increased dopamine release in mesolimbic dopamine systems, which
might be due to the up-regulation of 6-opioid receptor-mediated functions. Therefore, the
increased dopamine neurotransmission which related to the up-reguiation of 6-opioid
receptor-mediated functions may account for the enhancement of morphine-induced
appetitive effect in diabetic mice.
       In conclusion, the results from Experiment 3-1 support the hypothesis that the
morphine-induced place preference may be mainly mediated through the activation ofthe p2-
opioid receptor, and suggest that the enhancement ofthe morphine-induced place preference
in diabetic may be due to the up-regulation of6,-opioid receptor-mediated functions.
       In Experiment 3-2, methamphetamine produced a dose-dependent and significant
place preference in both diabetic and non-diabetic mice. This methamphetamine-induced
place preference was attenuated by pretreatment with quinpirole in both diabetic and non-
diabetic mice. White and Wang (1984) reported that somatodendric dopamine-autoreceptors,
which regulate the impulse flow of most mesolimbic dopamine neurons in the ventral
tegmental area, exhibit the pharmacological characteristics ofdopamine D2 receptors. On !he
other hand, quinpirole possesses a high affmity for the recently described dopamine D3
receptors. Sokoloffet al. (1990) reported that quinpirole has an approximately 100-fold higher
affinity for the dopamine D3 receptor than for the dopamine D2 receptor. Tang et al. (1994)
reported that quinpirole inhibits dopamine release through the activation of dopamine D2 and
dopamine D3 receptors. Therefore, the present results suggest that the attenuation of
methamphetamine-induced place preference by quinpirole may be mediated by a reduction in
dopamine transmission through the activation of dopamine autoreceptors. In this regard, we
also demonstrated that methamphetamine-induced place preference was attenuated by
-
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pretreatment with 7-OH-DPAT in both diabetic and non-diabetic mice. Levesque et al. (1992)
reported that the selectivity of 7-OH-DPAT for dopamine D3 receptors is År100-, År1000- and
År10000-fold greater than that for dopamine D2, D4 and Di receptors, respectively, suggesting
that 7-OH-DPAT is a highly selective agonist for dopamine D, receptors. Furthermore, several
microdialysis and brain-slice studies have indicated that 7-OH-DPAT reduces dopamine
release in the nucleus accumbens and striatum (Damsma et al., 1993; Timmerman et al., 1991;
Yamada et al., 1994) Therefore, dopamine D3 receptors may play a role in controlling
dopamine release or synthesis as an autoreceptor in dopamine neuronal terminals in the limbic
area (Gobert et al. 1995). Thus, present data strongly suggest that the reduction of the
mesolimbic dopamine system activity can reduce the rewarding effect ofmethamphetamine.
       The nucleus accumbens is an important site for the mediation of the reinforcing
properties of drug of abuse. Furthermore, it has been reported that the dopamine-containing
neurons ofthe ventral tegmentum and their tracts that innervate the limbic and frontal cortex
are required for the acute reinforcing actions of cocaine and D-amphetamine (Roberts and
Koob, 1982; Yokel and Wise, 1975; 1976). Although Spyraki et al. (1982) failed to observe an
overall signifioant attenuation of amphetamine-induced place preference in rats with 6-
hydroxydopamine lesions of the nucleus accumbens, there was a significant correlation
between dopamine levels in the nucleus accumbens and the magnitude ofthe place preference.
Furthermore, dopamine depletion in the nucleus accumbens varied between 60 and 900/e of
that in the controls, and the importance of a severe depletion of dopamine in attenuating a
place-preference effect has been demonstrated. Moreover, it has been reported that the
microinjection of (+)-amphetamine into the nucleus accumbens resulted in a place preference
(Carr and White, 1986). These reports suggest that the nucleus accumbens is an important
substrate in the psychostimulant-induced place preference. Locomotor activity in the
experimental animals has been shown to be closely related to the activity of the mesolimbic
dopaminergic system. It is recently demonstrated that spontaneous locomotor activity in
diabetic mice was significantly greater than that in non-diabetic mice. Furthermore, Kamei et
al. (1994d) also demonstrated that dopamine turnover (DOPAC+HVAIdopamine) in the
limbic forebrain is significantly greater in diabetic mice than that in non-diabetic mice.
Moreover, it is reported that increased spontaneous locomotor activity in diabetic mice was
attenuated by pretreatment with 7-OH-DPAr (Kamei and Saitoh, 1996a). Based on these
results, we suggested that the enhanced spontaneous locomotor activity in diabetic mice may
result from increased dopamine release in mesolimbic dopamine systems, which might be due
-
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to the down-regulation ofpresynaptic dopamine D3 receptor-mediated functions (Kamei and
Saitoh, 1996a). In the present study, we also demonstrated that 7-OH-DPA r, at doses of 1 and
3 mg!kg, produced dose-dependent place aversion in non-diabetic mice. However, 7-OH-
DPAf produced neither place preference or place aversion in diabetic mice. It has been
reported that CGSI0746B (5-(4-methyl-1-piperazinyl)imidazo[2,1-b][1,3,5]-
benzothiadiazepine), an inhibitor of dopamine release, produced a place aversion (Schechter
and Meehan 1994). Furthermore, as mentioned above, 7-OH-DPAT inhibits dopamine release
from the nucleus accumbens, a major terminal area of the mesolimbic dopaminergic system,
through the activation of dopamine D3 receptors (Damsma et al. 1993; Timmerman et al.
1991; Yamada et al. 1994; Gobert et al. 1995). These results suggest that the activation of
dopamine D3 receptors in the mesolimbic dopamine system may produce place aversion. Thus,
it is possible that the reduction in place aversion caused by 7-OH-DPA[r in diabetic mice may
be related to the dysfunction ofdopamine D3 receptors. Furthermore, the Present findings also
support the previous hypothesis (Kamei and Saitoh, 1996a) that diabetic mice are
hyporesponsive to dopamine D3 receptor-mediated modulation of dopamine release in the
limbic area. Therefore, the increased dopamine neurotransmission which is associated with
the down-regulation ofpresynaptic dopamine D3 receptor-mediated functions may be account
for the enhancement of methamphetamine's reinforcing effect in diabetic mice. The
mechanisms which lead to this dysfunction of dopamine D3 receptors in diabetic mice are
unclear. It was previously suggested that some factor(s) derived from spleen cells may play an
important direct or indirect role in the alternation ofdopamine receptor functions (Kamei and
Saitoh, 1996b). It is possible that these factor(s) in diabetic mice and the dysfunction of
dopamine D3 receptors may somehow be related.
       In Experiment 3-3, I demonstrated that although statistically significant difference in
cocaine-induced place preference between diabetic and non-diabetic mice was not observed,
cocaine preferentially produced place preference in non-diabetic mice as compared to those in
diabetic mice. In Experiment 3-2, I demonstrated that methamphetamine, an enhancer of
dopamine release, preferentially produced place preference in diabetic mice as compared to
those in non-diabetic mice. Furthermore, it has been shown that cocaine had no significant
effect on locomotor activity in diabetic mice, whereas methamphetamine produced a
significant locomotor-enhancing effect in diabetic mice (Saitoh et al., 1995). Based on the
results of this study and reports from Saitoh et al. (1995), it is possible that the
pharmacological actions of cocaine in diabetic mice were less than those in non-diabetic mice.
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       In Experiment 3-2, the methamphetamine-induced place preference in both diabetic
and non-diabetic mice was significantly antagonized by pretreatment with not only quinpirole,
a dopamine D21D3 receptor agonist, but also 7-OH-DPAT, a selective dopamine D3 receptor
    .agonist. Moreover, 7-OH-DPA[r produced significant place aversion in non-diabetic mice, but
not in diabetic mice. Based on these results, I suggested that the increased dopamine
neurotransmission which associated with the down-regulation of presynaptic dopamine D3
receptor-mediated function may account for the enhancement of methamphetamin's
reinforcing effect in diabetic mice. In contrast with the reinforcing effects of
methamphetamine, it has been reported that the reinforcing and stimulant properties of
cocaine was shown to correlate with their binding properties at the dopamine transporter
(Bergman et al., 1989; Ritz et al., 1987). Furthermore, mice lacking the dopamine transporter
are indifferent to the stimulant effects of cocaine (Giros et al., 1996). Figlewicz et al. (1994)
demonstrated that direct administration of insulin into the CNS resulted in significantly
increased the dopamine transporter mRNA levels relative to vehicle-treated controls. In
addition reports indicated that the dopamine transporter mRNA expression in ventral
tegmental arealsubstantia nigra compacta and ventral medial bundle decreased in
experimentally-induced diabetic rats (Figlewicz et al., 1996; Petrisic et al., 1997). Thus, these
results and the present data suggest that changes in the doparnine transporter regulation in the
dopamine neurons of the mesolimbiclnigrostriatal pathway and the reduction of cocaine's
reinforcing effect in diabetic mice may some how be related. However, further studies are
necessary before this issue can be resolved with greater certainty. In conclusion, cocaine-
induced place preference was attenuated in diabetic mice as compared to those in non-diabetic
mice. This might be due to in part by the alteration in the dopamine transporter function.
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Conclusions
       The above findings lead to the following conclusions:
(1) Activation of protein kinase C (PKC) plays the critical role in the attenuation of pt-opioid
receptor agonist-induced pharmacological action in diabetic mice. Furthermore, intracellular
Ca2' differentially modulates the pt- and 6-opioid receptor•bmediated antinociception. Finally,
changes in p- and 6-opioid receptor agonist-induced antinociception in diabetic mice may be
due to intracellular calcium overload caused by the dysfunction of the calcium storage
function (Fig. A).
(2) The findings of this study demonstrated that pretreatment with PKC and PKA inhibitors
suppress naloxone-precipitated withdrawal jumping in morphine-dependent non-diabetic mice,
and inhibit the naloxone-precipitated increase in cortical NA turnover. Moreover, increased
intracellular calcium augmented naloxone-precipitated withdrawal jumping and the turnover
rate of NA in the frontal cortex in morphine-dependent non-diabetic mice. Naloxone-
precipitated withdrawal jumping was significantly less in morphine-dependent diabetic mice
than in morphine-dependent non-diabetic mice. The reduction of naloxone-precipitated
withdrawal jumping in morphine-dependent diabetic mice may be due to the dysfunction of
central noradrenergic neurons andlor central noradrenergic receptor function. Furthermore,
the mechanisms underling the reduction of naloxone-precipitated withdrawal jumping in
morphine-dependent diabetic mice may be due to the activation of PKC activity and the
dysfunction ofintracellular calcium storage (Fig. B).
(3) The reinforcing effect of morphine and methamphetamine in diabetic mice is greater than
that in non-diabetic mice. The enhancement of the reinforcing effect of morphine in diabetic
mice may be due to the up-regulation of pt,-opioid receptor-mediated functions. Furthermore,
the enhancement of methamphetamine-induced place preference in diabetic mice may be due
to dysfunction ofthe presynaptic dopamine D, receptors. On the other hand, the reinforcing
property of cocaine in diabetic mice was less than that in non-diabetic mice. The reduction of
the reinforcing property of cocaine in diabetic mice might be caused by the dysfunction ofthe
dopamine-transporter, which may be the cause for the enhancement of dopaminergic
transmission in the nucleus accumbens. I have hypothesized that the differential sensitivity
-
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needed to produce the reinforcing effect of morphine, methamphetamine and
diabetic mice may result from the dysfunction ofcentral dopaminergic systems.
cocame m
From the above findings, I conclude that the etiology of several central diabetic neuropathies
may be due to the abnormality of the intracellular events, especially activation of PKC and
dysfunction of intracellular calcium storage. The reductions of p-opioid receptor-mediated
pharmacological action and naloxone-precipitated withdrawal jumping in diabetic mice may
be caused by both the activation of PKC and the increase in the [Ca2']i. Furthermore, the
differential sensitivity of p-and 6-opioid receptor agonist-induced antinociception in
diabetic mice may be due to the increase in the [Ca2']i.
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Fig. A. Activation ofPKC may desensitize the p-opioid receptor function. The activation of
PKC in diabetic mice may desensitize the p-opioid receptor function. Furthermore, pt-opioid
receptor mediated antinociception may antagonize by the increase in [Ca2']i, whereas 6-opioid
receptor-mediated antinociception may enhance.
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Fig. B. Schematic illustration of diagram of the hypothesized response of identified neuronal
element during normal physiological activity, morphine tolerance and dependence in non-
diabetic and diabetic mice. Note that the magnitudes ofthe responses depicted are illustrative
only. PLC= phospholipase C, AC= adenylate cyclase, G= G-protein, PKC= protein kinase C,
PKA= protein kinase A, e = inhibition, [ lÅr == activation, a = increase, s = decrease. In
non-diabetic mice, chronic treatment with morphine increases the level of G-protein,
adenylate cyclase and phospholipase C (tolerantldependent sate). These changes mediated via
persistent activation of opioid receptors. In opiate dependent-state, the combined presence of
the morphine and up-regulated intracellular pathways would return excitability ofthe neuron
to normal state. Removal ofthe morphine would leave the up-regulated intracellular pathways
unopposed, leading to withdrawal activation of the neurons (withdrawal state). In diabetic
mice, p-opioid receptor-mediated function may be desensitized by the phosphorylation via
activated PKC. It is possible that p-opioid receptor-mediated inhibition of intracellular
pathways in diabetic mice may be weaker than that in non-diabetic mice. Consequently,
increase of the level of intracellular substrates in diabetic mice by chronic treatment with
morphine may be less than that in non-diabetic mice. Furthermore, the increase of [Ca2'], in
diabetic mice reduce the adaptive change induced by naloxone. Therefore, activation of the
neurons induced by withdrawal in diabetic mice may be less than those in non-diabetic mice.
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